

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUIDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer

agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:17:30 ON 05 JUN 2008

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:17:38 ON 05 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 JUN 2008 HIGHEST RN 1025498-38-7

DICTIONARY FILE UPDATES: 4 JUN 2008 HIGHEST RN 1025498-38-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10518496.str



chain nodes :

11 12 13 14 15

ring nodes :

1 2 3 4 5 6 7

chain bonds :

11-12 12-13 12-14 13-15

ring bonds :

1-2 1-6 1-7 2-3 3-4 4-5 4-7 5-6

exact/norm bonds :


1-2 1-6 2-3 3-4 4-5 4-7 5-6 11-12 12-13 12-14 13-15

exact bonds :  
1-7  
isolated ring systems :  
containing 1 :

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 11:CLASS 12:CLASS  
13:CLASS 14:CLASS 15:Atom 16:CLASS

L1 STRUCTURE UPLOADED

=> d l1  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full  
FULL SEARCH INITIATED 11:17:53 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 21366 TO ITERATE

100.0% PROCESSED 21366 ITERATIONS 1016 ANSWERS  
SEARCH TIME: 00.00.01

L2 1016 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	178.57

FILE 'CAPLUS' ENTERED AT 11:18:05 ON 05 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 5 Jun 2008 VOL 148 ISS 23  
FILE LAST UPDATED: 4 Jun 2008 (20080604/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l2 full  
L3 50 L2


=> d ibib abs hitstr tot



ACCESSION NUMBER: 2008:121112 CAPLUS  
 DOCUMENT NUMBER: 148:192110  
 TITLE: Quinuclidine derivatives as M3 antagonists  
 INVENTOR(S): Amari, Gabriele; Rizzi, Andrea; Patacchini, Riccardo;  
 Cenacchi, Valentina; Villetti, Gino; Catena Ruiz, Juan  
 Lorenzo; Masip Masip, Isabel  
 PATENT ASSIGNEE(S): Chiesi Farmaceutici S.p.A., Italy  
 SOURCE: PCT Int. Appl., 25pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008012290	A2	20080131	WO 2007-EP57585	20070723
WO 2008012290	A3	20080313		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1882691	A1	20080130	EP 2006-117883	20060726
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
US 20080039493	A1	20080214	US 2007-881146	20070725
PRIORITY APPLN. INFO.:			EP 2006-117883	A 20060726
OTHER SOURCE(S):	MARPAT 148:192110			

GI



AB Quinuclidine derivs., such as I [R1 = H, F, Cl, Br, iodo, C1-C4-alkyl; R2 = optionally substituted 2- or 3-thienyl, or substituted phenyl; R3 = (CH2)1-4-COR4 or (CH2)1-4-S(O)nR4; R4 = optionally substituted Ph or

optionally substituted 2- or 3-thienyl; n = 0, 1 or 2; X- = pharmaceutically acceptable anion] in the form of single enantiomers or mixts. thereof, were prepared for therapeutic use as muscarinic M3 receptor antagonists for the treatment or prevention of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, cough and emphysema. Thus, quinuclidine derivative II was prepared via a quaternization reaction of (3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]carbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester with 2-bromo-1-(2-thienyl)ethanone in MeCN and CHCl<sub>3</sub>. The prepared quinuclidines were tested for M3 receptor antagonist activity using isolated guinea pig trachea as indication of action against acetylcholine induced bronchospasm.

IT 1004312-95-1P 1004312-96-2P 1004312-97-3P  
1004312-98-4P 1004312-99-5P 1004313-00-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of quinuclidine derivs. for therapeutic use


as

M3 antagonists)

RN 1004312-95-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1004312-96-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(2-oxo-2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1004312-97-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(2-oxo-2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1004312-98-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(4-fluorophenyl)-2-oxoethyl]-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1004312-99-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-(phenylthio)ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Br<sup>-</sup>


RN 1004313-00-1 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[(phenylthio)methyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 1004312-94-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of quinuclidine derivs. for therapeutic use as M3 antagonists)  
 RN 1004312-94-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 552860-82-9  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of quinuclidine derivs. for therapeutic use as M3 antagonists)  
 RN 552860-82-9 CAPLUS  
 CN Carbamic acid, N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 385367-47-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of quinuclidine derivs. for therapeutic use as M3 antagonists)  
RN 385367-47-5 CAPLUS  
CN Carbamic acid, N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 2007:999179 CAPLUS  
DOCUMENT NUMBER: 147:323165  
TITLE: Cytisine and acetylcholine analogs and methods of treating mood disorders  
INVENTOR(S): Picciotto, Marina; Gundisch, Daniela; Munoz, Lenka; Andra, Matthias; Mineur, Yann  
PATENT ASSIGNEE(S): Yale University, USA; Rheinische Friedrich-Wilhelms-Universität Bonn  
SOURCE: PCT Int. Appl., 124pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007100430	A2	20070907	WO 2007-US2297	20070126
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2006-763197P P 20060127

OTHER SOURCE(S): MARPAT 147:323165

GI



AB Cytisine derivs., such as I [R = H, alkyl, acyl, carboxyl; R3, R5 = H, halogen, alkyl, alkenyl, alkynyl, substituted- or unsubstituted-phenyl, heteroaryl, etc.], and acetylcholine analogs were prepared for use in pharmaceutical compns. which modulate nicotinic acetylcholine receptor (nAChR) activity. These compds. were claimed for therapeutic use in the treatment of mood disorders, such as major depressive disorder, bipolar disorder, unipolar disorder, dysthymia (dysthymic disorder), postpartum depression, seasonal affective disorder or schizoaffective disorder. These compds. were also claimed for use in combination with tricyclic antidepressants, such as amitriptyline, clomipramine, desipramine, dothiepin hydrochloride, doxepin, imipramine, lofepramine, nortriptyline, protriptyline or trimipramine, with MAO inhibitors, such as isocarboxazid, phenelzine or tranylcypromine, and with serotonin reuptake inhibitors,


such as escitalopram oxalate, citalopram, fluvoxamine, paroxetine, sertraline or fluoxetine. Thus, 3-phenylcytisine I (R = R5 = H, R3 = Ph) was prepared via isolation of cytisine I (R = R3 = R5 = H) from seeds of Laburnum anagyroides and L. watereri, N-protection of cytisine and subsequent bromination to give intermediate bromide I (R = CO2CMe3, R3 = Br, R5 = H), and finally, a cross-coupling/deprotection reaction of the bromide with PhB(OH)2 using Na2CO3 and Pd(PPh3)4 in DME and H2O to form the target cytisine derivative. The prepared compds. were assayed in mice for binding affinity for a number of nAChR subtypes.

IT 753026-70-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of cytisine derivs. and acetylcholine analogs as nicotinic acetylcholine receptor ligands for therapeutic use in treatment of mood disorders)

RN 753026-70-9 CAPLUS

CN Carbamic acid, N-(3-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)




IT 195191-11-8P 753026-71-0P 753026-73-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of cytisine derivs. and acetylcholine analogs as nicotinic acetylcholine receptor ligands for therapeutic use in treatment of mood disorders)


RN 195191-11-8 CAPLUS

CN Carbamic acid, N-[1,1'-biphenyl]-3-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)



RN 753026-71-0 CAPLUS


CN Carbamic acid, N-(3-methylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)



RN 753026-73-2 CAPLUS

CN Carbamic acid, N-[3-(2-phenylethenyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)





L3 ANSWER 3 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:702698 CAPLUS

DOCUMENT NUMBER: 147:125811

TITLE: Combination comprising cyclooxygenase and lipooxygenase inhibitor for managing inflammation and associated disorders

INVENTOR(S): Jain, Rajesh; Jindal, Kour Chand

PATENT ASSIGNEE(S): Panacea Biotec Ltd., India

SOURCE: PCT Int. Appl., 37pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007072503	A2	20070628	WO 2006-IN496	20061218
WO 2007072503	A3	20071101		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: IN 2005-DE3431 A 20051221


AB This invention relates to pharmaceutical compns. comprising at least one analgesic and anti-inflammatory compound(s) that inhibits both cyclooxygenase (COX) and lipooxygenase (LOX) as active agent in combination with at least one another active agent(s) optionally with other pharmaceutically, acceptable excipients is provided. Also described are process for preparation of such compns. and method of using such compns. for the management of inflammation and pain and/or other associated disorders. Thus, tablet was prepared containing licofelone 200 mg, nimesulide 100 mg, AvicelPH 101 50 mg, lactose monohydrate 35 mg, starch 1500 30 mg, sodium lauryl sulfate 20 mg, croscarmellose sodium 15 mg, silicone dioxide 5 mg, starch 20 mg, magnesium stearate 5 mg, talc 5 mg and purified water as needed.

IT 171722-81-9, YM-46303

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination comprising cyclooxygenase and lipooxygenase inhibitor for managing inflammation and associated disorders)

RN 171722-81-9 CAPLUS

CN Carbamic acid, N-[1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-4-yl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L3 ANSWER 4 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:60686 CAPLUS

DOCUMENT NUMBER: 146:333161

TITLE: Novel Chemical Enhancers of Heat Shock Increase  
Thermal Radiosensitization through a Mitotic  
Catastrophe Pathway

AUTHOR(S): Sekhar, Konjeti R.; Sonar, Vijayakumar N.; Muthusamy,  
Venkatraj; Sasi, Soumya; Laszlo, Andrei; Sawani,  
Jamil; Horikoshi, Nobuo; Higashikubo, Ryuji; Bristow,  
Robert G.; Borrelli, Michael J.; Crooks, Peter A.;  
Lepock, James R.; Roti Roti, Joseph L.; Freeman,  
Michael L.

CORPORATE SOURCE: Department of Radiation Oncology, Vanderbilt-Ingram  
Cancer Center, Vanderbilt University School of  
Medicine, Nashville, TN, USA

SOURCE: Cancer Research (2007), 67(2), 695-701  
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Radiation therapy combined with adjuvant hyperthermia has the potential to  
provide outstanding local-regional control for refractory disease.  
However, achieving therapeutic thermal dose can be problematic. In the  
current investigation, we used a chemical-driven approach with the goal of  
designing and synthesizing novel small mols. that could function as  
thermal radiosensitizers. (Z)-(+)-2-(1-Benzenesulfonylindol-3-  
ylmethylene)-1-azabicyclo[2.2.2]octan-3-ol was identified as a compound that  
could lower the threshold for Hsf1 activation and thermal sensitivity.  
Enhanced thermal sensitivity was associated with significant thermal  
radiosensitization. We established the structural requirements for  
activity: the presence of an N-benzenesulfonylindole or N-benzylindole  
moiety linked at the indolic 3-position to a 2-(1-azabicyclo[2.2.2]octan-3-  
ol) or 2-(1-azabicyclo[2.2.2]octan-3-one) moiety. These small mols.  
functioned by exploiting the underlying biophys. events responsible for  
thermal sensitization. Thermal radiosensitization was characterized  
biochem. and found to include loss of mitochondrial membrane potential,  
followed by mitotic catastrophe. These studies identified a novel series  
of small mols. that represent a promising tool for the treatment of  
recurrent tumors by ionizing radiation.


IT 929256-72-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(chemical enhancers of heat shock increase thermal radiosensitization  
through mitotic catastrophe pathway)

RN 929256-72-4 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-[[1-(phenylsulfonyl)-1H-indol-3-  
yl]methylene]-, 3-(N-phenylcarbamate), (2Z)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

39

THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:676969 CAPLUS  
DOCUMENT NUMBER: 145:117429  
TITLE: Use of 3-substituted-2-(diphenylmethyl)-1-azabicyclo[2.2.2]octanes for treating MRG-X1 receptor-mediated diseases  
INVENTOR(S): Kunapuli, Priya; Strulovici, Berta  
PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
SOURCE: PCT Int. Appl., 39 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074146	A2	20060713	WO 2006-US55	20060103
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1855678	A2	20071121	EP 2006-717280	20060103
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
US 20080027095	A1	20080131	US 2007-794400	20070627
PRIORITY APPLN. INFO.:			US 2005-642230P	P 20050107
			WO 2006-US55	W 20060103

OTHER SOURCE(S): MARPAT 145:117429

AB The invention discloses a method for treating a disease or condition mediated by the human MRG-X1 receptor, e.g. as nociception, hyperalgesia, allodynia, pain related to central hypersensitivity conditions, somatic pain, visceral pain, acute pain, chronic pain, post-operative pain, headache, inflammatory pain, neurol. pain, musculoskeletal pain, cancer-related pain or vascular pain, in a human patient in need thereof, comprising administering to the patient a therapeutically effective amount of a 3-substituted-2-(diphenylmethyl)-1-azabicyclo[2.2.2]octane or a pharmaceutically acceptable salt thereof. The invention is also directed to the use of these compds. as mol. tools to directly explore the role of the MRG-X1 receptor in pain perception.


IT 887109-81-1 887109-82-2 887109-88-8  
887109-89-9

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(diphenylmethyl azabicyclo[2.2.2]octane derivs. for treatment of MRG-X1 receptor-mediated diseases)

RN 887109-81-1 CAPLUS

CN Carbamic acid, 1-naphthalenyl-, (3R)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887109-82-2 CAPLUS

CN Carbamic acid, (2-chlorophenyl)-, (3R)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887109-88-8 CAPLUS

CN Carbamic acid, (2-chlorophenyl)-, (3R)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887109-89-9 CAPLUS

CN Carbamic acid, (2-chlorophenyl)-, (3S)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L3 ANSWER 6 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:259381 CAPLUS

DOCUMENT NUMBER: 144:480368

TITLE: Identification of small molecule antagonists of the human mas-related gene-X1 receptor

AUTHOR(S): Kunapuli, Priya; Lee, Seungtaek; Zheng, Wei; Alberts, Melissa; Kornienko, Oleg; Mull, Rebecca; Kreamer, Anthony; Hwang, Jong-Ik; Simon, Melvin I.; Strulovici, Berta

CORPORATE SOURCE: Department of Automated Biotechnology, Merck Research Laboratories, North Wales, PA, 19454, USA

SOURCE: Analytical Biochemistry (2006), 351(1), 50-61  
CODEN: ANBCA2; ISSN: 0003-2697

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The recently identified mas-related-gene (MRG) family of receptors, located primarily in sensory neurons of the dorsal root ganglion, has been implicated in the perception of pain. Thus, antagonists of this class of receptors have been postulated to be useful analgesics. Toward this end, we developed a cell-based beta-lactamase (BLA) reporter gene assay to identify small mol. antagonists of the human MRG-X1 receptor from a library of compds. Single-cell clones expressing functional receptors were selected using the BLA reporter gene technol. The EC50 for the MRG agonist peptide, BAM15, appeared to be comparable between the BLA assay and the intracellular Ca2+ transient assays in these cells. Ultra high-throughput screening of approx. 1 million compds. in a 1.8-μl cell-based BLA reporter gene assay was conducted in a 3456-well plate format. Compds. exhibiting potential antagonist profile in the BLA assay were confirmed in the second messenger Ca2+ transient assay. A cell-based receptor trafficking assay was used to further validate the mechanism of action of these compds. Several classes of compds., particularly the 2,3-disubstituted azabicyclo-octanes, appear to be relatively potent antagonists at the human MRG-X1 receptors, as confirmed by the receptor trafficking assay and radioligand binding studies. Furthermore, the structure-activity relationship reveals that within this class of compds., the diphenylmethyl moiety is constant at the 2-substituent, whereas the 3-substituent is directly correlated with the antagonist activity of the compound


IT 887109-81-1 887109-82-2 887109-88-8  
887109-89-9

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(identification of small mol. antagonists of human mas-related gene-X1 receptor)

RN 887109-81-1 CAPLUS

CN Carbamic acid, 1-naphthalenyl-, (3R)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887109-82-2 CAPLUS

CN Carbamic acid, (2-naphthyl)-, (3R)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887109-88-8 CAPLUS

CN Carbamic acid, (3-chlorophenyl)-, (3R)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 887109-89-9 CAPLUS

CN Carbamic acid, (3-nitrophenyl)-, (3R)-2-(diphenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

20


THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2006:99752 CAPLUS  
 DOCUMENT NUMBER: 144:171147  
 TITLE: Process for preparing quinuclidinium carbamate derivatives  
 INVENTOR(S): Prat Quinones, Maria; Busquets Baque, Nuria; Pujol Noguera, Ferran; Ibarzo Casamian, Francisco, Javier  
 PATENT ASSIGNEE(S): Almirall Prodesfarma, SA, Spain  
 SOURCE: PCT Int. Appl., 33 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006010452	A1	20060202	WO 2005-EP7424	20050708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
ES 2246170	A1	20060201	ES 2004-1880	20040729
ES 2246170	B1	20070401		
EP 1781651	A1	20070509	EP 2005-762590	20050708
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
CN 101018786	A	20070815	CN 2005-80024812	20050708
JP 2008508203	T	20080321	JP 2007-522953	20050708
PRIORITY APPLN. INFO.:			ES 2004-1880	A 20040729
			WO 2005-EP7424	W 20050708
OTHER SOURCE(S):		MARPAT 144:171147		
GI				



I



II

AB This invention relates to a new process for preparing carbamate derivs., such as I [R = (CH<sub>2</sub>)<sub>m</sub>-A-(CH<sub>2</sub>)<sub>n</sub>-B; R<sub>1</sub> = CH<sub>2</sub>Ph, 2-, 3-furanyl, 2-, 3-thienyl, 2-, 3-furanylmethyl, 2-, 3- thienylmethyl, etc.; R<sub>2</sub> = Ph, CH<sub>2</sub>Ph, alkyl, alkenyl, alkynyl, cycloalkyl, 2-, 3-furanylmethyl, 2-, 3- thienylmethyl, etc.; A = linking group, such as CH<sub>2</sub>, CH:CH, CO, O, S, SO, SO<sub>2</sub>, NH, etc.;

B = CN, NO<sub>2</sub>, alkyl, alkoxy cycloalkylmethyl, aryl, heteroaryl, etc.; m = 0-8; n = 0-4], by reacting, in a first step, a corresponding azabicyclic alc. with a compound W-(CH<sub>2</sub>)<sub>m</sub>-A-(CH<sub>2</sub>)<sub>n</sub>-B (W = leaving group, such as Br) and reacting the product of this first step with an acylating agent G-CONR<sub>1</sub>R<sub>2</sub> (G = leaving group, such as Cl). Thus, quinuclidinium carbamate II was prepared via refluxing Ph(CH<sub>2</sub>)<sub>3</sub>Br with (3R)-3-quinuclidinol in THF to form (3R)-3-hydroxy-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octane bromide in 100% yield, and subsequently, reacting the intermediate quinuclidinium alc. with PhCH<sub>2</sub>N(Ph)COCl using NaH in DMF and mineral oil to give the desired quinuclidinium carbamate with 46% yield for the carbamoylation step.


IT 439908-03-9P 439908-55-1P 439908-92-6P  
637744-69-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(process for preparing quinuclidinium carbamate derivs. useful as intermediates in pharmaceutical synthesis)

RN 439908-03-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br<sup>-</sup>

RN 439908-55-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[butylphenylamino]carbonyl]oxy]-1-(3-phenyl-2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




● Br<sup>-</sup>

RN 439908-92-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 637744-69-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2005:286359 CAPLUS  
 DOCUMENT NUMBER: 143:19236  
 TITLE: 2-(Arylmethyl)-3-substituted quinuclidines as selective  $\alpha 7$  nicotinic receptor ligands  
 AUTHOR(S): Mazurov, Anatoly; Klucik, Jozef; Miao, Lan; Phillips, Teresa Y.; Seamans, Angela; Schmitt, Jeffrey D.; Hauser, Terry A.; Johnson, Raymond T.; Miller, Craig  
 CORPORATE SOURCE: Medicinal Chemistry, Targacept, Inc., Winston-Salem, NC, 27101, USA  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(8), 2073-2077  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 143:19236

AB A series of 2-(arylmethyl)-3-substituted quinuclidines was developed as  $\alpha 7$  neuronal nicotinic acetylcholine receptor (nAChR) agonists based on a putative pharmacophore model. The series is highly selective for the  $\alpha 7$  over other nAChRs (e.g., the  $\alpha 4\beta 2$  of the CNS, and the muscle and ganglionic subtypes) and is functionally tunable at  $\alpha 7$ . One member of the series, (+)-N-(1-azabicyclo[2.2.2]oct-3-yl)benzo[b]furan-2-carboxamide, has potent agonistic activity for the  $\alpha 7$  nAChR (EC<sub>50</sub> = 33 nM, I<sub>max</sub> = 1.0), at concns. below those that result in desensitization.

IT 852475-90-2P 852475-91-3P 852475-92-4P  
 852475-93-5P 852475-94-6P 852475-95-7P  
 852475-96-8P 852475-97-9P 852475-98-0P  
 852475-99-1P 852476-00-7P 852476-01-8P  
 852476-02-9P 852476-03-0P 852476-04-1P  
 852476-05-2P 852476-06-3P 852476-08-5P  
 852476-09-6P 852476-10-9P 852476-12-1P  
 852476-14-3P 852476-16-5P 852476-65-4P  
 874635-04-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(arylmethyl-substituted quinuclidines as selective  $\alpha 7$  nicotinic receptor ligands)

RN 852475-90-2 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-91-3 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[(6-methoxy-3-pyridinyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-92-4 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[(6-phenoxy-3-pyridinyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-93-5 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[(5-methoxy-3-pyridinyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 852475-94-6 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[[5-(1-methylethoxy)-3-pyridinyl]methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)




Relative stereochemistry.



RN 852475-95-7 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(2-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-96-8 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(5-pyrimidinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-97-9 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(3-quinolinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-98-0 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(phenylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852475-99-1 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[(4-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-00-7 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[[4-(dimethylamino)phenyl]methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-01-8 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[(4-fluorophenyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-02-9 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-[[4-(methylsulfonyl)phenyl]methyl]-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-03-0 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(1H-imidazol-4-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-04-1 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(3-thienylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-05-2 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(2-furanylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-06-3 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(2-benzofuranylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-08-5 CAPLUS

CN Carbamic acid, (4-fluorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-09-6 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-10-9 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(3-pyridinylmethyl)-, phenylcarbamate (ester), (2R,3R)-rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-12-1 CAPLUS

CN Carbamic acid, (4-phenoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-14-3 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-4-yl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-16-5 CAPLUS

CN Carbamic acid, (2-phenylcyclopropyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 852476-65-4 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 874635-04-8 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.




IT 195190-96-6P 195191-06-1P 852477-07-7P  
852477-08-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(arylmethyl-substituted quinuclidines as selective  $\alpha 7$  nicotinic receptor ligands)

RN 195190-96-6 CAPLUS


CN Carbamic acid, (4-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 195191-06-1 CAPLUS  
 CN 1-Azabicyclo[2.2.2]octan-3-ol, phenylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 852477-07-7 CAPLUS  
 CN Carbamic acid, [4-(phenylthio)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 852477-08-8 CAPLUS  
 CN Carbamic acid, [4-(phenylthio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



ACCESSION NUMBER: 2004:710489 CAPLUS  
 DOCUMENT NUMBER: 141:235681  
 TITLE: Synthesis and evaluation of phenylcarbamate derivatives as ligands for nicotinic acetylcholine receptors  
 AUTHOR(S): Guendisch, Daniela; Andrae, Matthias; Munoz, Lenka; Tilotta, Maria Cristina  
 CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Rhein. Friedr.-Wilhelm-University, Bonn, D-53115, Germany  
 SOURCE: Bioorganic & Medicinal Chemistry (2004), 12(18), 4953-4962  
 CODEN: BMECEP; ISSN: 0968-0896  
 PUBLISHER: Elsevier Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 141:235681


AB Phenylcarbamate derivs. were synthesized and evaluated in radioligand binding assays for different nicotinic acetylcholine receptor (nAChR) subtypes. Carbamate derivs. bearing a pyrrolidine or piperidine moiety 8-20 exhibited much lower affinity for  $\alpha 7^*$  nAChR than the analogs in the quinuclidine series 21-25, although the same structural elements are present. Furthermore, in contrast to the quinuclidine analogs 21-25, all (S)-pyrrolidine derivs. 8-12 and the piperidine analogs 15 and 16 exhibited higher affinities for  $\alpha 4\beta 2^*$  nAChR.

IT 195191-06-1P 195191-11-8P 753026-69-6P  
 753026-70-9P 753026-71-0P 753026-72-1P  
 753026-73-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (synthesis and evaluation of phenylcarbamate derivs. as ligands for nicotinic acetylcholine receptors)


RN 195191-06-1 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, phenylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 195191-11-8 CAPLUS

CN Carbamic acid, N-[1,1'-biphenyl]-3-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)




RN 753026-69-6 CAPLUS


CN Carbamic acid, (3-fluorophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 753026-70-9 CAPLUS  
 CN Carbamic acid, N-(3-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)




RN 753026-71-0 CAPLUS  
 CN Carbamic acid, N-(3-methylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)



RN 753026-72-1 CAPLUS  
 CN Carbamic acid, [3-(trifluoromethyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 753026-73-2 CAPLUS  
 CN Carbamic acid, N-[3-(2-phenylethenyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)





REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:353186 CAPLUS  
DOCUMENT NUMBER: 140:375177  
TITLE: Preparation of melanocortin-4 receptor binding compounds  
INVENTOR(S): Vos, Tricia J.; Solomon, Michael E.; Claiborne, Christopher F.; Maguire, Martin P.; Dai, Mingshi; Patane, Michael; Marsilje, Thomas H.  
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 299 pp., Cont.-in-part of U.S. 6,699,873.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 20040082779	A1	20040429	US 2003-462436	20030616
US 7375125	B2	20080520		
US 6699873	B1	20040302	US 2001-778468	20010207
CA 2529445	A1	20051222	CA 2004-2529445	20040615
WO 2005121100	A1	20051222	WO 2004-US19124	20040615
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004320025	A1	20060119	AU 2004-320025	20040615
EP 1644337	A1	20060412	EP 2004-776621	20040615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006527776	T	20061207	JP 2006-521070	20040615
PRIORITY APPLN. INFO.:			US 1999-147288P	P 19990804
			US 2000-223277P	P 20000803
			US 2000-632309	B2 20000804
			US 2001-778468	A2 20010207
			US 2003-462436	A 20030616
			WO 2004-US19124	W 20040615
OTHER SOURCE(S):		MARPAT 140:375177		
GI				



AB The title compds. of formula B-Z-E [wherein B = an anchor moiety; Z = a central moiety; E = an MC4-R interacting moiety], e.g. I [wherein P1-P4 = (un)substituted C, wherein one of P1-R4 is optionally replaced by N atom, or the ring bearing P1-P4 is thiophene ring wherein P3R4 together are replaced by a S atom; Z1-Z5 = (un)substituted CH; L2 = a bond, (un)substituted C1-2 alkylene, 2 carbon carbonyl chain, wherein one of the carbons is optionally replaced by O, NH, S; t = CH2, CHR3, CR3R4; s = CH2, CHR5, CR5R6, or t-s taken together = CH:CH, CR3:CH, CH:CR5, CR3:CR5; R3-R6 = alkyl, alkylcarbonyl, alkoxyacrbonyl, etc.; R = H, alkyl, alkylcarbonyl], were prepared and tested as melanocortin-4 receptor (MC4-R) binding agonists and antagonists. For example,  $\alpha$ -tolunitrile in THF was added to a solution of diisopropylamine in THF, which had been cooled to  $-78^{\circ}\text{C}$  and treated with BuLi. HMPA and 1-chloromethylnaphthalene in THF were added, the reaction cooled and stirred for 1 h, and the reaction quenched with H2O to give 2-(2-naphthalen-1-ylethyl)benzonitrile. Treatment with H2S and 1,3-diaminopropane, followed by heating to  $80^{\circ}\text{C}$  for 72 h and work up, gave II. In a scincillation proximity assay (SPA) using high-throughput receptor binding screening, II showed exemplary inhibition of MC4-R. The invention compds., primarily 2-(2-arylalkylsulfanylphenyl)- 4,5-dihydro-1H-imidazole and 1,4,5,6-tetrahydropyrimidine derivs., are useful in the treatment of disorders associated with weight loss (no data). The pharmaceutical composition

comprising the title compds. is claimed.

IT 326486-03-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(inactive as MC4-R binding compound; preparation and high throughput MC4-R receptor binding screening of arylalkylsulfanylphenyl-substituted imidazoles and pyrimidines and analogs)


RN 326486-03-7 CAPLUS

CN Carbamic acid, (2-ethoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326486-02-6


CMF C16 H22 N2 O3




CM 2

CRN 64-18-6


CMF C H2 O2



IT 325826-44-6P, [2-(Naphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester 325826-51-5P, [2-(2-Methylnaphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester 326484-34-8P 326484-38-2P 326484-48-4P 326484-49-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (target compound; preparation and high throughput MC4-R receptor binding screening of arylalkylsulfanylphenyl-substituted imidazoles and pyrimidines and analogs)  
 RN 325826-44-6 CAPLUS  
 CN Carbamic acid, [2-[(1-naphthalenylmethyl)thio]phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 325826-51-5 CAPLUS  
 CN Carbamic acid, [2-[[2-methyl-1-naphthalenyl)methyl]thio]phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 326484-34-8 CAPLUS  
 CN Carbamic acid, [2-[(1-naphthalenylmethyl)thio]phenyl]-,  
 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-44-6  
 CMF C25 H26 N2 O2 S



CM 2


CRN 64-18-6  
 CMF C H2 O2

O=CH-OH

RN 326484-38-2 CAPLUS  
 CN Carbamic acid, [2-[[5-bromo-2-methoxyphenyl)methyl]thio]phenyl]-,  
 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1


CRN 326484-37-1  
 CMF C22 H25 Br N2 O3 S



CM 2

CRN 64-18-6

CMF C H2 O2




RN 326484-48-4 CAPLUS

CN Carbamic acid, [2-[(2-naphthalenylmethyl)thio]phenyl]-,  
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326484-47-3


CMF C25 H26 N2 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2




RN 326484-49-5 CAPLUS

CN Carbamic acid, [2-[[2-methyl-1-naphthalenyl)methyl]thio]phenyl]-,  
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-51-5


CMF C26 H28 N2 O2 S



CM 2

CRN 64-18-6



CMF C H2 O2





L3 ANSWER 11 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:176560 CAPLUS  
 DOCUMENT NUMBER: 140:217656  
 TITLE: Preparation of aryl-substituted tetrahydropyrimidines and related compounds as melanocortin-4 receptor binding compounds  
 INVENTOR(S): Maguire, Martin P.; Dai, Mingshi; Vos, Tricia J.  
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA  
 SOURCE: U.S., 216 pp., Cont.-in-part of U.S. Ser. No. 632309.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6699873	B1	20040302	US 2001-778468	20010207
WO 2002062766	A2	20020815	WO 2002-US3566	20020207
WO 2002062766	A3	20021003		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002250029	A1	20020819	AU 2002-250029	20020207
EP 1363890	A2	20031126	EP 2002-718920	20020207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20040082779	A1	20040429	US 2003-462436	20030616
US 7375125	B2	20080520		
PRIORITY APPLN. INFO.:			US 1999-147288P	P 19990804
			US 2000-223277P	P 20000803
			US 2000-632309	A2 20000804
			US 2001-778468	A 20010207
			WO 2002-US3566	W 20020207
OTHER SOURCE(S):			MARPAT 140:217656	
GI				



AB The title compds. [I and related compds.; A = CH, CF, CCl, C(alkyl), etc.;

B = CH, CF, CCl, C(alkyl), etc.; C = CH, CCl, S, etc.; G, H = CH<sub>2</sub>, S; D = CH<sub>2</sub>; E, F = (un)substituted CH<sub>2</sub>; X = C(alkoxy); Y = CH, C(C.tplbond.CH), CCl, CBr, CCl, CF; Z = CH; or pharmaceutically acceptable salts thereof] were prepared for treating a melanocortin-4 receptor (MC4-R) associated state in a mammal. For example, stirring a solution of  $\alpha$ -tolunitrile with diisopropylamine and BuLi in hexanes at -78° under nitrogen for 1 h, followed by addition of HMPA and 1-chloromethylnaphthalene in THF, afforded 2-(2-naphthalen-1-ylethyl)benzonitrile. Heating the benzonitrile with 1,3-diaminopropane in the presence of H<sub>2</sub>S at 80° for 72 h gave the tetrahydropyrimidinyl cycloaddn. product II. The latter exhibited exemplary inhibition of MC4-R in a scintillation proximity assay. I are useful for the treatment of disorders associated with pigmentation, bones, or weight loss (no data).

IT 326484-34-8P 326484-38-2P 326484-48-4P  
326484-49-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MC4-R binding compound; preparation of aryl-substituted tetrahydropyrimidines and related compds. as melanocortin-4 receptor binding compds. for treatment of pigmentation, bone, and weight loss disorders)


RN 326484-34-8 CAPLUS

CN Carbamic acid, [2-[(1-naphthalenylmethyl)thio]phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-44-6

CMF C25 H26 N2 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2


O=CH-OH

RN 326484-38-2 CAPLUS

CN Carbamic acid, [2-[[5-bromo-2-methoxyphenyl)methyl]thio]phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)


CM 1

CRN 326484-37-1  
CMF C22 H25 Br N2 O3 S



CM 2


CRN 64-18-6  
CMF C H2 O2



RN 326484-48-4 CAPLUS  
CN Carbamic acid, [2-[(2-naphthalenylmethyl)thio]phenyl]-,  
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)


CM 1

CRN 326484-47-3  
CMF C25 H26 N2 O2 S



CM 2

CRN 64-18-6  
CMF C H2 O2




RN 326484-49-5 CAPLUS  
CN Carbamic acid, [2-[[[(2-methyl-1-naphthalenyl)methyl]thio]phenyl]-,  
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-51-5


CMF C26 H28 N2 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2



REFERENCE COUNT:


10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 12 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:3665 CAPLUS  
DOCUMENT NUMBER: 140:77298  
TITLE: Preparation of 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of treatment using these compounds  
INVENTOR(S): Mazurov, Anatoly A.; Klucik, Jozef; Miao, Lan; Seamans, Angela S.; Phillips, Teresa Youngpeter; Schmitt, Jeffrey Daniel; Miller, Craig Harrison  
PATENT ASSIGNEE(S): Targacept, Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 162,129.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 20040002513	A1	20040101	US 2003-372642	20030221
US 6953855	B2	20051011		
US 6432975	B1	20020813	US 1998-210113	19981211
US 20030045523	A1	20030306	US 2002-162129	20020604
AU 2004215386	A1	20040910	AU 2004-215386	20040220
CA 2514135	A1	20040910	CA 2004-2514135	20040220
WO 2004076449	A2	20040910	WO 2004-US5044	20040220
WO 2004076449	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1594869	A2	20051116	EP 2004-713356	20040220
EP 1594869	B1	20071219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007708	A	20060214	BR 2004-7708	20040220
CN 1751041	A	20060322	CN 2004-80004736	20040220
JP 2006518746	T	20060817	JP 2006-503737	20040220
AT 381563	T	20080115	AT 2004-713356	20040220
NZ 541794	A	20080328	NZ 2004-541794	20040220
US 20050255040	A1	20051117	US 2005-157119	20050620
ZA 2005006515	A	20060628	ZA 2005-6515	20050815
MX 2005PA08926	A	20051005	MX 2005-PA8926	20050822
IN 2005KN01718	A	20070323	IN 2005-KN1718	20050829
NO 2005004052	A	20051021	NO 2005-4052	20050831
US 20060247270	A1	20061102	US 2006-458231	20060718
PRIORITY APPLN. INFO.:			US 1998-210113	A1 19981211
			US 2002-162129	A2 20020604
			US 2003-372642	A 20030221
			WO 2004-US5044	A 20040220
			US 2005-157119	A1 20050620
OTHER SOURCE(S):	MARPAT 140:77298			
GI				



I



II

AB The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes I [A1 = (CH<sub>2</sub>)<sub>n</sub>; A2 = (CH<sub>2</sub>)<sub>m</sub>; A3 = (CH<sub>2</sub>)<sub>p</sub>; m, n = 1, 2; p = 1 - 4; X = O, NR'; Z = NR', covalent bond, A; A = CR'R'', CR'R''CR'R'', CR':CR', C.tplbond.C (wherein, when Z = bond or A, X = N); Ar = (un)substituted carbocyclic, heterocyclic monocyclic or fused polycyclic aryl; Cy = (un)substituted 5- or 6-membered heteroarom. ring; wavy lines = relative or absolute stereochem. (cis or trans, R or S); R', R'' = H, (un)branched C1-8-alkyl, C3-8-cycloalkyl, heterocyclyl, aryl, arylalkyl {wherein, substituents = alkyl, alkenyl, heterocyclyl, cycloalkyl, (un)substituted aryl, (un)substituted arylalkyl, F, Cl, Br, I, OR', NR'R'', CF<sub>3</sub>, CN, NO<sub>2</sub>, C.tplbond.CR', SR', N<sub>3</sub>, C(:O)NR'R'', NR'C(:O)R'', C(:O)R', C(:O)OR', OC(:O)R', O(CR'R'')rC(:O)R', O(CR'R'')rNR'C(:O)R', O(CR'R'')rNR'SO<sub>2</sub>R', OC(:O)NR'R'', NR'C(:O)OR', SO<sub>2</sub>R', SO<sub>2</sub>NR'R'', NR'SO<sub>2</sub>R''}; R'R'' = ring; r = 1 - 6] and II, methods of preparing the compds. and methods of treatment using the compds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroarom., preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compds. exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the α7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.

IT 639494-40-9P 639494-43-2P 639494-46-5P


639494-49-8P 639494-53-4P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-substituted-2(arylalkyl)-1-azabicycloalkanes exhibiting activity at nicotinic acetylcholine receptors)



RN 639494-40-9 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, 2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 639494-43-2 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-yl, 2-(3-pyridinylmethyl)-, phenylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 639494-46-5 CAPLUS

CN Carbamic acid, (4-fluorophenyl)-, 2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 639494-49-8 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, 2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 639494-53-4 CAPLUS

CN Carbamic acid, [4-(methylthio)phenyl]-, 2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



IT	639483-23-1P	639483-24-2P	639483-25-3P
	639483-26-4P	639483-27-5P	639483-28-6P
	639483-29-7P	639483-30-0P	639483-31-1P
	639483-32-2P	639483-33-3P	639483-34-4P
	639483-35-5P	639483-36-6P	639483-37-7P
	639483-38-8P	639483-39-9P	639483-40-2P
	639483-41-3P	639483-42-4P	639483-43-5P
	639483-44-6P	639483-45-7P	639483-46-8P
	639483-47-9P	639483-48-0P	639483-49-1P
	639483-50-4P	639483-51-5P	639483-52-6P
	639483-53-7P	639483-54-8P	639483-55-9P
	639483-56-0P	639483-57-1P	639483-59-3P
	639483-60-6P	639483-61-7P	639483-62-8P
	639483-63-9P	639483-65-1P	639483-66-2P
	639483-67-3P	639483-68-4P	639483-69-5P
	639483-70-8P	639483-71-9P	639483-72-0P
	639483-73-1P	639483-74-2P	639483-75-3P
	639483-76-4P	639483-77-5P	639483-78-6P
	639483-79-7P	639483-80-0P	639483-81-1P
	639483-82-2P	639483-83-3P	639483-84-4P
	639483-85-5P	639483-86-6P	639483-87-7P
	639483-88-8P	639483-89-9P	639483-90-2P
	639483-91-3P	639483-92-4P	639483-93-5P
	639483-94-6P	639483-95-7P	639483-96-8P
	639483-97-9P	639483-98-0P	639483-99-1P
	639484-00-7P	639484-01-8P	639484-02-9P
	639484-03-0P	639484-04-1P	639484-05-2P
	639484-06-3P	639484-07-4P	639484-08-5P
	639484-09-6P	639484-10-9P	639484-11-0P
	639484-12-1P	639484-13-2P	639484-14-3P
	639484-15-4P	639484-16-5P	639484-17-6P
	639484-18-7P	639484-19-8P	639484-20-1P
	639484-21-2P	639484-22-3P	639484-23-4P
	639484-24-5P	639484-25-6P	639484-26-7P
	639484-27-8P	639484-28-9P	639484-29-0P
	639484-30-3P	639484-31-4P	639484-32-5P
	639484-33-6P	639484-34-7P	639484-35-8P
	639484-36-9P	639484-37-0P	639484-38-1P
	639484-39-2P	639484-40-5P	639484-41-6P
	639484-42-7P	639484-43-8P	639484-44-9P
	639484-45-0P	639484-46-1P	639484-47-2P
	639484-48-3P	639484-49-4P	639484-50-7P
	639484-51-8P	639484-52-9P	639484-53-0P
	639484-54-1P	639484-55-2P	639484-56-3P
	639484-57-4P	639484-58-5P	639484-60-9P
	639484-61-0P	639484-62-1P	639484-63-2P
	639484-64-3P	639484-65-4P	639484-66-5P
	639484-67-6P	639484-68-7P	639484-69-8P
	639484-70-1P	639484-71-2P	639484-72-3P
	639484-73-4P	639484-74-5P	639484-75-6P
	639484-76-7P	639484-77-8P	639484-78-9P
	639484-79-0P	639484-80-3P	639484-81-4P
	639484-82-5P	639484-83-6P	639484-84-7P



639484-85-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-substituted-2(arylalkyl)-1-azabicycloalkanes exhibiting activity at nicotinic acetylcholine receptors)

RN 639483-23-1 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(3-pyridinylmethyl)-, phenylcarbamate (ester), (2R,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-24-2 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(3-pyridinylmethyl)-, phenylcarbamate (ester), (2R,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-25-3 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(3-pyridinylmethyl)-, phenylcarbamate (ester), (2S,3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-26-4 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(3-pyridinylmethyl)-, phenylcarbamate (ester), (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-27-5 CAPLUS

CN Carbamic acid, (4-fluorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-28-6 CAPLUS

CN Carbamic acid, (4-fluorophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-29-7 CAPLUS

CN Carbamic acid, (4-fluorophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-30-0 CAPLUS

CN Carbamic acid, (4-fluorophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-31-1 CAPLUS

CN Carbamic acid, (4-chlorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-32-2 CAPLUS

CN Carbamic acid, (4-chlorophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-33-3 CAPLUS

CN Carbamic acid, (4-chlorophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-34-4 CAPLUS

CN Carbamic acid, (4-chlorophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-35-5 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-36-6 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-37-7 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-38-8 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-39-9 CAPLUS

CN Carbamic acid, (3-fluorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-40-2 CAPLUS

CN Carbamic acid, (3-fluorophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-41-3 CAPLUS

CN Carbamic acid, (3-fluorophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-42-4 CAPLUS

CN Carbamic acid, (3-fluorophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-43-5 CAPLUS

CN Carbamic acid, (3-chlorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-44-6 CAPLUS

CN Carbamic acid, (3-chlorophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-45-7 CAPLUS

CN Carbamic acid, (3-chlorophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-46-8 CAPLUS

CN Carbamic acid, (3-chlorophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639483-47-9 CAPLUS

CN Carbamic acid, (3-bromophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 639483-48-0 CAPLUS

CN Carbamic acid, (3-bromophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-49-1 CAPLUS

CN Carbamic acid, (3-bromophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-50-4 CAPLUS

CN Carbamic acid, (3-bromophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-51-5 CAPLUS

CN Carbamic acid, (2-fluorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-52-6 CAPLUS

CN Carbamic acid, (2-fluorophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-53-7 CAPLUS

CN Carbamic acid, (2-fluorophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-54-8 CAPLUS

CN Carbamic acid, (2-fluorophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-55-9 CAPLUS

CN Carbamic acid, (2-chlorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-56-0 CAPLUS

CN Carbamic acid, (2-chlorophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-57-1 CAPLUS

CN Carbamic acid, (2-chlorophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-59-3 CAPLUS

CN Carbamic acid, (2-chlorophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-60-6 CAPLUS

CN Carbamic acid, (2-bromophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-61-7 CAPLUS

CN Carbamic acid, (2-bromophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-62-8 CAPLUS

CN Carbamic acid, (2-bromophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-63-9 CAPLUS

CN Carbamic acid, (2-bromophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-65-1 CAPLUS

CN Carbamic acid, (3,4-dichlorophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-66-2 CAPLUS

CN Carbamic acid, (3,4-dichlorophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-67-3 CAPLUS

CN Carbamic acid, (3,4-dichlorophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-68-4 CAPLUS

CN Carbamic acid, (3,4-dichlorophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-69-5 CAPLUS

CN Carbamic acid, (2-methylphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-70-8 CAPLUS

CN Carbamic acid, (2-methylphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-71-9 CAPLUS

CN Carbamic acid, (2-methylphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-72-0 CAPLUS

CN Carbamic acid, (2-methylphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639483-73-1 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-2-yl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 639483-74-2 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-2-yl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-75-3 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-2-yl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-76-4 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-2-yl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-77-5 CAPLUS

CN Carbamic acid, (3-methylphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-78-6 CAPLUS

CN Carbamic acid, (3-methylphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-79-7 CAPLUS

CN Carbamic acid, (3-methylphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-80-0 CAPLUS

CN Carbamic acid, (3-methylphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-81-1 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-3-yl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-82-2 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-3-yl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-83-3 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-3-yl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-84-4 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-3-yl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-85-5 CAPLUS

CN Carbamic acid, (4-methylphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-86-6 CAPLUS

CN Carbamic acid, (4-methylphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-87-7 CAPLUS

CN Carbamic acid, (4-methylphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-88-8 CAPLUS

CN Carbamic acid, (4-methylphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-89-9 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-4-yl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-90-2 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-4-yl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-91-3 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-4-yl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-92-4 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-4-yl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-93-5 CAPLUS

CN Carbamic acid, (2-cyanophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-94-6 CAPLUS


CN Carbamic acid, (2-cyanophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639483-95-7 CAPLUS  
 CN Carbamic acid, (2-cyanophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 639483-96-8 CAPLUS  
 CN Carbamic acid, (2-cyanophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639483-97-9 CAPLUS  
 CN Carbamic acid, (3-cyanophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 639483-98-0 CAPLUS  
 CN Carbamic acid, (3-cyanophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639483-99-1 CAPLUS  
 CN Carbamic acid, (3-cyanophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 639484-00-7 CAPLUS  
 CN Carbamic acid, (3-cyanophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-01-8 CAPLUS

CN Carbamic acid, (4-cyanophenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-02-9 CAPLUS

CN Carbamic acid, (4-cyanophenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-03-0 CAPLUS


CN Carbamic acid, (4-cyanophenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639484-04-1 CAPLUS  
 CN Carbamic acid, (4-cyanophenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639484-05-2 CAPLUS  
 CN Carbamic acid, [3-(trifluoromethyl)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 639484-06-3 CAPLUS  
 CN Carbamic acid, [3-(trifluoromethyl)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-07-4 CAPLUS

CN Carbamic acid, [3-(trifluoromethyl)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-08-5 CAPLUS

CN Carbamic acid, [3-(trifluoromethyl)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-09-6 CAPLUS

CN Carbamic acid, [4-(dimethylamino)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-10-9 CAPLUS

CN Carbamic acid, [4-(dimethylamino)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-11-0 CAPLUS

CN Carbamic acid, [4-(dimethylamino)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-12-1 CAPLUS

CN Carbamic acid, [4-(dimethylamino)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-13-2 CAPLUS

CN Carbamic acid, (2-methoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-14-3 CAPLUS

CN Carbamic acid, (2-methoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-15-4 CAPLUS

CN Carbamic acid, (2-methoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-16-5 CAPLUS

CN Carbamic acid, (2-methoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-17-6 CAPLUS

CN Carbamic acid, (2-phenoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-18-7 CAPLUS

CN Carbamic acid, (2-phenoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-19-8 CAPLUS

CN Carbamic acid, (2-phenoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-20-1 CAPLUS

CN Carbamic acid, (2-phenoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639484-21-2 CAPLUS

CN Carbamic acid, [2-(methylthio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 639484-22-3 CAPLUS

CN Carbamic acid, [2-(methylthio)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-23-4 CAPLUS

CN Carbamic acid, [2-(methylthio)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-24-5 CAPLUS

CN Carbamic acid, [2-(methylthio)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-25-6 CAPLUS

CN Carbamic acid, [2-(phenylthio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-26-7 CAPLUS

CN Carbamic acid, [2-(phenylthio)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-27-8 CAPLUS

CN Carbamic acid, [2-(phenylthio)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-28-9 CAPLUS

CN Carbamic acid, [2-(phenylthio)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-29-0 CAPLUS

CN Carbamic acid, (3-methoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-30-3 CAPLUS

CN Carbamic acid, (3-methoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-31-4 CAPLUS

CN Carbamic acid, (3-methoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-32-5 CAPLUS

CN Carbamic acid, (3-methoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-33-6 CAPLUS

CN Carbamic acid, (3-methoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-34-7 CAPLUS

CN Carbamic acid, (3-phenoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-35-8 CAPLUS

CN Carbamic acid, (3-phenoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-36-9 CAPLUS

CN Carbamic acid, (3-phenoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-37-0 CAPLUS

CN Carbamic acid, [3-(methythio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-38-1 CAPLUS

CN Carbamic acid, [3-(methylthio)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-39-2 CAPLUS

CN Carbamic acid, [3-(methylthio)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-40-5 CAPLUS

CN Carbamic acid, [3-(methylthio)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-41-6 CAPLUS

CN Carbamic acid, [3-(phenylthio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-42-7 CAPLUS

CN Carbamic acid, [3-(phenylthio)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-43-8 CAPLUS

CN Carbamic acid, [3-(phenylthio)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-44-9 CAPLUS

CN Carbamic acid, [3-(phenylthio)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639484-45-0 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 639484-46-1 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-47-2 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-48-3 CAPLUS

CN Carbamic acid, (4-methoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-49-4 CAPLUS

CN Carbamic acid, (4-phenoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-50-7 CAPLUS

CN Carbamic acid, (4-phenoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-51-8 CAPLUS

CN Carbamic acid, (4-phenoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-52-9 CAPLUS

CN Carbamic acid, (4-phenoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-53-0 CAPLUS

CN Carbamic acid, [4-(methylthio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-54-1 CAPLUS

CN Carbamic acid, [4-(methylthio)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-55-2 CAPLUS

CN Carbamic acid, [4-(methylthio)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-56-3 CAPLUS

CN Carbamic acid, [4-(methylthio)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-57-4 CAPLUS

CN Carbamic acid, [4-(phenylthio)phenyl]-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-58-5 CAPLUS

CN Carbamic acid, [4-(phenylthio)phenyl]-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-60-9 CAPLUS

CN Carbamic acid, [4-(phenylthio)phenyl]-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-61-0 CAPLUS

CN Carbamic acid, [4-(phenylthio)phenyl]-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-62-1 CAPLUS

CN Carbamic acid, (2,4-dimethoxyphenyl)-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-63-2 CAPLUS

CN Carbamic acid, (2,4-dimethoxyphenyl)-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-64-3 CAPLUS


CN Carbamic acid, (2,4-dimethoxyphenyl)-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639484-65-4 CAPLUS  
 CN Carbamic acid, (2,4-dimethoxyphenyl)-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639484-66-5 CAPLUS  
 CN Carbamic acid, 2-thienyl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 639484-67-6 CAPLUS  
 CN Carbamic acid, 2-thienyl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-68-7 CAPLUS

CN Carbamic acid, 2-thienyl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-69-8 CAPLUS

CN Carbamic acid, 2-thienyl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 639484-70-1 CAPLUS

CN Carbamic acid, 3-thienyl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 639484-71-2 CAPLUS

CN Carbamic acid, 3-thienyl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-72-3 CAPLUS

CN Carbamic acid, 3-thienyl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-73-4 CAPLUS

CN Carbamic acid, 3-thienyl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-74-5 CAPLUS

CN Carbamic acid, benzo[b]thien-3-yl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-75-6 CAPLUS

CN Carbamic acid, benzo[b]thien-3-yl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-76-7 CAPLUS

CN Carbamic acid, benzo[b]thien-3-yl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-77-8 CAPLUS

CN Carbamic acid, benzo[b]thien-3-yl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-78-9 CAPLUS

CN Carbamic acid, 1-naphthalenyl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-79-0 CAPLUS

CN Carbamic acid, 1-naphthalenyl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-80-3 CAPLUS

CN Carbamic acid, 1-naphthalenyl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-81-4 CAPLUS

CN Carbamic acid, 1-naphthalenyl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-82-5 CAPLUS

CN Carbamic acid, 2-naphthalenyl-, (2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-83-6 CAPLUS

CN Carbamic acid, 2-naphthalenyl-, (2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-84-7 CAPLUS

CN Carbamic acid, 2-naphthalenyl-, (2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 639484-85-8 CAPLUS

CN Carbamic acid, 2-naphthalenyl-, (2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 195190-96-6 195191-06-1

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of 3-substituted-2(arylalkyl)-1-azabicycloalkanes exhibiting activity at nicotinic acetylcholine receptors)


RN 195190-96-6 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 195191-06-1 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-yl, phenylcarbamate (ester) (9CI) (CA INDEX NAME)



REFERENCE COUNT:



59

THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2004:2883 CAPLUS  
 DOCUMENT NUMBER: 140:59820  
 TITLE: Preparation of novel quinuclidine derivatives for  
 therapeutic use in medicinal compositions as M3  
 muscarinic receptor antagonists  
 INVENTOR(S): Prat Quinones, Maria; Buil Alberro, Maria Antonia;  
 Fernandez Forner, Maria Dolors  
 PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain  
 SOURCE: PCT Int. Appl., 82 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000840	A2	20031231	WO 2003-EP6472	20030618
WO 2004000840	A3	20071115		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
ES 2203327	A1	20040401	ES 2002-1439	20020621
ES 2203327	B1	20050616		
CA 2490082	A1	20031231	CA 2003-2490082	20030618
AU 2003279384	A1	20040106	AU 2003-279384	20030618
EP 1515968	A2	20050323	EP 2003-740284	20030618
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003012169	A	20050329	BR 2003-12169	20030618
CN 1675206	A	20050928	CN 2003-819327	20030618
JP 2005533799	T	20051110	JP 2004-514785	20030618
NZ 537252	A	20060728	NZ 2003-537252	20030618
RU 2321588	C2	20080410	RU 2005-101409	20030618
MX 2004PA12272	A	20050408	MX 2004-PA12272	20041207
ZA 2004010211	A	20050906	ZA 2004-10211	20041217
NO 2005000217	A	20050318	NO 2005-217	20050113
US 20060094751	A1	20060504	US 2005-518496	20050919
PRIORITY APPLN. INFO.:			ES 2002-1439	A 20020621
			WO 2003-EP6472	W 20030618
OTHER SOURCE(S):	MARPAT 140:59820			
GI				



AB Quinuclidine derivs., such as I and II [R = (CH<sub>2</sub>)<sub>m</sub>-A-(CH<sub>2</sub>)<sub>n</sub>-B; R<sub>1</sub> = unsubstituted, halo substituted, alkyl substituted, or cyano substituted



Ph, 2-thienylmethyl, 2-thienyl, 2-furylmethyl, 2-furyl, 3-thienylmethyl, 3-thienyl, 3-furylmethyl, 3-furyl; R2 = benzyl, phenethyl, 2-furylmethyl, 3-furylmethyl, 2-thienylmethyl or 3-thienylmethyl group or a straight or branched alkyl group having 3 or 8 carbon atoms, an alkenyl group having 3 to 8 carbons atoms, or a cycloalkyl group of 3 to 6 carbon atoms; A = CH2, R3C:CH, CH:CR3, CO, O, S, SO, SO2, NR3, CR3R4; B = O2CR3, CO2R3, cyano, etc.; R3, R4 = H, alkyl, R3R4 = alicyclic ring; X- = anion, such as Cl-, Br-, I- or F3CCO2-; m = 0-8, n = 0-4], and pharmaceutical compns. comprising them were prepared for use in therapy as antagonists of M3 muscarinic receptors (no biol. testing data presented) and are claimed for use in the treatment of respiratory, urol. and gastrointestinal diseases. Thus, butylphenylcarbamic acid (3R)-1-azabicyclo[2.2.2]oct-3-yl ester was prepared in 22% yield by refluxing (R)-3-quinuclidinol in toluene with sodium for 2h and then adding butylphenylcarbamoyl chloride and refluxing for an addnl. 1 h. Pharmaceutical compns. containing the prepared

quinuclidines

were presented.

IT 385367-13-5P 385367-28-2P 385367-46-4P

385367-47-5P 439909-77-0P 439910-43-7P

637744-75-3P 637744-77-5P 637744-79-7P


RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of novel quinuclidine derivs. for therapeutic use in medicinal compns. as M3 muscarinic receptor antagonists)

RN 385367-13-5 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 385367-28-2 CAPLUS

CN Carbamic acid, (3-fluorophenyl)[(3-fluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-46-4 CAPLUS

CN Carbamic acid, (3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-47-5 CAPLUS

CN Carbamic acid, N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-77-0 CAPLUS


CN Carbamic acid, phenyl(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439910-43-7 CAPLUS


CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.1]hept-4-yl ester (9CI) (CA INDEX NAME)



RN 637744-75-3 CAPLUS

CN Carbamic acid, [(5-bromo-2-thienyl)methyl](2,4,5-trifluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 637744-77-5 CAPLUS

CN Carbamic acid, (4-fluoro-2-methylphenyl)[(3-methyl-2-thienyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 637744-79-7 CAPLUS

CN Carbamic acid, (3-fluoro-4-methoxyphenyl)(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 17656-14-3P 17656-16-5P 385367-14-6P  
 385367-68-0P 385367-71-5P 385367-72-6P  
 385367-73-7P 385367-74-8P 385367-75-9P  
 385367-76-0P 439907-53-6P 439907-55-8P  
 439907-57-0P 439907-58-1P 439907-59-2P  
 439907-61-6P 439907-63-8P 439907-65-0P  
 439907-67-2P 439907-69-4P 439907-71-8P  
 439907-73-0P 439907-75-2P 439907-77-4P  
 439907-79-6P 439907-81-0P 439907-83-2P  
 439907-85-4P 439907-87-6P 439907-89-8P  
 439907-90-1P 439907-92-3P 439907-94-5P  
 439907-95-6P 439907-97-8P 439907-99-0P  
 439908-00-6P 439908-01-7P 439908-02-8P  
 439908-03-9P 439908-04-0P 439908-06-2P  
 439908-08-4P 439908-10-8P 439908-12-0P  
 439908-14-2P 439908-16-4P 439908-18-6P  
 439908-20-0P 439908-22-2P 439908-24-4P  
 439908-26-6P 439908-28-8P 439908-30-2P  
 439908-32-4P 439908-34-6P 439908-36-8P  
 439908-38-0P 439908-40-4P 439908-42-6P  
 439908-43-7P 439908-45-9P 439908-47-1P  
 439908-50-6P 439908-52-8P 439908-54-0P  
 439908-55-1P 439908-56-2P 439908-58-4P  
 439908-60-8P 439908-62-0P 439908-64-2P  
 439908-66-4P 439908-68-6P 439908-70-0P  
 439908-72-2P 439908-74-4P 439908-76-6P  
 439908-78-8P 439908-80-2P 439908-82-4P  
 439908-84-6P 439908-86-8P 439908-87-9P  
 439908-88-0P 439908-89-1P 439908-90-4P  
 439908-91-5P 439908-92-6P 439908-93-7P  
 439908-94-8P 439908-95-9P 439908-97-1P  
 439908-99-3P 439909-01-0P 439909-03-2P  
 439909-05-4P 439909-07-6P 439909-08-7P  
 439909-09-8P 439909-10-1P 439909-11-2P  
 439909-12-3P 439909-14-5P 439909-16-7P  
 439909-18-9P 439909-20-3P 439909-22-5P  
 439909-24-7P 439909-26-9P 439909-29-2P  
 439909-32-7P 439909-34-9P 439909-36-1P  
 439909-39-4P 439909-41-8P 439909-43-0P  
 439909-45-2P 439909-47-4P 439909-49-6P  
 439909-51-0P 439909-53-2P 439909-54-3P  
 439909-56-5P 439909-58-7P 439909-60-1P  
 439909-62-3P 439909-64-5P 439909-66-7P  
 439909-68-9P 439909-70-3P 439909-72-5P  
 439909-75-8P 439909-79-2P 439909-81-6P  
 439909-83-8P 439909-85-0P 439909-87-2P  
 439909-89-4P 439909-91-8P 439909-93-0P  
 439909-94-1P 439909-95-2P 439910-19-7P


439910-21-1P 439910-25-5P 439910-27-7P  
 439910-30-2P 439910-33-5P 439910-45-9P  
 637744-43-5P 637744-64-0P 637744-67-3P  
 637744-68-4P 637744-69-5P 637744-70-8P  
 637744-71-9P 637744-72-0P 637744-76-4P  
 637744-78-6P 637744-80-0P 637744-84-4P  
 637744-85-5P 637744-89-9P 637744-90-2P  
 637744-91-3P 637744-94-6P 637744-97-9P  
 637744-99-1P 637745-13-2P 637745-15-4P  
 637745-17-6P 637745-18-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel quinuclidine derivs. for therapeutic use in medicinal compns. as M3 muscarinic receptor antagonists)


RN 17656-14-3 CAPLUS

CN Carbamic acid, diphenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 17656-16-5 CAPLUS


CN Carbamic acid, ethylphenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 385367-14-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-68-0 CAPLUS


CN Carbamic acid, (cyclohexylmethyl)(2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-71-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyloxy]-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 385367-72-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(2-methylphenyl)(phenylmethyl)amino]carbonyloxy]-, iodide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-73-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(2-methylphenyl)[(2,4,5-trifluorophenyl)methyl]amino]carbonyloxy]-, iodide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-74-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl](3-methylphenyl)amino]carbonyloxy]-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 385367-75-9 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)(phenylmethyl)amino]carbonyloxy]-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-76-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(cyclohexylmethyl)(2-fluorophenyl)amino]carbonyloxy]-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.






RN 439907-53-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-52-5  
 CMF C22 H27 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439907-55-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-methyl-3-pentenyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-54-7

CMF C27 H35 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-57-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-56-9

CMF C30 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439907-58-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 439907-59-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 439907-61-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-hydroxyethyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-60-5

CMF C23 H29 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-63-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(1-methylethyl)-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-62-7

CMF C24 H31 N2 O2


Absolute stereochemistry.



CM 2


CRN 14477-72-6

CMF C2 F3 O2




RN 439907-65-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-propyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 439907-64-9  
 CMF C24 H31 N2 O2

Absolute stereochemistry.




CM 2  
 CRN 14477-72-6  
 CMF C2 F3 O2



RN 439907-67-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-cyanopropyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 439907-66-1  
 CMF C25 H30 N3 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-69-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclopropylmethyl)-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-68-3

CMF C25 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-71-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-ethoxyethyl)-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-70-7  
 CMF C25 H33 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439907-73-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(5-ethoxy-5-oxopentyl)-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-72-9  
 CMF C28 H37 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-75-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-phenylbutyl)-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-74-1

CMF C31 H37 N2 O2

Absolute stereochemistry.




CM 2

CRN 14477-72-6

CMF C2 F3 O2





RN 439907-77-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-fluorophenoxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-76-3

CMF C30 H34 F N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-79-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-hydroxypropyl)-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-78-5

CMF C24 H31 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-81-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-(acetyloxy)butyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-80-9

CMF C27 H35 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-83-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-oxo-4-(2-thienyl)butyl]-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-82-1  
 CMF C29 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439907-85-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-84-3  
 CMF C30 H35 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-87-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-86-5

CMF C28 H39 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-89-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-88-7

CMF C30 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439907-90-1 CAPLUS

CN Carbamic acid, (4-fluorophenyl)(phenylmethyl)-, (3R)-1-  
azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439907-92-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)(phenylmethyl)amino]carbonyloxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1)  
 (9CI) (CA INDEX NAME)

CM 1


CRN 439907-91-2  
 CMF C24 H28 F N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439907-94-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)(phenylmethyl)amino]carbonyloxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-93-4  
 CMF C30 H34 F N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439907-95-6 CAPLUS

CN Carbamic acid, (4-methylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439907-97-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-methylphenyl)(phenylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-96-7

CMF C25 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-99-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-methylphenyl)(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-98-9

CMF C31 H37 N2 O2

Absolute stereochemistry.




CM 2

CRN 14477-72-6

CMF C2 F3 O2






RN 439908-00-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2-methoxyethoxy)ethyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA  
INDEX NAME)


Absolute stereochemistry.



RN 439908-01-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenylethyl)-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA  
INDEX NAME)


Absolute stereochemistry.



RN 439908-02-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-  
1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-03-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-04-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 439908-06-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-cyanophenoxy)propyl]-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-05-1  
 CMF C31 H34 N3 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2



RN 439908-08-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(1-naphthalenyloxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-07-3

CMF C34 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-10-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(methylphenylamino)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-09-5

CMF C31 H38 N3 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-12-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-(phenylthio)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-11-9

CMF C30 H35 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-14-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-oxo-4-phenylbutyl)-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-13-1  
 CMF C31 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439908-16-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-  
 1-[3-(2,4,6-trimethylphenoxy)propyl]-, (3R)-, salt with trifluoroacetic  
 acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-15-3  
 CMF C33 H41 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-18-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2-chlorophenoxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-17-5

CMF C30 H34 Cl N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-20-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyloxy]-1-[3-[3-(trifluoromethyl)phenoxy]propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-19-7

CMF C31 H34 F3 N2 O3

Absolute stereochemistry.






CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-22-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-([1,1'-biphenyl]-4-yloxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-21-1

CMF C36 H39 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-24-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2,4-difluorophenoxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-23-3

CMF C30 H33 F2 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-26-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-methoxyphenoxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-25-5

CMF C31 H37 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-28-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-27-7


CMF C34 H41 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
CMF C2 F3 O2




RN 439908-30-2 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(1,3-benzodioxol-5-yloxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-29-9  
CMF C31 H35 N2 O5

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
CMF C2 F3 O2




RN 439908-32-4 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[2-(aminocarbonyl)phenoxy]propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-31-3  
CMF C31 H36 N3 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-34-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[3-(dimethylamino)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-33-5

CMF C32 H40 N3 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-36-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(acetylamino)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-35-7

CMF C32 H38 N3 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-38-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(methoxycarbonyl)phenoxy]propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-37-9

CMF C32 H37 N2 O5


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-40-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-nitrophenoxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-39-1

CMF C30 H34 N3 O5


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-42-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(hydroxymethyl)phenoxy]propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 439908-41-5

CMF C31 H37 N2 O4

Absolute stereochemistry.






CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439908-43-7 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-45-9 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 439908-47-1 CAPLUS  
 CN Carbamic acid, butylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 439908-50-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-methyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-49-3  
 CMF C19 H29 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439908-52-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(4-methyl-3-pentenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-51-7  
 CMF C24 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439908-54-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-53-9  
 CMF C27 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439908-55-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 439908-56-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 439908-58-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-hydroxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-57-3  
 CMF C20 H31 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439908-60-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(1-methylethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-59-5  
CMF C21 H33 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
CMF C2 F3 O2




RN 439908-62-0 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-propyl-  
, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-61-9  
CMF C21 H33 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
CMF C2 F3 O2




RN 439908-64-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(3-cyanopropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-63-1  
 CMF C22 H32 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439908-66-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(cyclopropylmethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-65-3  
 CMF C22 H33 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-68-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (butylphenylamino)carbonyl]oxy]-1-(2-ethoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-67-5

CMF C22 H35 N2 O3

Absolute stereochemistry.




CM 2

CRN 14477-72-6

CMF C2 F3 O2






RN 439908-70-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(5-ethoxy-5-oxopentyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-69-7  
 CMF C25 H39 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439908-72-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(3-hydroxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-71-1  
 CMF C21 H33 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-74-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[3-(1H-pyrrol-1-yl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 439908-73-3

CMF C25 H36 N3 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-76-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-(acetyloxy)butyl]-3-  
 [[(butylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid  
 (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-75-5  
 CMF C24 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439908-78-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[4-oxo-  
 4-(2-thienyl)butyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
 (CA INDEX NAME)

CM 1

CRN 439908-77-7  
 CMF C26 H35 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-80-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(4-phenylbutyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-79-9

CMF C28 H39 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-82-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (butylphenylamino)carbonyl]oxy]-1-[3-(3-hydroxyphenoxy)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 439908-81-3

CMF C27 H37 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-84-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (butylphenylamino)carbonyl]oxy]-1-heptyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-83-5

CMF C25 H41 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-86-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (butylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 439908-85-7

CMF C27 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439908-87-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-88-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[2-(2-methoxyethoxy)ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-89-1 CAPLUS

CN Carbamic acid, butyl(4-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-90-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[3-(4-fluorophenoxy)propyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-91-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br<sup>-</sup>

RN 439908-92-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)




Absolute stereochemistry.



RN 439908-93-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[butylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-94-8 CAPLUS

CN Carbamic acid, phenyl(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-95-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 439908-97-1 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-96-0  
 CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2



RN 439908-99-3 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenylpropyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-98-2

CMF C28 H33 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-01-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenyl-2-propenyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-00-9

CMF C28 H31 N2 O2 S


Absolute stereochemistry.  
Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-03-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-02-1

CMF C28 H33 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-05-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-04-3  
 CMF C28 H33 N2 O4 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-07-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-06-5  
 CMF C26 H37 N2 O2 S

Absolute stereochemistry.



CM 2


CRN 14477-72-6  
CMF C2 F3 O2



RN 439909-08-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-09-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 439909-10-1 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 439909-11-2 CAPLUS  
 CN Carbamic acid, phenyl(2-phenylethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439909-12-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 439909-14-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-13-4  
 CMF C25 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2



RN 439909-16-7 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid




(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-15-6

CMF C31 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-18-9 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-17-8


CMF C30 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
CMF C2 F3 O2




RN 439909-20-3 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-19-0  
CMF C31 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
CMF C2 F3 O2




RN 439909-22-5 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-21-4  
CMF C31 H35 N2 O2


Absolute stereochemistry.  
Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-24-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-23-6

CMF C31 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-26-9 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid  
 (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-25-8  
 CMF C31 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-29-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid  
 (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-28-1  
 CMF C29 H41 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-32-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-31-6

CMF C29 H35 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-34-9 CAPLUS

CN Carbamic acid, pentylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 439909-36-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[ (pentylphenylamino)carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 439909-39-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (pentylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-38-3

CMF C28 H39 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-41-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (pentylphenylamino)carbonyl]oxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-40-7

CMF C27 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-43-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (pentylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-42-9  
 CMF C28 H39 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-45-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (pentylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-44-1  
 CMF C28 H37 N2 O2

Absolute stereochemistry.  
 Double bond geometry unknown.






CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-47-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(pentylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 439909-46-3

CMF C28 H39 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-49-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-  
 [[(pentylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid  
 (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-48-5  
 CMF C28 H39 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-51-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[pentylphenylamino)carbonyl]oxy  
 ]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-50-9  
 CMF C26 H43 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-53-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (pentylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-52-1

CMF C26 H37 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-54-3 CAPLUS

CN Carbamic acid, 4-pentenylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439909-56-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-pentenylphenylamino)carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-55-4

CMF C22 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-58-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-pentenylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-57-6

CMF C28 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-60-1 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-pentenylphenylamino)carbonyl]oxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-59-8

CMF C27 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-62-3 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-pentenylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-61-2

CMF C28 H37 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-64-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-pentenylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 439909-63-4

CMF C28 H35 N2 O2

Absolute stereochemistry.


Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-66-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[4-pentenylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1)  
(9CI) (CA INDEX NAME)

CM 1

CRN 439909-65-6

CMF C28 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-68-9 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[4-pentenylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-67-8  
 CMF C28 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-70-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[4-pentenylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-69-0  
 CMF C26 H41 N2 O2




Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-72-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[4-pentenylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-71-4

CMF C20 H29 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-75-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (4-pentenylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
 (CA INDEX NAME)

CM 1


CRN 439909-74-7  
 CMF C26 H35 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-79-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
 (CA INDEX NAME)

CM 1

CRN 439909-78-1  
 CMF C22 H27 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-81-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-80-5

CMF C28 H33 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-83-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenylpropyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-82-7  
 CMF C28 H33 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-85-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenyl-2-propenyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-84-9  
 CMF C28 H31 N2 O2 S


Absolute stereochemistry.  
 Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-87-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-86-1

CMF C28 H33 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-89-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-88-3  
 CMF C28 H33 N2 O4 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-91-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-90-7  
 CMF C26 H37 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-93-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-92-9

CMF C20 H25 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-94-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-95-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 439910-19-7 CAPLUS



CN Carbamic acid, cyclopentyl(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 439910-21-1 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[cyclopentyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439910-20-0

CMF C21 H31 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439910-25-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[cyclopentyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439910-24-4  
CMF C27 H37 N2 O2 S

Absolute stereochemistry.




CM 2

CRN 14477-72-6  
CMF C2 F3 O2



RN 439910-27-7 CAPLUS  
CN Carbamic acid, (2-furanylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 439910-30-2 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-furanylmethyl)phenylamino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439910-29-9  
CMF C22 H27 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439910-33-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-furanylmethyl)phenylamino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 439910-32-4

CMF C28 H33 N2 O3


Absolute stereochemistry.




CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439910-45-9 CAPLUS  
 CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester  
 (9CI) (CA INDEX NAME)



RN 637744-43-5 CAPLUS  
 CN Formic acid, compd. with 1-azabicyclo[2.2.1]heptyl N-phenyl-N-(phenylmethyl)carbamate (1:1) (CA INDEX NAME)


CM 1

CRN 439910-43-7  
 CMF C20 H22 N2 O2




CM 2

CRN 64-18-6  
 CMF C H2 O2




RN 637744-64-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide  
 (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 637744-67-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3-fluorophenyl)methyl]amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 637744-68-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3-fluorophenyl)methyl]amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.





RN 637744-69-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 637744-70-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 637744-71-9 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(cyclohexylmethyl)(2-fluorophenyl)amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)-  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 637744-72-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(cyclohexylmethyl)(2-fluorophenyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)-  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 637744-76-4 CAPLUS  
 CN Formic acid, compd. with (3R)-1-azabicyclo[2.2.2]octyl  
 N-[(5-bromo-2-thienyl)methyl]-N-(2,4,5-trifluorophenyl)carbamate (1:1)  
 (CA INDEX NAME)

CM 1


CRN 637744-75-3  
 CMF C19 H18 Br F3 N2 O2 S

Absolute stereochemistry.



CM 2


CRN 64-18-6  
 CMF C H2 O2



RN 637744-78-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluoro-2-methylphenyl)[(3-methyl-2-thienyl)methyl]amino]carbonyloxy]-1-(2-phenoxyethyl)-, bromide (1:1),  
 (3R)- (CA INDEX NAME)

Absolute stereochemistry.






● Br<sup>-</sup>

RN 637744-80-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluoro-4-methoxyphenyl)(3-thienylmethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.  
 Double bond geometry unknown.




● Br<sup>-</sup>

RN 637744-84-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(pentylphenylamino)carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637744-83-3  
 CMF C22 H33 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 637744-85-5 CAPLUS

CN Formic acid, compd. with 1-azabicyclo[2.2.2]octyl N-phenyl-N-(phenylmethyl)carbamate (1:1) (CA INDEX NAME)

CM 1

CRN 439910-45-9


CMF C21 H24 N2 O2



CM 2

CRN 64-18-6


CMF C H2 O2



RN 637744-89-9 CAPLUS

CN Carbamic acid, butyl(2,5-difluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 637744-90-2 CAPLUS

CN Carbamic acid, (2,6-difluorophenyl)-4-pentenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 637744-91-3 CAPLUS

CN Carbamic acid, cyclopentyl[(4,5-dimethyl-2-thienyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 637744-94-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl](2,4,5-trifluorophenyl)amino]carbonyloxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637744-93-5

CMF C28 H29 Br F3 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 637744-97-9 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluoro-2-methylphenyl)[(3-methyl-2-thienyl)methyl]amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637744-96-8

CMF C29 H34 F N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 637744-99-1 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluoro-4-methoxyphenyl)(3-thienylmethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 637744-98-0  
 CMF C29 H32 F N2 O3 S

Absolute stereochemistry.  
 Double bond geometry unknown.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 637745-13-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[butyl(2,5-difluorophenyl)amino]carbonyl]oxy]-1-heptyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637745-12-1  
 CMF C25 H39 F2 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 637745-15-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-cyanopropyl)-3-[[[(2,6-difluorophenyl)-4-pentenylamino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 637745-14-3

CMF C23 H30 F2 N3 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 637745-17-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[cyclopentyl[(4,5-dimethyl-2-thienyl)methyl]amino]carbonyl]oxy]-1-methyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 637745-16-5  
 CMF C21 H33 N2 O2 S

Absolute stereochemistry.




CM 2

CRN 14477-72-6  
 CMF C2 F3 O2



RN 637745-18-7 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.





ACCESSION NUMBER: 2003:678653 CAPLUS  
 DOCUMENT NUMBER: 139:207821  
 TITLE: Use of cyclooxygenase inhibitors and antimuscarinic agents for the treatment of incontinence  
 INVENTOR(S): Versi, Ebrahim  
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA  
 SOURCE: PCT Int. Appl., 51 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070233	A1	20030828	WO 2003-US4561	20030214
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2475374	A1	20030828	CA 2003-2475374	20030214
AU 2003211078	A1	20030909	AU 2003-211078	20030214
EP 1476146	A1	20041117	EP 2003-742765	20030214
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003007772	A	20041207	BR 2003-7772	20030214
CN 1633283	A	20050629	CN 2003-804160	20030214
JP 2005526040	T	20050902	JP 2003-569190	20030214
EP 1915992	A1	20080430	EP 2008-101136	20030214
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, SE, SI, SK, TR			
US 20030191172	A1	20031009	US 2003-368091	20030218
MX 2004PA08037	A	20041126	MX 2004-PA8037	20040818
ZA 2004006148	A	20060531	ZA 2004-6148	20060317
PRIORITY APPLN. INFO.:			US 2002-357888P	P 20020219
			EP 2003-742765	A3 20030214
			WO 2003-US4561	W 20030214
AB	The invention provides a method for the use of a cyclooxygenase-2 inhibitor, alone or in combination with an antimuscarinic agent, for the treatment or prophylaxis of a urinary incontinence condition in a subject in need of such treatment or prevention, comprising administering to the subject an effective amount of the cyclooxygenase-2 inhibitor and, optionally, the antimuscarinic agent.			
IT	171722-81-9, YM-46303 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (cyclooxygenase inhibitors and antimuscarinic agents for treatment of incontinence)			
RN	171722-81-9 CAPLUS			
CN	Carbamic acid, N-[1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-4-yl ester, hydrochloride (1:1) (CA INDEX NAME)			



● HCl

REFERENCE COUNT:

10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:511328 CAPLUS

DOCUMENT NUMBER: 139:85531

TITLE: Preparation of 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives

INVENTOR(S): Catena Ruiz, Juan Lorenzo; Farrerons Gallemi, Carles; Fernandez Serrat, Anna; Miquel Bono, Ignacio Jose; Balsa Lopez, Dolors; Lagunas Arnal, Carmen; Salcedo Roca, Carolina; Toledo Mesa, Natividad; Fernandez Garcia, Andres

PATENT ASSIGNEE(S): Laboratorios S.A.L.V.A.T., S.A., Spain

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003053966	A2	20030703	WO 2002-EP14470	20021218
WO 2003053966	A3	20031113		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2470956	C	20030703	CA 2002-2470956	20021218
AU 2002361158	A1	20030709	AU 2002-361158	20021218
EP 1461336	A2	20040929	EP 2002-796673	20021218
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002015348	A	20041116	BR 2002-15348	20021218
HU 2005000107	A2	20050530	HU 2005-107	20021218
JP 2005516954	T	20050609	JP 2003-5546821	20021218
CN 1832948	A	20060913	CN 2002-827836	20021218
MX 2004PA06206	A	20041206	MX 2004-PA6206	20040621
NO 2004003064	A	20040917	NO 2004-3064	20040719
US 20050043349	A1	20050224	US 2004-499130	20041012
PRIORITY APPLN. INFO.:			ES 2002-43	A 20011220
			WO 2002-EP14470	W 20021218

OTHER SOURCE(S): MARPAT 139:85531

GI



AB The title compds. I (R1, R2 and R3 = H, OH, NO2, SH, CN, F, Cl, Br, I,

COOH, CONH<sub>2</sub>, (C1-C4)-alkoxycarbonyl, (C1-C4)-alkylsulfanyl, (C1-C4)-alkylsulfinyl, (C1-C4)-alkylsulfonyl, (C1-C4)-alkoxyl optionally substituted with one or several F, and (C1-C4)-alkyl optionally substituted with one or several F or OH; R<sub>4</sub> = cycloalkyl, Ph, heteroaryl or a bicyclic ring system; R<sub>5</sub> = cycloalkyl, (C5-C10)-alkyl, a substituted (C1-C10)-alkyl; and X- = physiol. acceptable anion) were prepared. I is a selective muscarinic M<sub>3</sub> receptor antagonists vs. M<sub>2</sub> receptor and may be used for the treatment of urinary incontinence (particularly, the one caused by overactive bladder), irritable bowel syndrome, and respiratory disorders (particularly, chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema, and rhinitis), as well as in ophthalmic interventions. Thus, (R)-benzylphenylcarbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester hydrochloride was treated with bromocyclopropane to give (R)-I (R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> = H, R<sub>4</sub> = Ph, R<sub>5</sub> = cyclopropylmethyl, X = Br). The M<sub>2</sub>/M<sub>3</sub> ratio of (R)-I (R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> = H, R<sub>4</sub> = 4-FC<sub>6</sub>H<sub>4</sub>, R<sub>5</sub> = 3-phenoxypropyl, X = Br) was 80.

IT 552830-52-1P 552830-53-2P 552830-54-3P  
 552830-55-4P 552830-56-5P 552830-57-6P  
 552830-58-7P 552830-59-8P 552830-60-1P  
 552830-61-2P 552830-62-3P 552830-63-4P  
 552830-64-5P 552830-65-6P 552830-66-7P  
 552830-67-8P 552830-68-9P 552830-69-0P  
 552830-70-3P 552830-71-4P 552830-72-5P  
 552830-73-6P 552830-74-7P 552830-75-8P  
 552830-76-9P 552830-77-0P 552830-78-1P  
 552830-79-2P 552830-80-5P 552830-81-6P  
 552830-82-7P 552830-83-8P 552830-84-9P  
 552830-85-0P 552830-86-1P 552830-87-2P  
 552830-88-3P 552830-89-4P 552830-90-7P  
 552830-91-8P 552830-92-9P 552830-93-0P  
 552830-94-1P 552830-95-2P 552830-96-3P  
 552830-97-4P 552830-98-5P 552830-99-6P  
 552831-00-2P 552831-01-3P 552831-02-4P  
 552831-03-5P 552831-04-6P 552831-05-7P  
 552831-06-8P 552831-07-9P 552831-08-0P  
 552831-09-1P 552831-10-4P 552831-11-5P  
 552831-12-6P 552831-13-7P 552831-14-8P  
 552831-15-9P 552831-16-0P 552831-17-1P  
 552831-18-2P 552831-19-3P 552831-20-6P  
 552831-21-7P 552831-22-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivs. as muscarinic receptor antagonists)

RN 552830-52-1 CAPLUS



CN 1-Azoniabicyclo[2.2.2]octane, 1-cyclopropyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-53-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[(2-chlorophenyl)methyl]-3-  
 [[phenyl(phenylmethyl)amino]carbonyloxy]-, chloride (1:1), (3R)- (CA  
 INDEX NAME)

Absolute stereochemistry.




RN 552830-54-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[[[3-(methylthio)-1H-1,2,4-triazol-5-  
 yl]thio]methyl]-3-[[phenyl(phenylmethyl)amino]carbonyloxy]-, chloride  
 (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-55-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-ethoxy-2-oxoethyl)-3-  
 [[phenyl(phenylmethyl)amino]carbonyloxy]-, bromide (1:1), (3R)- (CA  
 INDEX NAME)

Absolute stereochemistry.



RN 552830-56-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-  
 [[[3-methylphenyl](phenylmethyl)amino]carbonyloxy]-, bromide (1:1),  
 (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-57-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-[[[(3-fluorophenyl)(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-58-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyl]oxy]-1-[2-(3-methylphenyl)ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552830-59-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(4-ethoxyphenyl)ethyl]-3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-60-1 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyloxy]-1-[2-(4-nitrophenyl)ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.






RN 552830-61-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[(2,4-difluorophenyl)thio]ethyl]-3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-62-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl]phenylamino]carbonyloxy]-1-(3-phenoxypropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-63-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclobutylmethyl)-3-[[[(4-fluorophenyl)methyl](3-methylphenyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-64-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(3,4-dimethoxyphenyl)ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-65-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-(4-methoxyphenyl)-2-oxoethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-66-7 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-(1H-pyrrol-2-yl)ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-67-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552830-68-9 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-(3-methoxyphenoxy)-2-oxoethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-69-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(cyclopentylamino)-2-oxoethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-70-3 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[(2-fluorophenyl)amino]-2-oxoethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-71-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[[4-(acetylamino)phenyl]thio]ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552830-72-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[(2,3-dimethylphenyl)thio]ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-73-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-[(1-methyl-1H-imidazol-2-yl)thio]ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-74-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-[(2-methoxyphenyl)sulfinyl]ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552830-75-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-[(2-methoxyphenyl)thio]-2-oxoethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-76-9 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(benzoyloxy)ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.






● Br<sup>-</sup>

RN 552830-77-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(benzoylamino)ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Cl<sup>-</sup>


RN 552830-78-1 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-79-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-[(phenylsulfonyl)amino]ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-80-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2-cyanophenoxy)propyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-81-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-(3-nitrophenoxy)propyl]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-82-7 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-[(5-methyl-2-pyrimidinyl)oxy]propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-83-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-(2-pyridinylthio)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-84-9 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2-benzoxazolylthio)propyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-85-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-[(2-fluorophenyl)sulfonyl]propyl]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552830-86-1 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[acetyl(4-chlorophenyl)amino]propyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Cl<sup>-</sup>

RN 552830-87-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-[(4-fluorophenyl)[(phenylmethoxy)carbonyl]amino]propyl]-, chloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● Cl<sup>-</sup>

RN 552830-88-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-1-[3-oxo-3-(phenylamino)propyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Cl<sup>-</sup>

RN 552830-89-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(benzoyloxy)propyl]-3-[[[(2-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br<sup>-</sup>

RN 552830-90-7 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-[[4-(acetylamino)phenyl]thio]ethyl]-3-[[[(3-fluorophenyl)[(4-fluorophenyl)methyl]amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 552830-91-8 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3,4-difluorophenyl)methyl]phenylamino]carbonyloxy]-1-[3-(4-fluorophenoxy)-2-hydroxypropyl]-, hydroxide, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 552830-92-9 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(3-chloro-5-fluorophenyl)ethyl]-3-[[[(3,4-difluorophenyl)methyl](2-fluorophenyl)amino]carbonyloxy]-,



chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-93-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-cyclohexylethyl)-3-[[[(3,4-difluorophenyl)methyl](2-fluorophenyl)amino]carbonyl]oxy]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-94-1 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3,4-difluorophenyl)methyl](2-fluorophenyl)amino]carbonyl]oxy]-1-[2-(phenylsulfonyl)ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552830-95-2 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3,4-difluorophenyl)methyl](3-methylphenyl)amino]carbonyloxy]-1-[2-(phenylthio)ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552830-96-3 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3,4-difluorophenyl)methyl](3-methylphenyl)amino]carbonyloxy]-1-[3-[(4-fluorophenyl)thio]propyl]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 552830-97-4 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3,4-difluorophenyl)methyl](3-fluorophenyl)amino]carbonyloxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)-  
(CA INDEX NAME)

Absolute stereochemistry.




● Br<sup>-</sup>

RN 552830-98-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3,4-difluorophenyl)methyl](3-fluorophenyl)amino]carbonyloxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br<sup>-</sup>

RN 552830-99-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclopropylmethyl)-3-[[[(2-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyloxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552831-00-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(phenylmethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552831-01-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-[2-(phenylthio)ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Cl<sup>-</sup>

RN 552831-02-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-1-(3-phenoxypropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br<sup>-</sup>

RN 552831-03-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3,4-difluorophenoxy)propyl]-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN	552831-04-6	CAPLUS
CN	1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-methylphenyl)(2-thienylmethyl)amino]carbonyl]oxy]-1-(2-oxo-2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)	


Absolute stereochemistry.



● Br<sup>-</sup>

RN 552831-05-7 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-methylphenyl)(2-thienylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br<sup>-</sup>

RN 552831-06-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)(2-thienylmethyl)amino]carbonyl]oxy]-1-(phenylmethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.






RN 552831-07-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclobutylmethyl)-3-[[[(3-fluorophenyl)(2-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552831-08-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[[(3-methyl-2-thienyl)methyl]phenylamino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552831-09-1 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-bromo-2-thienyl)methyl]phenylamino]carbonyloxy]-1-(cyclopropylmethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552831-10-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-bromo-2-thienyl)methyl]phenylthio]carbonyloxy]-1-(phenylthio)methyl-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552831-11-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-3-  
 [[[(5-methyl-2-thienyl)methyl]phenylamino]carbonyl]oxy]-, bromide (1:1),  
 (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552831-12-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-chloro-2-thienyl)methyl](2-  
 fluorophenyl)amino]carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)-  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 552831-13-7 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl]phenylamino]carbonyl]oxy]-1-(cyclopropylmethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552831-14-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl]phenylamino]carbonyl]oxy]-1-[2-(phenylthio)ethyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Cl<sup>-</sup>

RN 552831-15-9 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl](3-methylphenyl)amino]carbonyloxy]-1-[(phenylthio)methyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● Cl<sup>-</sup>


RN 552831-16-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl](4-fluorophenyl)amino]carbonyloxy]-1-(cyclopropylmethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 552831-17-1 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl](4-fluorophenyl)amino]carbonyl]oxy]-1-(2-oxo-2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552831-18-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(5-bromo-2-thienyl)methyl](4-fluorophenyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552831-19-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclobutylmethyl)-3-[[[(3-fluorophenyl)(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552831-20-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(3-fluorophenyl)(3-thienylmethyl)amino]carbonyl]oxy]-1-(2-oxo-2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 552831-21-7 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(cyclohexylmethyl)phenylamino]carbonyl]oxy]-1-(2-oxo-2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 552831-22-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(cyclohexylmethyl)phenylamino]carbonyl]oxy]-1-(3-phenoxypropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.





● Br<sup>-</sup>

IT 552860-70-5 552860-71-6 552860-72-7  
 552860-73-8 552860-75-0 552860-76-1  
 552860-77-2 552860-78-3 552860-79-4  
 552860-80-7 552860-81-8 552860-82-9  
 552860-83-0


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivs. as muscarinic receptor antagonists)

RN 552860-70-5 CAPLUS

CN Carbamic acid, (3-methylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552860-71-6 CAPLUS

CN Carbamic acid, (3-fluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-72-7 CAPLUS  
 CN Carbamic acid, [(4-fluorophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-73-8 CAPLUS  
 CN Carbamic acid, [(4-fluorophenyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-75-0 CAPLUS  
CN Carbamic acid, (2-fluorophenyl)[(4-fluorophenyl)methyl]-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



● HCl

RN 552860-76-1 CAPLUS  
CN Carbamic acid, (3-fluorophenyl)[(4-fluorophenyl)methyl]-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



● HCl

RN 552860-77-2 CAPLUS  
CN Carbamic acid, [(3,4-difluorophenyl)methyl]phenyl-, (3R)-1-  
azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-78-3 CAPLUS  
 CN Carbamic acid, [(3,4-difluorophenyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-79-4 CAPLUS  
 CN Carbamic acid, [(3,4-difluorophenyl)methyl](2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552860-80-7 CAPLUS  
 CN Carbamic acid, [(3,4-difluorophenyl)methyl](3-fluorophenyl)-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX  
 NAME)


Absolute stereochemistry.



● HCl

RN 552860-81-8 CAPLUS  
 CN Carbamic acid, (2-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX  
 NAME)


Absolute stereochemistry.



● HCl

RN 552860-82-9 CAPLUS  
 CN Carbamic acid, N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (1:1) (CA INDEX  
 NAME)


Absolute stereochemistry.



● HCl

RN 552860-83-0 CAPLUS  
 CN Carbamic acid, (cyclohexylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl  
 ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 385367-79-3P 552831-24-0P 552831-25-1P  
 552831-26-2P 552831-27-3P 552831-28-4P  
 552831-29-5P 552831-30-8P 552831-31-9P  
 552831-32-0P 552831-33-1P 552831-34-2P  
 552831-35-3P 552831-36-4P 552831-37-5P  
 552831-38-6P 552831-39-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivs. as muscarinic receptor antagonists)

RN 385367-79-3 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 552831-24-0 CAPLUS

CN Carbamic acid, (3-methylphenyl)(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552831-25-1 CAPLUS

CN Carbamic acid, (2-fluorophenyl)(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 552831-26-2 CAPLUS

CN Carbamic acid, (3-fluorophenyl)(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-27-3 CAPLUS

CN Carbamic acid, [(4-methyl-2-thienyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HCl

RN 552831-28-4 CAPLUS  
 CN Carbamic acid, [(4-bromo-2-thienyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552831-29-5 CAPLUS  
 CN Carbamic acid, [(5-methyl-2-thienyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552831-30-8 CAPLUS  
 CN Carbamic acid, [(5-chloro-2-thienyl)methyl](2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552831-31-9 CAPLUS  
 CN Carbamic acid, [(5-bromo-2-thienyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-32-0 CAPLUS

CN Carbamic acid, [(5-bromo-2-thienyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-33-1 CAPLUS

CN Carbamic acid, (3-fluorophenyl)(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-34-2 CAPLUS

CN Carbamic acid, (2-fluorophenyl)[(3-methyl-2-thienyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552831-35-3 CAPLUS  
 CN Carbamic acid, (2-fluorophenyl)[(5-methyl-2-thienyl)methyl]-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX  
 NAME)


Absolute stereochemistry.



● HCl

RN 552831-36-4 CAPLUS  
 CN Carbamic acid, [(5-chloro-2-thienyl)methyl](3-fluorophenyl)-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX  
 NAME)


Absolute stereochemistry.



● HCl

RN 552831-37-5 CAPLUS  
 CN Carbamic acid, [(5-ethyl-2-thienyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 552831-38-6 CAPLUS  
 CN Carbamic acid, phenyl(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 552831-39-7 CAPLUS

CN Carbamic acid, (3-methylphenyl)(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

L3 ANSWER 16 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2002:615577 CAPLUS  
 DOCUMENT NUMBER: 137:169536  
 TITLE: Preparation of aryl-substituted tetrahydropyrimidines  
 and related compounds as melanocortin-4 receptor  
 binding compounds  
 INVENTOR(S): Maguire, Martin P.; Dai, Mingshi; Vos, Tricia J.  
 PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc., USA  
 SOURCE: PCT Int. Appl., 228 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002062766	A2	20020815	WO 2002-US3566	20020207
WO 2002062766	A3	20021003		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 6699873 B1 20040302 US 2001-778468 20010207 AU 2002250029 A1 20020819 AU 2002-250029 20020207 EP 1363890 A2 20031126 EP 2002-718920 20020207 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR PRIORITY APPLN. INFO.: US 2001-778468 A 20010207 US 1999-147288P P 19990804 US 2000-223277P P 20000803 US 2000-632309 A2 20000804 WO 2002-US3566 W 20020207 OTHER SOURCE(S): MARPAT 137:169536 GI				



AB Title compds. I [wherein A and B = independently (un)substituted biaryl, (hetero)aryl, Ph, (cyclo)alkyl, (cyclo)alkoxy, alkenyl, alkynyl, OH, acyl(oxy), carbamoyl, amino, thiol, amidino, imino, NO<sub>2</sub>, N<sub>3</sub>, etc.; L1 and L2 = covalent bond or (un)substituted alkyl optionally interrupted by O, S, or N; r = covalent bond, CH, CH<sub>2</sub>, CHR<sub>1</sub>, CR<sub>1</sub>R<sub>2</sub>, or H; t = CH, CH<sub>2</sub>, CHR<sub>3</sub>, CR<sub>3</sub>R<sub>4</sub>, or H; s = CHR<sub>5</sub>, CR<sub>5</sub>R<sub>6</sub>, or absent; R = H, (un)substituted alkyl,

arylalkyl, or heteroalkyl, and may optionally be linked to A, B, L1, or L2; R1-R6 = independently (un)substituted alkyl, halo, thiol, thioether, thioalkyl, alkoxy, and may be optionally linked to each other to form addnl. ring moieties, e.g., quinoxaliny; or pharmaceutically acceptable salts thereof] were prepared as melanocortin-4 receptor binding (MC4-R) compds. For example, stirring a solution of  $\alpha$ -tolunitrile with diisopropylamine and BuLi in hexanes at  $-78^{\circ}$  under nitrogen for 1 h, followed by addition of HMPA and 1-chloromethylnaphthalene in THF, afforded 2-(2-naphthalen-1-ylethyl)benzonitrile. Heating the benzonitrile with 1,3-diaminopropane in the presence of H<sub>2</sub>S at  $80^{\circ}$  for 72 h gave the tetrahydropyrimidinyl cycloaddn. product II. The latter exhibited exemplary inhibition of MC4-R in a scintillation proximity assay. I are useful for the treatment of disorders associated with pigmentation, bones, or weight loss (no data).


IT 325826-44-6P, [2-(Naphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester 325826-51-5P, [2-(2-Methylnaphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester 326484-34-8P 326484-38-2P 326484-48-4P 326484-49-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(MC4-R binding compound; preparation of aryl-substituted tetrahydropyrimidines and related compds. as melanocortin-4 receptor binding compds. for treatment of pigmentation, bone, and weight loss disorders)

RN 325826-44-6 CAPLUS


CN Carbamic acid, [2-[(1-naphthalenylmethyl)thio]phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 325826-51-5 CAPLUS

CN Carbamic acid, [2-[(2-methyl-1-naphthalenyl)methyl]thio]phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)






RN 326484-34-8 CAPLUS  
 CN Carbamic acid, [2-[(1-naphthalenylmethyl)thio]phenyl]-,  
 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-44-6  
 CMF C25 H26 N2 O2 S



CM 2


CRN 64-18-6  
 CMF C H2 O2

$\text{O}=\text{CH}-\text{OH}$

RN 326484-38-2 CAPLUS  
 CN Carbamic acid, [2-[[5-bromo-2-methoxyphenyl)methyl]thio]phenyl]-,  
 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1


CRN 326484-37-1  
 CMF C22 H25 Br N2 O3 S



CM 2

CRN 64-18-6

CMF C H2 O2




RN 326484-48-4 CAPLUS

CN Carbamic acid, [2-[(2-naphthalenylmethyl)thio]phenyl]-,  
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326484-47-3


CMF C25 H26 N2 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2




RN 326484-49-5 CAPLUS

CN Carbamic acid, [2-[[2-methyl-1-naphthalenyl)methyl]thio]phenyl]-,  
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-51-5


CMF C26 H28 N2 O2 S



CM 2


CRN 64-18-6

CMF C H2 O2




L3 ANSWER 17 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2002:504786 CAPLUS  
 DOCUMENT NUMBER: 137:79107  
 TITLE: Preparation of quinuclidine carbamate derivatives as  
 M3 antagonists  
 INVENTOR(S): Buil Albero, Maria Antonia; Fernandez Forner, Maria  
 Dolors; Prat Quinones, Maria  
 PATENT ASSIGNEE(S): Almirall Prodesfarma, S.A., Spain  
 SOURCE: PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002051841	A1	20020704	WO 2001-EP15169	20011220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2441896	A1	20020704	CA 2001-2441896	20011220
AU 2002228015	A1	20020708	AU 2002-228015	20011220
AU 2002228015	B2	20070823		
EP 1345937	A1	20030924	EP 2001-989610	20011220
EP 1345937	B1	20050928		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016450	A	20030930	BR 2001-16450	20011220
EE 200300295	A	20031015	EE 2003-295	20011220
HU 2003003529	A2	20040128	HU 2003-3529	20011220
HU 2003003529	A3	20080328		
CN 1492868	A	20040428	CN 2001-822829	20011220
JP 2004530641	T	20041007	JP 2002-552936	20011220
NZ 526580	A	20050429	NZ 2001-526580	20011220
AT 305468	T	20051015	AT 2001-989610	20011220
ES 2248409	T3	20060316	ES 2001-989610	20011220
RU 2296762	C2	20070410	RU 2003-122341	20011220
US 20040266816	A1	20041230	US 2002-193622	20020710
US 7208501	B2	20070424		
US 20040242629	A1	20041202	US 2003-404395	20030331
US 7312231	B2	20071225		
IN 2003DN00939	A	20070105	IN 2003-DN939	20030617
MX 2003PA05583	A	20040505	MX 2003-PA5583	20030619
BG 107930	A	20040831	BG 2003-107930	20030619
ZA 2003004769	A	20040920	ZA 2003-4769	20030619
NO 2003002889	A	20030808	NO 2003-2889	20030623
HK 1055120	A1	20060106	HK 2003-107423	20031015
US 20080021060	A1	20080124	US 2007-806927	20070605
PRIORITY APPLN. INFO.:			ES 2000-3084	A 20001222
			WO 2001-EP15169	W 20011220
			US 2002-193622	A1 20020710
			US 2003-404395	A1 20030331
OTHER SOURCE(S):	MARPAT 137:79107			
GI				



I



II

AB The title compds. I (R1 = unsubstituted, halo substituted, alkyl substituted, or cyano substituted Ph, 2-thienylmethyl, 2-thienyl, 2-furylmethyl, 2-furyl, 3-thienylmethyl, 3-thienyl, 3-furylmethyl, 3-furyl; R2 = benzyl, phenethyl, 2-furylmethyl, 3-furylmethyl, 2-thienylmethyl or 3-thienylmethyl group or a straight or branched alkyl group having 3 or 8 carbon atoms, an alkenyl group having 3 to 8 carbons atoms, or a cycloalkyl group of 3 to 6 carbon atoms; p = 1 or 2; the substitution in the azoniabicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asym. carbons) and their pharmaceutically acceptable salts II (A = CH2, R3C:CH, CH:CR3, CO, O, S, SO, SO2, NR3, CR3R4; B = O2CR3, CO2R3, cyano, etc.; R3, R4 = H, alkyl, R3R4 = alicyclic ring; m = 0-8, n = 0-4) were prepared as M3 antagonists. Thus, (R)-3-hydroxy-1-azabicyclo[2.2.2]octane was treated with phenylbutylcarbonyl chloride to give the corresponding carbamate. The binding to receptor M3 receptor IC50 of benzylphenylcarbamic acid (R)-1-azabicyclo[2.2.2]octyl-3-yl ester was 5.0 nM.


IT 385367-13-5P 439907-90-1P 439907-95-6P  
439908-47-1P 439908-89-1P 439908-94-8P  
439909-11-2P 439909-34-9P 439909-54-3P  
439909-77-0P 439910-19-7P 439910-27-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of quinuclidine carbamate derivs. as M3 antagonists)

RN 385367-13-5 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 439907-90-1 CAPLUS

CN Carbamic acid, (4-fluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439907-95-6 CAPLUS

CN Carbamic acid, (4-methylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-47-1 CAPLUS

CN Carbamic acid, butylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-89-1 CAPLUS

CN Carbamic acid, butyl(4-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-94-8 CAPLUS

CN Carbamic acid, phenyl(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-11-2 CAPLUS

CN Carbamic acid, phenyl(2-phenylethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-34-9 CAPLUS

CN Carbamic acid, pentylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-54-3 CAPLUS

CN Carbamic acid, 4-pentenylphenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-77-0 CAPLUS

CN Carbamic acid, phenyl(3-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439910-19-7 CAPLUS

CN Carbamic acid, cyclopentyl(2-thienylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 439910-27-7 CAPLUS

CN Carbamic acid, (2-furanylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT	439907-53-6P	439907-55-8P	439907-57-0P
	439907-58-1P	439907-59-2P	439907-61-6P
	439907-63-8P	439907-65-0P	439907-67-2P
	439907-69-4P	439907-71-8P	439907-73-0P
	439907-75-2P	439907-77-4P	439907-79-6P
	439907-81-0P	439907-83-2P	439907-85-4P
	439907-87-6P	439907-89-8P	439907-92-3P
	439907-94-5P	439907-97-8P	439907-99-0P
	439908-00-6P	439908-01-7P	439908-02-8P
	439908-03-9P	439908-04-0P	439908-06-2P
	439908-08-4P	439908-10-8P	439908-12-0P
	439908-14-2P	439908-16-4P	439908-18-6P
	439908-20-0P	439908-22-2P	439908-24-4P
	439908-26-6P	439908-28-8P	439908-30-2P
	439908-32-4P	439908-34-6P	439908-36-8P
	439908-38-0P	439908-40-4P	439908-42-6P
	439908-45-9P	439908-50-6P	439908-52-8P



439908-54-0P 439908-55-1P 439908-56-2P  
 439908-58-4P 439908-60-8P 439908-62-0P  
 439908-64-2P 439908-66-4P 439908-68-6P  
 439908-70-0P 439908-72-2P 439908-74-4P  
 439908-76-6P 439908-78-8P 439908-80-2P  
 439908-82-4P 439908-84-6P 439908-86-8P  
 439908-87-9P 439908-88-0P 439908-90-4P  
 439908-91-5P 439908-92-6P 439908-93-7P  
 439908-95-9P 439908-97-1P 439908-99-3P  
 439909-01-0P 439909-03-2P 439909-05-4P  
 439909-07-6P 439909-08-7P 439909-09-8P  
 439909-10-1P 439909-12-3P 439909-14-5P  
 439909-16-7P 439909-18-9P 439909-20-3P  
 439909-22-5P 439909-24-7P 439909-26-9P  
 439909-29-2P 439909-32-7P 439909-36-1P  
 439909-37-2P 439909-39-4P 439909-41-8P  
 439909-43-0P 439909-45-2P 439909-47-4P  
 439909-49-6P 439909-51-0P 439909-53-2P  
 439909-56-5P 439909-58-7P 439909-60-1P  
 439909-62-3P 439909-64-5P 439909-66-7P  
 439909-68-9P 439909-70-3P 439909-72-5P  
 439909-75-8P 439909-79-2P 439909-81-6P  
 439909-83-8P 439909-85-0P 439909-87-2P  
 439909-89-4P 439909-91-8P 439909-93-0P  
 439909-94-1P 439909-95-2P 439910-21-1P  
 439910-25-5P 439910-30-2P 439910-33-5P  
 439910-43-7P 439910-45-9P 439910-49-3P  
 439910-50-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of quinuclidine carbamate derivs. as M3 antagonists)

RN 439907-53-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(phenylmethyl)amino]carbonyloxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-52-5

CMF C22 H27 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-55-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-methyl-3-pentenyl)-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-54-7  
 CMF C27 H35 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439907-57-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-56-9  
 CMF C30 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439907-58-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 439907-59-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 439907-61-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-hydroxyethyl)-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-60-5  
 CMF C23 H29 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439907-63-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(1-methylethyl)-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-62-7  
CMF C24 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
CMF C2 F3 O2




RN 439907-65-0 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-propyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-64-9  
CMF C24 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
CMF C2 F3 O2




RN 439907-67-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-cyanopropyl)-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-66-1  
 CMF C25 H30 N3 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439907-69-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclopropylmethyl)-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-68-3  
 CMF C25 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-71-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-ethoxyethyl)-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-70-7

CMF C25 H33 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-73-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(5-ethoxy-5-oxopentyl)-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-72-9  
 CMF C28 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439907-75-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-phenylbutyl)-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-74-1  
 CMF C31 H37 N2 O2

Absolute stereochemistry.






CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-77-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-fluorophenoxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-76-3


CMF C30 H34 F N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
CMF C2 F3 O2




RN 439907-79-6 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-hydroxypropyl)-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-78-5  
CMF C24 H31 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
CMF C2 F3 O2




RN 439907-81-0 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-(acetyloxy)butyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-80-9  
CMF C27 H35 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-83-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-oxo-4-(2-thienyl)butyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-82-1

CMF C29 H33 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-85-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-84-3

CMF C30 H35 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-87-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-86-5

CMF C28 H39 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-89-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-88-7

CMF C30 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439907-92-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)(phenylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439907-91-2  
 CMF C24 H28 F N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439907-94-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-93-4  
 CMF C30 H34 F N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-97-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-methylphenyl)(phenylmethyl)amino]carbonyloxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-96-7

CMF C25 H31 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439907-99-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-methylphenyl)(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439907-98-9

CMF C31 H37 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-00-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(2-methoxyethoxy)ethyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.






RN 439908-01-7 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenylethyl)-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA  
 INDEX NAME)

Absolute stereochemistry.



RN 439908-02-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-  
 1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-03-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-04-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 439908-06-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-cyanophenoxy)propyl]-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-05-1  
 CMF C31 H34 N3 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2



RN 439908-08-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(1-naphthalenyloxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-07-3

CMF C34 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-10-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(methylphenylamino)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-09-5

CMF C31 H38 N3 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-12-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-(phenylthio)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-11-9

CMF C30 H35 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-14-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(4-oxo-4-phenylbutyl)-3-  
 [[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
 trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-13-1  
 CMF C31 H35 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439908-16-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-  
 1-[3-(2,4,6-trimethylphenoxy)propyl]-, (3R)-, salt with trifluoroacetic  
 acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-15-3  
 CMF C33 H41 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-18-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2-chlorophenoxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-17-5

CMF C30 H34 Cl N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-20-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyloxy]-1-[3-[3-(trifluoromethyl)phenoxy]propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-19-7

CMF C31 H34 F3 N2 O3

Absolute stereochemistry.






CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-22-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-([1,1'-biphenyl]-4-yloxy)propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-21-1

CMF C36 H39 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-24-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(2,4-difluorophenoxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-23-3

CMF C30 H33 F2 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-26-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-methoxyphenoxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-25-5

CMF C31 H37 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-28-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-[3-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-27-7


CMF C34 H41 N2 O3

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
CMF C2 F3 O2




RN 439908-30-2 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(1,3-benzodioxol-5-yloxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-29-9  
CMF C31 H35 N2 O5

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
CMF C2 F3 O2




RN 439908-32-4 CAPLUS  
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[2-(aminocarbonyl)phenoxy]propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-31-3  
CMF C31 H36 N3 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-34-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[3-(dimethylamino)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-33-5

CMF C32 H40 N3 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-36-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(acetylamino)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-35-7

CMF C32 H38 N3 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-38-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(methoxycarbonyl)phenoxy]propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-37-9

CMF C32 H37 N2 O5


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-40-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(4-nitrophenoxy)propyl]-3-  
[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with  
trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-39-1

CMF C30 H34 N3 O5


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-42-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[4-(hydroxymethyl)phenoxy]propyl]-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 439908-41-5

CMF C31 H37 N2 O4

Absolute stereochemistry.






CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439908-45-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 439908-50-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-methyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-49-3

CMF C19 H29 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-52-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(4-methyl-3-pentenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 439908-51-7

CMF C24 H37 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-54-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-53-9

CMF C27 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-55-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.

Double bond geometry unknown.



RN 439908-56-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 439908-58-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-hydroxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-57-3  
 CMF C20 H31 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-60-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(1-methylethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-59-5

CMF C21 H33 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-62-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-propyl-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-61-9

CMF C21 H33 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-64-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(3-cyanopropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-63-1

CMF C22 H32 N3 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-66-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(cyclopropylmethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-65-3  
 CMF C22 H33 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439908-68-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-ethoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-67-5  
 CMF C22 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-70-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (butylphenylamino)carbonyl]oxy]-1-(5-ethoxy-5-oxopentyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-69-7

CMF C25 H39 N2 O4

Absolute stereochemistry.




CM 2

CRN 14477-72-6

CMF C2 F3 O2





RN 439908-72-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(3-hydroxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-71-1

CMF C21 H33 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-74-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[3-(1H-pyrrol-1-yl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-73-3

CMF C25 H36 N3 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-76-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[4-(acetyloxy)butyl]-3-  
 [[(butylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid  
 (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-75-5

CMF C24 H37 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-78-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[4-oxo-4-(2-thienyl)butyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
 (CA INDEX NAME)

CM 1


CRN 439908-77-7  
 CMF C26 H35 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439908-80-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(4-phenylbutyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439908-79-9  
 CMF C28 H39 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439908-82-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (butylphenylamino)carbonyl]oxy]-1-[3-(3-hydroxyphenoxy)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 439908-81-3

CMF C27 H37 N2 O4


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439908-84-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-heptyl-  
 , (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-83-5  
 CMF C25 H41 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439908-86-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
 (CA INDEX NAME)

CM 1

CRN 439908-85-7  
 CMF C27 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439908-87-9 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-phenylethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)



Absolute stereochemistry.



RN 439908-88-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[2-(2-methoxyethoxy)ethyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-90-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[3-(4-fluorophenoxy)propyl]-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-91-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(2-phenoxyethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-92-6 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439908-93-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.





RN 439908-95-9 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 439908-97-1 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-96-0  
 CMF C28 H33 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439908-99-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenylpropyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439908-98-2  
 CMF C28 H33 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-01-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenyl-2-propenyl)-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-00-9  
 CMF C28 H31 N2 O2 S


Absolute stereochemistry.  
 Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-03-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-02-1

CMF C28 H33 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-05-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-04-3  
 CMF C28 H33 N2 O4 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-07-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-06-5

CMF C26 H37 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-08-7 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-thienylmethyl)amino]carbonyloxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 439909-09-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(2-

thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-10-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-12-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 439909-14-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-13-4  
 CMF C25 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-16-7 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-15-6

CMF C31 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-18-9 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-17-8

CMF C30 H35 N2 O3

Absolute stereochemistry.




CM 2

CRN 14477-72-6

CMF C2 F3 O2






RN 439909-20-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
 (CA INDEX NAME)

CM 1


CRN 439909-19-0  
 CMF C31 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-22-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1)  
 (9CI) (CA INDEX NAME)

CM 1

CRN 439909-21-4  
 CMF C31 H35 N2 O2


Absolute stereochemistry.  
 Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-24-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-23-6

CMF C31 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-26-9 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid  
 (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-25-8  
 CMF C31 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-29-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid  
 (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-28-1  
 CMF C29 H41 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-32-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(2-phenylethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-31-6

CMF C29 H35 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-36-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[ (pentylphenylamino)carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-37-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (pentylphenylamino)carbonyl]oxy]-1-(2-propen-1-yl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 439909-39-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (pentylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-38-3

CMF C28 H39 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-41-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(pentylphenylamino)carbonyl]oxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-40-7

CMF C27 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-43-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (pentylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-42-9  
 CMF C28 H39 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-45-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (pentylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-44-1  
 CMF C28 H37 N2 O2


Absolute stereochemistry.  
 Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-47-4 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(pentylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 439909-46-3

CMF C28 H39 N2 O3

Absolute stereochemistry.




CM 2

CRN 14477-72-6

CMF C2 F3 O2






RN 439909-49-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-  
 [[(pentylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid  
 (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-48-5  
 CMF C28 H39 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-51-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[pentylphenylamino)carbonyl]oxy  
 ]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-50-9  
 CMF C26 H43 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-53-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (pentylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-52-1

CMF C26 H37 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-56-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (4-pentenylphenylamino)carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-55-4  
 CMF C22 H31 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-58-7 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (4-pentenylphenylamino)carbonyl]oxy]-1-(3-phenoxypropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-57-6  
 CMF C28 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-60-1 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[4-pentenylphenylamino)carbonyl]oxy]-1-(2-phenoxyethyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-59-8

CMF C27 H35 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-62-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (4-pentenylphenylamino)carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-61-2  
 CMF C28 H37 N2 O2

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-64-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (4-pentenylphenylamino)carbonyl]oxy]-1-(3-phenyl-2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-63-4  
 CMF C28 H35 N2 O2


Absolute stereochemistry.  
 Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-66-7 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (4-pentenylphenylamino)carbonyl]oxy]-1-[2-(phenylmethoxy)ethyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-65-6

CMF C28 H37 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-68-9 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[4-pentenylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-67-8  
 CMF C28 H37 N2 O4

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-70-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[4-pentenylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-69-0  
 CMF C26 H41 N2 O2


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-72-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[4-pentenylphenylamino)carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-71-4

CMF C20 H29 N2 O2

Absolute stereochemistry.




CM 2

CRN 14477-72-6

CMF C2 F3 O2






RN 439909-75-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[ (4-pentenylphenylamino)carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
 (CA INDEX NAME)

CM 1


CRN 439909-74-7  
 CMF C26 H35 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-79-2 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
 (CA INDEX NAME)

CM 1

CRN 439909-78-1  
 CMF C22 H27 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-81-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-80-5

CMF C28 H33 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-83-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenylpropyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-82-7  
 CMF C28 H33 N2 O2 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-85-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenyl-2-propenyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-84-9  
 CMF C28 H31 N2 O2 S


Absolute stereochemistry.  
 Double bond geometry unknown.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-87-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-[2-(phenylmethoxy)ethyl]-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-86-1

CMF C28 H33 N2 O3 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2




RN 439909-89-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-(3-hydroxyphenoxy)propyl]-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 439909-88-3  
 CMF C28 H33 N2 O4 S

Absolute stereochemistry.



CM 2

CRN 14477-72-6  
 CMF C2 F3 O2




RN 439909-91-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-90-7  
 CMF C26 H37 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439909-93-0 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439909-92-9

CMF C20 H25 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6


CMF C2 F3 O2



RN 439909-94-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-1-[3-(2-thienyl)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 439909-95-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-phenoxyethyl)-3-[[[phenyl(3-thienylmethyl)amino]carbonyl]oxy]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 439910-21-1 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[cyclopentyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 439910-20-0

CMF C21 H31 N2 O2 S


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439910-25-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[cyclopentyl(2-thienylmethyl)amino]carbonyl]oxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 439910-24-4

CMF C27 H37 N2 O2 S

Absolute stereochemistry.






CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439910-30-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-furanylmethyl)phenylamino]carbonyl]oxy]-1-(2-propenyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 439910-29-9

CMF C22 H27 N2 O3


Absolute stereochemistry.



CM 2

CRN 14477-72-6

CMF C2 F3 O2



RN 439910-33-5 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-furanylmethyl)phenylamino]carbonyloxy]-1-(3-phenylpropyl)-, (3R)-, salt with trifluoroacetic acid (1:1) (9CI)  
(CA INDEX NAME)

CM 1

CRN 439910-32-4

CMF C28 H33 N2 O3


Absolute stereochemistry.



CM 2


CRN 14477-72-6

CMF C2 F3 O2




RN 439910-43-7 CAPLUS

CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.1]hept-4-yl ester  
(9CI) (CA INDEX NAME)



RN 439910-45-9 CAPLUS


CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester  
(9CI) (CA INDEX NAME)



RN 439910-49-3 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[3-(3-hydroxyphenoxy)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




● Br<sup>-</sup>

RN 439910-50-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(butylphenylamino)carbonyl]oxy]-1-[3-(4-fluorophenoxy)propyl]-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 439908-43-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);  
 USES (Uses)  
 (preparation of quinuclidine carbamate derivs. as M3 antagonists)  
 RN 439908-43-7 CAPLUS  
 CN Carbamic acid, phenyl(phenylmethyl)-, (3S)-1-azabicyclo[2.2.2]oct-3-yl  
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:10471 CAPLUS

DOCUMENT NUMBER: 136:69742

TITLE: Preparation of quinuclidinecarbamates derived from  
arylalkylamines as M3 muscarinic receptor antagonists

INVENTOR(S): Farrerons Gallemlí, Carles; Catena Ruiz, Juan Lorenzo;  
Fernandez Serrat, Anna; Miquel Bono, Ignacio Jose;  
Balsa Lopez, Dolors; Bonilla Navarro, Jose Ignacio;  
Lagunas Arnal, Carmen; Salcedo Roca, Carolina;  
Fernandez Garcia, Andres

PATENT ASSIGNEE(S): Laboratorios S.A.L.V.A.T., S.A., Spain

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Spanish

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2002000652	A1	20020103	WO 2001-ES252	20010625
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2414514	A1	20020103	CA 2001-2414514	20010625
AU 2001066100	A	20020108	AU 2001-66100	20010625
EP 1300407	A1	20030409	EP 2001-943553	20010625
EP 1300407	B1	20040225		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012297	A	20030506	BR 2001-12297	20010625
HU 2003001414	A2	20030929	HU 2003-1414	20010625
HU 2003001414	A3	20080328		
JP 2004501916	T	20040122	JP 2002-505776	20010625
AT 260277	T	20040315	AT 2001-943553	20010625
PT 1300407	T	20040531	PT 2001-943553	20010625
ES 2213703	T3	20040901	ES 2001-943553	20010625
CZ 294251	B6	20041110	CZ 2003-261	20010625
AP 1420	A	20050614	AP 2003-2722	20010625
AU 2001266100	B2	20050630	AU 2001-266100	20010625
AU 2001266100	B9	20051006		
DE 20122417	U1	20050908	DE 2001-20122417	20010625
NO 2002006211	A	20030226	NO 2002-6211	20021223
KR 751981	B1	20070828	KR 2002-717706	20021226
MX 2003PA00141	A	20030527	MX 2003-PA141	20030107
BG 107474	A	20030930	BG 2003-107474	20030117
ZA 2003000644	A	20040210	ZA 2003-644	20030123
IN 2003CN00150	A	20050408	IN 2003-CN150	20030124
US 20040063950	A1	20040401	US 2003-312227	20030728
US 6916828	B2	20050712		
HK 1054934	A1	20041021	HK 2003-107175	20031006
US 20040235887	A1	20041125	US 2004-875592	20040623
US 7115629	B2	20061003		
IN 2007CN00210	A	20070824	IN 2007-CN210	20070118
PRIORITY APPLN. INFO.:			ES 2000-1661	A 20000627
			EP 2001-943553	A 20010625

WO 2001-ES252  
IN 2003-CN150  
US 2003-312227

W 20010625  
A3 20030124  
A1 20030728

OTHER SOURCE(S): MARPAT 136:69742  
GI




AB The quinuclidinecarbamates I [R1, R2, R3 = H, OH, SH, CN, F, Cl, Br, I, (C1-C4)-alkylthio, (C1-C4)-alkoxyl, (C1-C4)-alkoxyl substituted by one or several F radicals, carbamoylamine, (C1-C4)-alkyl and (C1-C4)-alkyl substituted by one or several F or OH radicals; R4 = a substituted or non-substituted cycloalkyl or cycloaryl radical (a heteroalkyl radical or not)] were prepared as antagonists of the M3 muscarinic receptor, and selectively, the M2 receptor. The amine of the quinuclidine ring can also be forming quaternary ammonium salts or in an oxidized state (N-oxide). I can be used in the treatment of urinary incontinence (particularly due to bladder instability), irritable bowel syndrome, diseases of the respiratory tract (particularly chronic obstructive pulmonary disease, chronic bronchitis, asthma, emphysema and rhinitis) and in ophthalmol. operations. Thus, (R)-quinuclidinol was converted to the chloroformate and reacted with N-phenylbenzylamine to give (R)-I (R1 = R2 = R3 = H, R4 = Ph) (II). The M3 muscarinic receptor constant Ki of II was 0.31 nM.

IT 385367-12-4P 385367-13-5P 385367-14-6P  
385367-15-7P 385367-16-8P 385367-17-9P  
385367-18-0P 385367-19-1P 385367-20-4P  
385367-21-5P 385367-22-6P 385367-23-7P  
385367-24-8P 385367-25-9P 385367-26-0P  
385367-27-1P 385367-28-2P 385367-29-3P  
385367-30-6P 385367-31-7P 385367-32-8P  
385367-33-9P 385367-34-0P 385367-35-1P  
385367-36-2P 385367-37-3P 385367-38-4P  
385367-39-5P 385367-40-8P 385367-41-9P  
385367-42-0P 385367-43-1P 385367-44-2P  
385367-45-3P 385367-46-4P 385367-47-5P  
385367-48-6P 385367-49-7P 385367-50-0P  
385367-51-1P 385367-52-2P 385367-53-3P  
385367-54-4P 385367-55-5P 385367-56-6P  
385367-57-7P 385367-58-8P 385367-59-9P  
385367-60-2P 385367-61-3P 385367-62-4P  
385367-63-5P 385367-64-6P 385367-65-7P  
385367-66-8P 385367-67-9P 385367-68-0P  
385367-69-1P 385367-70-4P 385367-71-5P  
385367-72-6P 385367-73-7P 385367-74-8P  
385367-75-9P 385367-76-0P 385367-78-2P  
385367-79-3P 385424-09-9P 385424-10-2P  
385424-11-3P 385424-12-4P


RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of quinuclidinecarbamates derived from arylalkylamines as quinuclidinecarbamates)

RN 385367-12-4 CAPLUS  
 CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester  
 (9CI) (CA INDEX NAME)




RN 385367-13-5 CAPLUS  
 CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl  
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 385367-14-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● I<sup>-</sup>


RN 385367-15-7 CAPLUS  
 CN Carbamic acid, phenyl(phenylmethyl)-, 1-oxido-1-azabicyclo[2.2.2]oct-3-yl  
 ester (9CI) (CA INDEX NAME)



RN 385367-16-8 CAPLUS

CN Carbamic acid, (2-fluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-17-9 CAPLUS

CN Carbamic acid, (3-chlorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-18-0 CAPLUS

CN Carbamic acid, (3-bromophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-19-1 CAPLUS

CN Carbamic acid, (2,6-difluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 385367-20-4 CAPLUS

CN Carbamic acid, (3,4-difluorophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-21-5 CAPLUS

CN Carbamic acid, (3-methylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-22-6 CAPLUS

CN Carbamic acid, (2,6-dimethylphenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-23-7 CAPLUS

CN Carbamic acid, (2,3-dihydro-1H-inden-5-yl)(phenylmethyl)-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-24-8 CAPLUS

CN Carbamic acid, (4-cyanophenyl)(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-  
3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-25-9 CAPLUS

CN Carbamic acid, (2-hydroxyphenyl)(phenylmethyl)-, (3R)-1-  
azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-26-0 CAPLUS

CN Carbamic acid, (2-fluoro-5-methylphenyl)[(2-fluorophenyl)methyl]-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-27-1 CAPLUS

CN Carbamic acid, [(2-bromophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-28-2 CAPLUS

CN Carbamic acid, (3-fluorophenyl)[(3-fluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-29-3 CAPLUS


CN Carbamic acid, (2,3-difluorophenyl)[(2-fluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-30-6 CAPLUS  
 CN Carbamic acid, [(4-chlorophenyl)methyl](2-fluoro-5-methylphenyl)-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-31-7 CAPLUS  
 CN Carbamic acid, (3-chlorophenyl)[(2,3-difluorophenyl)methyl]-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385367-32-8 CAPLUS  
 CN Carbamic acid, [(2,4-dichlorophenyl)methyl](2,4-difluorophenyl)-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-33-9 CAPLUS

CN Carbamic acid, [(2,4-difluorophenyl)methyl](3-methylphenyl)-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-34-0 CAPLUS

CN Carbamic acid, (3-chlorophenyl)[(2-fluoro-4-methoxyphenyl)methyl]-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-35-1 CAPLUS


CN Carbamic acid, (2-chlorophenyl)[(2,5-difluorophenyl)methyl]-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-36-2 CAPLUS  
 CN Carbamic acid, [(2-fluoro-5-methoxyphenyl)methyl]phenyl-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-37-3 CAPLUS  
 CN Carbamic acid, [(3,4-difluorophenyl)methyl]phenyl-, (3R)-1-  
 azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-38-4 CAPLUS  
 CN Carbamic acid, [(4-chloro-3-fluorophenyl)methyl](2-fluorophenyl)-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-39-5 CAPLUS  
 CN Carbamic acid, [(3-chloro-4-fluorophenyl)methyl]phenyl-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-40-8 CAPLUS  
 CN Carbamic acid, [(3,4-dichlorophenyl)methyl]phenyl-, (3R)-1-  
 azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-41-9 CAPLUS  
 CN Carbamic acid, [(3,5-difluorophenyl)methyl](3-methylphenyl)-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-42-0 CAPLUS  
CN Carbamic acid, [(3-fluoro-4-methylphenyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385367-43-1 CAPLUS  
CN Carbamic acid, [(3-fluoro-4-methoxyphenyl)methyl](2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-44-2 CAPLUS  
CN Carbamic acid, (3-chlorophenyl)[(2,3,4-trifluorophenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




Absolute stereochemistry.



RN 385367-45-3 CAPLUS

CN Carbamic acid, (3-methylphenyl)[(2,3,5-trifluorophenyl)methyl]-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-46-4 CAPLUS

CN Carbamic acid, (3-methylphenyl)[(2,4,5-trifluorophenyl)methyl]-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-47-5 CAPLUS


CN Carbamic acid, N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-48-6 CAPLUS  
CN Carbamic acid, (4-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-49-7 CAPLUS  
CN Carbamic acid, (3-methylphenyl)[(2-methylphenyl)methyl]-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385367-50-0 CAPLUS  
CN Carbamic acid, phenyl[[4-(trifluoromethyl)phenyl]methyl]-,  
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-51-1 CAPLUS

CN Carbamic acid, [[4-(trifluoromethyl)phenyl]methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-52-2 CAPLUS

CN Carbamic acid, [[4-(1,1-dimethylethyl)phenyl]methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-53-3 CAPLUS

CN Carbamic acid, [[4-(hydroxymethyl)phenyl]methyl](2-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-54-4 CAPLUS

CN Carbamic acid, [(4-cyanophenyl)methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-55-5 CAPLUS

CN Carbamic acid, [[4-(aminocarbonyl)phenyl]methyl]phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-56-6 CAPLUS


CN Carbamic acid, (2-fluorophenyl)[(2-hydroxyphenyl)methyl]-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-57-7 CAPLUS  
 CN Carbamic acid, [(3-hydroxyphenyl)methyl](3-methylphenyl)-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-58-8 CAPLUS  
 CN Carbamic acid, [(4-hydroxyphenyl)methyl]phenyl-, (3R)-1-  
 azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-59-9 CAPLUS  
 CN Carbamic acid, (3-chlorophenyl)[[3-(phenylmethoxy)phenyl]methyl]-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-60-2 CAPLUS  
 CN Carbamic acid, phenyl[[3-(trifluoromethoxy)phenyl]methyl]-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-61-3 CAPLUS  
 CN Carbamic acid, [[4-(1-methylethoxy)phenyl]methyl]phenyl-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385367-62-4 CAPLUS  
 CN Carbamic acid, (3-chlorophenyl)[[3-methoxy-4-(phenylmethoxy)phenyl]methyl]-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-63-5 CAPLUS

CN Carbamic acid, (1,3-benzodioxol-5-ylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-64-6 CAPLUS

CN Carbamic acid, [(2,3-dihydro-1,4-benzodioxin-6-yl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-65-7 CAPLUS


CN Carbamic acid, (cyclopropylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-66-8 CAPLUS  
 CN Carbamic acid, (cyclobutylmethyl)phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385367-67-9 CAPLUS  
 CN Carbamic acid, (cyclopentylmethyl)(3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385367-68-0 CAPLUS  
 CN Carbamic acid, (cyclohexylmethyl)(2-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 385367-69-1 CAPLUS  
 CN Carbamic acid, (1-cyclohexen-1-ylmethyl)(2-fluorophenyl)-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-70-4 CAPLUS  
 CN Carbamic acid, (3-chlorophenyl)(3-cyclohexen-1-ylmethyl)-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-71-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl]phenylamino]car  
 bonyl]oxy]-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-72-6 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(2-methylphenyl)(phenylmethyl)amino]carbonyl]oxy]-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-73-7 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(2-methylphenyl)(2,4,5-trifluorophenyl)methyl]amino]carbonyl]oxy]-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 385367-74-8 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(4-fluorophenyl)methyl](3-methylphenyl)amino]carbonyloxy]-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 385367-75-9 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(2-fluorophenyl)(phenylmethyl)amino]carbonyloxy]-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



● I<sup>-</sup>


RN 385367-76-0 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[(cyclohexylmethyl)(2-fluorophenyl)amino]carbonyl]oxy]-1-methyl-, iodide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



● I<sup>-</sup>


RN 385367-78-2 CAPLUS  
 CN Carbamic acid, phenyl(phenylmethyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 385367-79-3 CAPLUS  
 CN Carbamic acid, phenyl(phenylmethyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 385424-09-9 CAPLUS

CN Carbamic acid, [(4-methylcyclohexyl)methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385424-10-2 CAPLUS

CN Carbamic acid, [[4-(1-methylethenyl)cyclohexyl]methyl](3-methylphenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 385424-11-3 CAPLUS


CN Carbamic acid, (bicyclo[2.2.1]hept-2-ylmethyl)(3-fluorophenyl)-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 385424-12-4 CAPLUS  
 CN Carbamic acid, (bicyclo[2.2.1]hept-5-en-2-ylmethyl)phenyl-,  
 (3R)-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:743993 CAPLUS  
 DOCUMENT NUMBER: 136:134659  
 TITLE: Synthesis and preliminary evaluation of a  
 carbon-11-labelled agonist of the  $\alpha 7$  nicotinic  
 acetylcholine receptor  
 AUTHOR(S): Dolle, Frederic; Valette, Heric; Hinnen, Francoise;  
 Vaufrey, Francoise; Demphel, Stephane; Coulon,  
 Christine; Ottaviani, Michele; Bottlaender, Michel;  
 Crouzel, Christian  
 CORPORATE SOURCE: Service Hospitalier Frederic Joliot, Departement de  
 Recherche Medicale, CEA, Orsay, F-91401, Fr.  
 SOURCE: Journal of Labelled Compounds & Radiopharmaceuticals  
 (2001), 44(11), 785-795  
 CODEN: JLCRD4; ISSN: 0362-4803  
 PUBLISHER: John Wiley & Sons Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 136:134659  
 GI




AB N-(4-bromophenyl)carbamate acid quinuclidin-3-yl ester I was prepared from [11C]methane, 4-bromoaniline, and 3-quinuclidinol as a potential  $\alpha 7$ -nicotinic acetylcholine receptor imaging agent. Chlorination of [11C]methane followed by reaction with 98:2 nitrogen/oxygen over iron provided [11C]phosgene; reaction of [11C]phosgene with 4-bromoaniline generated an isocyanate in situ which reacted with 3-quinuclidinol to give I. 25-35 MCi (0.92-1.29 GBq) of I was obtained within 30 min of radiosynthesis (HPLC purification included) with specific radioactivities ranging from 500 to 800 mCi/ $\mu$ mol (18.5-29.6 GBq/ $\mu$ mol). Biodistribution studies in rats demonstrated a relatively good brain uptake of I (0.8-1.2% I.D./g tissue in various brain regions), but without preferential concentration in brain regions rich in  $\alpha 7$ -subtype nicotinic receptors (e.g. hippocampus, pons and colliculi). No specific binding could be demonstrated in pre-saturation studies performed with both the cold compound and nicotine; therefore, this ligand is not suitable for further exploration in PET imaging.

IT 393138-35-7P  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);  
 BIOL (Biological study); PREP (Preparation)  
 (preparation of a [11C]labeled quinuclidinyl bromophenylcarbamate as an  $\alpha 7$ -nicotinic acetylcholine receptor agonist and potential PET imaging agent)  
 RN 393138-35-7 CAPLUS  
 CN Carbamic-11C acid, (4-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester  
 (9CI) (CA INDEX NAME)



IT 195190-96-6P  
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);  
 BIOL (Biological study); PREP (Preparation)  
 (preparation of a quinuclidinyl bromophenylcarbamate as an  
 $\alpha$ 7-nicotinic acetylcholine receptor agonist)  
 RN 195190-96-6 CAPLUS  
 CN Carbamic acid, (4-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)  
 (CA INDEX NAME)





REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



ACCESSION NUMBER:	2001:115125	CAPLUS
DOCUMENT NUMBER:	134:178566	
TITLE:	Preparation of melanocortin-4 receptor binding compounds	
INVENTOR(S):	Maguire, Martin P.; Dai, Mingshi; Vos, Tricia J.	
PATENT ASSIGNEE(S):	Millennium Pharmaceuticals, Inc., USA	
SOURCE:	PCT Int. Appl., 215 pp.	
	CODEN: PIXXD2	
DOCUMENT TYPE:	Patent	
LANGUAGE:	English	
FAMILY ACC. NUM. COUNT:	4	
PATENT INFORMATION:		

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001010842	A2	20010215	WO 2000-US21327	20000804
WO 2001010842	A3	20010816		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2381008	A1	20010215	CA 2000-2381008	20000804
EP 1204645	A2	20020515	EP 2000-953837	20000804
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
BR 2000012984	A	20020716	BR 2000-12984	20000804
JP 2003528810	T	20030930	JP 2001-515309	20000804
MX 2002PA01160	A	20020702	MX 2002-PA1160	20020201
AU 2004202804	A1	20040722	AU 2004-202804	20040624
PRIORITY APPLN. INFO.:			US 1999-147288P	P 19990804
			US 2000-223277P	P 20000803
			AU 2000-66216	A3 20000804
			WO 2000-US21327	W 20000804
OTHER SOURCE(S):		MARPAT 134:178566		
GI				



AB The title compds. of formula B-Z-E [wherein B = an anchor moiety; Z = a central moiety; E = an MC4-R interacting moiety], e.g. I [wherein P2, P3,

and P4 = independently CH, CF, CCl, CBr, C(alkyl), C(alkoxy), C(CN), C(OH), or CI; W1 = covalent bond or CH2; W2 = CH2, CHR3, or CR3R4; W3 = CH2, CHR5, or CR5R6; R = H or alkyl; Z1 = CH or covalently linked to Z2 to form a naphthyl ring; Z2 = CH, C(C.tplbond.CH), CCl, CBr, CI, CF, or covalently linked to Z1 to form a naphthyl ring; Z5 = CH or C(OMe); R3-R6 = independently Me or Et], were prepared and tested as melanocortin-4 receptor (MC4-R) binding agonists and antagonists. For example,  $\alpha$ -tolunitrile in THF was added to a solution of diisopropylamine in THF, which had been cooled to -78°C and treated with BuLi. HMPA and 1-chloromethylnaphthalene in THF were added, the reaction cooled and stirred for 1 h, and the reaction quenched with H2O to give 2-(2-naphthalen-1-ylethyl)benzonitrile. Treatment with H2S and 1,3-diaminopropane, followed by heating to 80°C for 72 h and work up, gave II. In a scintillation proximity assay (SPA) using high-throughput receptor binding screening, II showed exemplary inhibition of MC4-R. The invention compds., primarily 2-(2-arylalkylsulfanylphenyl)-4,5-dihydro-1H-imidazole and 1,4,5,6-tetrahydropyrimidine derivs., are useful in the treatment of disorders associated with weight loss and pigmentation (no data).

IT 326486-03-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(inactive as MC4-R binding compound; preparation and high throughput MC4-R receptor binding screening of arylalkylsulfanylphenyl-substituted imidazoles and pyrimidines and analogs)


RN 326486-03-7 CAPLUS

CN Carbamic acid, (2-ethoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326486-02-6

CMF C16 H22 N2 O3



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH

IT 325826-44-6P, [2-(Naphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester 325826-51-5P, [2-(2-Methylnaphthalen-1-ylmethylsulfanyl)phenyl]carbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester 326484-34-8P 326484-38-2P 326484-48-4P 326484-49-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation and high throughput MC4-R receptor binding screening of arylalkylsulfanylphenyl-substituted imidazoles and

pyrimidines and analogs)


RN 325826-44-6 CAPLUS

CN Carbamic acid, [2-[(1-naphthalenylmethyl)thio]phenyl]-,  
1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 325826-51-5 CAPLUS

CN Carbamic acid, [2-[[2-methyl-1-naphthalenyl)methyl]thio]phenyl]-,  
1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 326484-34-8 CAPLUS

CN Carbamic acid, [2-[(1-naphthalenylmethyl)thio]phenyl]-,  
1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-44-6


CMF C25 H26 N2 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2




RN 326484-38-2 CAPLUS

CN Carbamic acid, [2-[[ (5-bromo-2-methoxyphenyl)methyl]thio]phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326484-37-1


CMF C22 H25 Br N2 O3 S



CM 2

CRN 64-18-6

CMF C H2 O2



RN 326484-48-4 CAPLUS


CN Carbamic acid, [2-[(2-naphthalenylmethyl)thio]phenyl]-,

1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 326484-47-3

CMF C25 H26 N2 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH


RN 326484-49-5 CAPLUS

CN Carbamic acid, [2-[[2-(methyl-1-naphthalenyl)methyl]thio]phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monoformate (9CI) (CA INDEX NAME)

CM 1

CRN 325826-51-5

CMF C26 H28 N2 O2 S



CM 2

CRN 64-18-6

CMF C H2 O2

O=CH-OH



L3 ANSWER 21 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:558084 CAPLUS

DOCUMENT NUMBER: 129:285907

TITLE: Selective muscarinic antagonists. II. Synthesis and antimuscarinic properties of biphenyllylcarbamate derivatives

AUTHOR(S): Naito, Ryo; Takeuchi, Makoto; Morihira, Koichiro; Hayakawa, Masahiko; Ikeda, Ken; Shibamura, Tadao; Isomura, Yasuo

CORPORATE SOURCE: Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, 305-8585, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1998), 46(8), 1286-1294

CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 129:285907

AB A novel series of biphenyllylcarbamate derivs. were synthesized and evaluated for binding to M1, M2 and M3 receptors and for antimuscarinic activities. Receptor binding assays indicated that biphenyl-2-ylcarbamate derivs. had high affinities for M1 and M3 receptors and good selectivities for M3 receptor over M2 receptor, indicating that the biphenyl-2-yl group is a novel hydrophobic replacement for the benzhydryl group in the muscarinic antagonist field. In this series, quinuclidin-4-yl biphenyl-2-ylcarbamate monohydrochloride (81, YM-46303) exhibited the highest affinities for M1 and M3 receptors, and selectivity for M3 over M2 receptor. Compared to oxybutynin, YM-46303 showed approx. ten times higher inhibitory activity on bladder pressure in reflexly-evoked rhythmic contraction, and about 5-fold greater selectivity for urinary bladder contraction against salivary secretion in rats. Moreover, selective antagonistic activity was also observed in vitro. Further evaluation of antimuscarinic effects on bradycardia and pressor in pithed rats, and on tremor in mice, showed that YM-46303 can be useful for the treatment of urinary urge incontinence as a bladder-selective M3 antagonist with potent activities and fewer side effects.

IT 171722-78-4P 171722-79-5P 171722-85-3P

171723-61-8P 171723-67-4P 214192-45-7P

214192-46-8P 214192-47-9P 214192-48-0P

214192-49-1P 214192-50-4P 214192-51-5P

214192-52-6P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP


(Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(synthesis and antimuscarinic properties of biphenyllylcarbamate derivs.)

RN 171722-78-4 CAPLUS


CN Carbamic acid, [1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171722-79-5 CAPLUS


CN Carbamic acid, [2-(1H-pyrrol-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171722-85-3 CAPLUS

CN Carbamic acid, [2-(phenylmethyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr

RN 171723-61-8 CAPLUS


CN Carbamic acid, (2-cyclohexylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 171723-60-7

CMF C20 H28 N2 O2






CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 171723-67-4 CAPLUS


CN Carbamic acid, [2-(phenylthio)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214192-45-7 CAPLUS


CN Carbamic acid, (2-phenoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214192-46-8 CAPLUS

CN 1-Azabicyclo[2.2.2]octan-3-ol, phenylcarbamate (ester), monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214192-47-9 CAPLUS  
 CN Carbamic acid, (2-ethylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 214192-48-0 CAPLUS  
 CN Carbamic acid, [1,1'-biphenyl]-2-yl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 214192-49-1 CAPLUS  
 CN Carbamic acid, [1,1'-biphenyl]-2-yl-, (3S)-1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 214192-50-4 CAPLUS  
 CN Carbamic acid, [1,1'-biphenyl]-3-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 195191-11-8  
 CMF C20 H22 N2 O2




CM 2

CRN 110-17-8  
 CMF C4 H4 O4

Double bond geometry as shown.



RN 214192-51-5 CAPLUS  
 CN Carbamic acid, [1,1'-biphenyl]-4-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 214192-52-6 CAPLUS  
 CN Carbamic acid, [2-(2-cyclohexen-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl

ester, ethanedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 171723-89-0


CMF C20 H26 N2 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




IT 171722-81-9, YM 46303 171723-89-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(synthesis and antimuscarinic properties of biphenyllylcarbamate  
derivs.)

RN 171722-81-9 CAPLUS

CN Carbamic acid, N-[1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-4-yl ester,  
hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 171723-89-0 CAPLUS

CN Carbamic acid, [2-(2-cyclohexen-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl

ester (9CI) (CA INDEX NAME)



REFERENCE COUNT:


12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:430068 CAPLUS  
DOCUMENT NUMBER: 129:108992  
TITLE: Preparation of 3-acyloxy-1-azabicyclo[2.2.1]heptane  
1-oxides as centrally active muscarinic agents.  
INVENTOR(S): Sabb, Annmarie L.; Stein, Reinhardt P.  
PATENT ASSIGNEE(S): American Home Products Corp., USA  
SOURCE: U.S., 8 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5773458	A	19980630	US 1997-953601	19971017
PRIORITY APPLN. INFO.:			US 1997-953601	19971017
OTHER SOURCE(S):	MARPAT	129:108992		
GI				



AB Title compds. (I; R = H, alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl; Y = O, S, NR<sub>2</sub>; R<sub>2</sub> = H, alkyl), were prepared for treatment of cognitive disorders associated with decreased levels of acetylcholine production or release

(no data). Thus, (exo)-1-azabicyclo[2.2.1]heptan-3-ol in THF/pyridine was treated with MeNCO to give the carbamate derivative, which was treated with m-chlorobenzoic acid in CH<sub>2</sub>Cl<sub>2</sub> to give (exo)-methylcarbamic acid 1-oxy-1-azabicyclo[2.2.1]hept-3-yl ester.


IT 209786-34-5P 209786-35-6P 209786-36-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 3-acyloxy-1-azabicyclo[2.2.1]heptane 1-oxides as centrally active muscarinic agents)

RN 209786-34-5 CAPLUS

CN Carbamic acid, cyclopropyl-, (1R,3S,4R)-1-oxido-1-azabicyclo[2.2.1]hept-3-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 209786-35-6 CAPLUS

CN Carbamic acid, cyclopropyl-, (1R,3S,4R)-1-oxido-1-azabicyclo[2.2.1]hept-3-

yl ester, rel-(-)- (9CI) (CA INDEX NAME)


Rotation (-). Absolute stereochemistry unknown.



RN 209786-36-7 CAPLUS

CN Carbamic acid, cyclopropyl-, (1R,3S,4R)-1-oxido-1-azabicyclo[2.2.1]hept-3-yl ester, rel-(+)- (9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



IT 174001-79-7P 174001-80-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 3-acyloxy-1-azabicyclo[2.2.1]heptane 1-oxides as centrally active muscarinic agents)

RN 174001-79-7 CAPLUS

CN Carbamic acid, cyclopropyl-, (1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 174001-80-0 CAPLUS

CN Carbamic acid, cyclopropyl-, (1S,3S,4R)-1-azabicyclo[2.2.1]hept-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT:

14


THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L3 ANSWER 23 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1997:617010 CAPLUS  
 DOCUMENT NUMBER: 127:293132  
 TITLE: Preparation of 1-azabicycloheptane derivatives for treatment of neurological illness.  
 INVENTOR(S): Sabb, Annmarie L.; Stein, Reinhardt P.  
 PATENT ASSIGNEE(S): American Home Products Corp., USA  
 SOURCE: U.S., 6 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5668144	A	19970916	US 1996-742425	19961030
PRIORITY APPLN. INFO.:			US 1996-742425	19961030
OTHER SOURCE(S):	MARPAT	127:293132		

GI




AB Title compds. (I; R = H, alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl; Y = O, S, NR<sub>2</sub>; R<sub>2</sub> = H, alkyl), were prepared Thus, (-)-(exo)-1-azabicyclo[2.2.1]heptane-3-ol, MeSCN, and pyridine were stirred at 60° in THF to give methylcarbamic acid (-)-(exo)-1-azabicyclo[2.2.1]hept-3-yl ester. The latter reversed scopolamine-induced hyperactivity in mice with a min. ED of 30 mg/kg.

IT 174001-79-7P 174001-80-0P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 1-azabicycloheptane derivs. as muscarinic agents)


RN 174001-79-7 CAPLUS  
 CN Carbamic acid, cyclopropyl-, (1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 174001-80-0 CAPLUS  
 CN Carbamic acid, cyclopropyl-, (1S,3S,4R)-1-azabicyclo[2.2.1]hept-3-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



ACCESSION NUMBER: 1997:579721 CAPLUS  
 DOCUMENT NUMBER: 127:234255  
 TITLE: Preparation of azabicyclic esters of carbamic acids  
 for use as nicotinic acetylcholine receptor agonists  
 INVENTOR(S): Macor, John; Wu, Edwin  
 PATENT ASSIGNEE(S): Astra Aktiebolag, Swed.  
 SOURCE: PCT Int. Appl., 35 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730998	A1	19970828	WO 1997-SE294	19970221
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9701082	A	19970825	ZA 1997-1082	19970210
CA 2246051	A1	19970828	CA 1997-2246051	19970221
AU 9722387	A	19970910	AU 1997-22387	19970221
AU 706944	B2	19990701		
EP 885221	A1	19981223	EP 1997-905544	19970221
EP 885221	B1	20020612		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CN 1211983	A	19990324	CN 1997-192461	19970221
CN 1063749	B	20010328		
BR 9707616	A	19990727	BR 1997-7616	19970221
HU 9901273	A2	19990728	HU 1999-1273	19970221
HU 9901273	A3	20000628		
NZ 331145	A	20000228	NZ 1997-331145	19970221
JP 2000505452	T	20000509	JP 1997-530075	19970221
RU 2172739	C2	20010827	RU 1998-117804	19970221
IL 125620	A	20010913	IL 1997-125620	19970221
CZ 289110	B6	20011114	CZ 1998-2659	19970221
AT 219081	T	20020615	AT 1997-905544	19970221
IN 1997DE00438	A	20050311	IN 1997-DE438	19970221
US 5998429	A	19991207	US 1997-836143	19970613
NO 9803711	A	19980813	NO 1998-3711	19980813
US 6054464	A	20000425	US 1999-276689	19990326
HK 1017357	A1	20010803	HK 1999-102514	19990609
PRIORITY APPLN. INFO.:			SE 1996-683	A 19960223
			WO 1997-SE294	W 19970221
			US 1997-836143	A1 19970613
OTHER SOURCE(S):	MARPAT	127:234255		
GI				



AB Azabicyclic carbamic esters, A-X-C(Y)-NH-Z {A = 1-azabicyclo[2.2.1]heptan-3-yl, 7-azabicyclo[2.2.1]heptan-2-yl, 1-azabicyclo[2.2.2]octan-3-yl, 2-azabicyclo[2.2.2]octan-5-yl; X = O, S; Y = O, S; Z = Ph, aryl, heteroaryl}, were prepared for use as nicotinic acetylcholine receptor agonists useful for treatment or prophylaxis of psychotic disorders and intellectual impairment disorders such as Alzheimer's disease, cognition deficit, autism, or attention deficit hyperactivity disorder. Thus, carbamic ester I was prepared in 60% yield by condensation of 3-quinuclidinol and 4-bromophenyl isocyanate. The prepared carbamic esters were tested for binding affinity for the  $\alpha 7$  nicotinic acetylcholine receptor.


IT 195190-96-6P 195190-97-7P 195190-98-8P  
 195190-99-9P 195191-00-5P 195191-01-6P  
 195191-03-8P 195191-04-9P 195191-05-0P  
 195191-06-1P 195191-07-2P 195191-08-3P  
 195191-09-4P 195191-10-7P 195191-11-8P  
 195191-12-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of azabicyclic esters of carbamic acids for use as nicotinic acetylcholine receptor agonists)


RN 195190-96-6 CAPLUS

CN Carbamic acid, (4-bromophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)  
 (CA INDEX NAME)




RN 195190-97-7 CAPLUS

CN Carbamic acid, (4-methylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)  
 (CA INDEX NAME)




RN 195190-98-8 CAPLUS

CN Carbamic acid, (3,4-dichlorophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 195190-99-9 CAPLUS


CN Carbamic acid, (4-methoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)  
 (CA INDEX NAME)




RN 195191-00-5 CAPLUS  
 CN Carbamic acid, (2-fluorophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)  
 (CA INDEX NAME)




RN 195191-01-6 CAPLUS  
 CN Carbamic acid, (3-methoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)  
 (CA INDEX NAME)




RN 195191-03-8 CAPLUS  
 CN Carbamic acid, (4-cyanophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)  
 (CA INDEX NAME)




RN 195191-04-9 CAPLUS  
 CN Carbamic acid, 2-pyridinyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA  
 INDEX NAME)




RN 195191-05-0 CAPLUS  
 CN 1-Azabicyclo[2.2.1]heptan-3-ol, phenylcarbamate (ester) (9CI) (CA INDEX  
 NAME)



RN 195191-06-1 CAPLUS  
 CN 1-Azabicyclo[2.2.2]octan-3-ol, phenylcarbamate (ester) (9CI) (CA INDEX NAME)




RN 195191-07-2 CAPLUS  
 CN Carbamic acid, 1-naphthalenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 195191-08-3 CAPLUS  
 CN 1-Azabicyclo[2.2.2]octan-3-ol, phenylcarbamate (ester), (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 195191-09-4 CAPLUS  
 CN 1-Azabicyclo[2.2.2]octan-3-ol, phenylcarbamate (ester), (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 195191-10-7 CAPLUS

CN Carbamic acid, 4-pyridinyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 195191-11-8 CAPLUS

CN Carbamic acid, N-[1,1'-biphenyl]-3-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester (CA INDEX NAME)



RN 195191-12-9 CAPLUS

CN Carbamic acid, 3-quinolinyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




IT 195191-13-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of azabicyclic esters of carbamic acids for use as nicotinic acetylcholine receptor agonists)

RN 195191-13-0 CAPLUS

CN Carbamic acid, (2,6-dichloro-4-pyridinyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1997:428265 CAPLUS  
 DOCUMENT NUMBER: 127:156253  
 TITLE: WAY-131256 is an orally active, efficacious, and in vivo functionally selective M1 agonist  
 AUTHOR(S): Sabb, Annmarie L.; Stein, Reinhardt P.; Vogel, Robert L.; Tasse, Rene; Amburn, Susan; Fairman, Denise K.; Kowal, Dianne; Malhotra, Deepa; Boast, Carl A.; Bartolomeo, Adam; Morris, Herman; Sailer, Tracy; Moyer, John A.; Abou-Gharbia, Magid; Ho, Douglas M.  
 CORPORATE SOURCE: CNS Medicinal Chemistry and CNS Disorders Division, Wyeth-Ayerst Research, Princeton, NJ, 08543-8000, USA  
 SOURCE: Drug Development Research (1997), 40(2), 185-192  
 CODEN: DDREDK; ISSN: 0272-4391  
 PUBLISHER: Wiley-Liss  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Computer modeling of carbachol docked in the human m1 receptor binding pocket has been used to discover a series of carbamate and thiocarbamate chiral, conformationally restricted analogs of carbachol based on azabicyclo[2.2.1]heptan-3-ol. These mols. have been evaluated for affinity and efficacy at human muscarinic receptors (m1-m5) transfected into a CHO cell line. None of these compds. was selective in binding. Thiocarbamate analogs had greater affinity for the m1 receptor subtype, but lower efficacy based on comparison of their ability to induce phosphoinositide (PI) turnover. Carbamate analogs had lower affinity for m1 receptors than thiocarbamates and varied in efficacy from 10% to 100% of the carbachol response in phosphoinositide (PI) turnover. One of these analogs, 3S,4R-azabicyclo[2.2.1]heptan-3-methylcarbamate (WAY-131256) (I) has been characterized as an m1/m2 agonist in vitro. I was equi-efficacious to the standard m1 agonist, xanomeline (Phase III) in vivo in a scopolamine-impaired radial arm maze paradigm (MED 1 mg/kg, 5.88 mmol/kg for VI and MED 1 mg/kg, 3.55 mmol/kg for xanomeline) and was approx. equal to xanomeline in an AF64A-impaired radial arm maze paradigm. Despite its lack of m1 selectivity in vitro, in vivo expts. on I indicated no significant effect on blood pressure or heart rate at 10 mg/kg (58.78 mmol/kg) (i.p.), and no peripheral side effects attributed to stimulation of either the m2 or m3 receptors (salivation, lacrimation, and chromodacryorrhea) up to doses of 30 mg/kg, 176.2 mmol/kg. These results may be explained by different receptor densities in various brain regions not accounted for in a transfected cell line or by metabolism of I to a m1 selective agonist in vivo. The results are discussed in relation treatment of Alzheimer's disease.


IT 174001-79-7 174001-80-0  
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)  
 (WAY-131256 is orally active and efficacious and in vivo functionally selective M1 muscarinic agonist in relation to structure-activity relations of carbamate and thiocarbamate analogs and treatment of Alzheimer's disease)

RN 174001-79-7 CAPLUS

CN Carbamic acid, cyclopropyl-, (1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.






RN 174001-80-0 CAPLUS


CN Carbamic acid, cyclopropyl-, (1S,3S,4R)-1-azabicyclo[2.2.1]hept-3-yl ester  
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




ACCESSION NUMBER: 1997:416851 CAPLUS  
 DOCUMENT NUMBER: 127:34136  
 TITLE: 1-Azabicycloheptane derivatives and their  
 pharmaceutical use as central muscarinic agents  
 INVENTOR(S): Sabb, Annmarie Louise; Stein, Reinhardt Peter  
 PATENT ASSIGNEE(S): American Home Products Corporation, USA  
 SOURCE: PCT Int. Appl., 18 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9717348	A1	19970515	WO 1996-US17569	19961030
W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LK, LR, LT, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2236836	A1	19970515	CA 1996-2236836	19961030
AU 9675518	A	19970529	AU 1996-75518	19961030
EP 861256	A1	19980902	EP 1996-937872	19961030
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, FI, RO				
JP 2000500139	T	20000111	JP 1997-518247	19961030
PRIORITY APPLN. INFO.:			US 1995-6337P	P 19951108
			WO 1996-US17569	W 19961030
OTHER SOURCE(S):		MARPAT 127:34136		
GI				




I



II

- AB Title compds. I [R = H, alkyl, haloalkyl, cycloalkyl, alkenyl, or alkynyl; Y = O, S, or NR<sub>2</sub>; R<sub>2</sub> = H or alkyl] and their pharmaceutically acceptable salts are useful as centrally active muscarinic agents. The compds. are useful for treatment of senile memory loss, Parkinson's disease, Down's syndrome, and other neurol. conditions related to acetylcholine deficiency. For instance, reaction of (-)-exo-1-azabicyclo[2.2.1]heptan-3-ol with Me isocyanate in THF and pyridine at 60° gave 55% title compound II. In a rat maze assay, II reversed scopolamine-induced disruption of performance with a min. ED of 1 mg/kg i.p.
- IT 174001-79-7P, exo-Cyclopropylcarbamic acid 1-azabicyclo[2.2.1]hept-3-yl ester 174001-80-0P, (-)-exo-Cyclopropylcarbamic acid 1-azabicyclo[2.2.1]hept-3-yl ester  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of azabicycloheptane derivs. as central muscarinic agonists)
- RN 174001-79-7 CAPLUS  
 CN Carbamic acid, cyclopropyl-, (1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 174001-80-0 CAPLUS

CN Carbamic acid, cyclopropyl-, (1S,3S,4R)-1-azabicyclo[2.2.1]hept-3-yl ester  
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



L3 ANSWER 27 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:205340 CAPLUS  
DOCUMENT NUMBER: 126:199461  
ORIGINAL REFERENCE NO.: 126:38563a  
TITLE: Preparation of 2-alkoxyphenylcarbamoyloxyquinuclidiniu  
m chlorides as topical anesthetics  
INVENTOR(S): Durinda, Jan; Gregan, Fridrich; Kralova, Katarina;  
Racanska, Eva  
PATENT ASSIGNEE(S): Farmaceuticka Fakulta UK, Slovakia; Prirodovedecka  
Fakulta UK  
SOURCE: Slovakia, 3 pp.  
CODEN: SLXXFO  
DOCUMENT TYPE: Patent  
LANGUAGE: Slovak  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
SK 278236	B6	19960508	SK 1992-2057	19920701
PRIORITY APPLN. INFO.:			SK 1992-2057	19920701
OTHER SOURCE(S):	CASREACT 126:199461; MARPAT 126:199461			
GI				




AB The title compds. [I; R = C1-8 alkyl], useful as topical anesthetics, were prepared Thus, reaction of 2-hexyloxyphenyl isocyanate with 3-quinuclidinol in PhMe afforded 70% I [R = n-hexyl] which showed IC50 of 1.00 mM/L against oxygen formation in spinach chloroplasts suspension.

IT 151643-45-7P 151643-46-8P 151643-47-9P  
151643-48-0P 151643-49-1P 151643-50-4P  
151643-51-5P 151643-52-6P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 2-alkoxyphenylcarbamoyloxyquinuclidinium chlorides as topical anesthetics)


RN 151643-45-7 CAPLUS

CN Carbamic acid, (2-methoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-46-8 CAPLUS  
 CN Carbamic acid, (2-ethoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-47-9 CAPLUS  
 CN Carbamic acid, (2-propoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-48-0 CAPLUS  
 CN Carbamic acid, (2-butoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-49-1 CAPLUS  
 CN Carbamic acid, [2-(pentyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-50-4 CAPLUS  
 CN Carbamic acid, [2-(hexyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151643-51-5 CAPLUS  
 CN Carbamic acid, [2-(octyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-52-6 CAPLUS

CN Carbamic acid, [2-(octyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L3 ANSWER 28 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:643737 CAPLUS  
DOCUMENT NUMBER: 125:275652  
ORIGINAL REFERENCE NO.: 125:51549a,51552a  
TITLE: Preparation of carbamate derivatives as selective  
muscarine M3 receptor antagonists  
INVENTOR(S): Takeuchi, Makoto; Naito, Makoto; Hayakawa, Masahiko;  
Ikeda, Masaru; Isomura, Yasuo  
PATENT ASSIGNEE(S): Yamanouchi Pharma Co Ltd, Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08198751	A	19960806	JP 1995-6142	19950119
PRIORITY APPLN. INFO.:			JP 1995-6142	19950119

OTHER SOURCE(S): MARPAT 125:275652

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; A = O, alkylene optionally interrupted by NR1; R1 = H, lower alkyl, lower alkoxy carbonyl; Y = (un)substituted phenyl; ring B = bridged and saturated N-containing heterocyclyl] and their pharmacol. acceptable

salts are prepared I possessing muscarine M3 receptor antagonism are useful for prevention and treatment of urinary system, respiratory, and digestive system diseases (no data). Thus, 1-phenyl-1-cyclobutanecarboxylic acid was reacted with diphenylphosphoryl azide in the presence of Et3N and then reacted with 3-quinuclidinol to give the title compound (II).


IT 182489-33-4P 182489-50-5P 182489-60-7P  
182489-70-9P 182489-85-6P 182489-91-4P  
182490-39-7P 182490-50-2P 182490-56-8P  
182490-63-7P 182490-71-7P 182490-83-1P  
182490-93-3P 182491-09-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of carbamate derivs. as selective muscarine M3 receptor antagonists)

RN 182489-33-4 CAPLUS


CN Carbamic acid, (1-phenylcyclopentyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182489-50-5 CAPLUS

CN Carbamic acid, (1-phenylcyclohexyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)







RN 182489-60-7 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[[1-azabicyclo[2.2.2]oct-3-yloxy)carbonyl]amino]-4-phenyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 182489-70-9 CAPLUS  
 CN Carbamic acid, (tetrahydro-4-phenyl-2H-pyran-4-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 182489-85-6 CAPLUS  
 CN Carbamic acid, (4-phenyl-4-piperidiny)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182489-91-4 CAPLUS  
 CN Carbamic acid, (1-methyl-4-phenyl-4-piperidiny)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182490-39-7 CAPLUS

CN Carbamic acid, (1-phenylcyclobutyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester  
(9CI) (CA INDEX NAME)




RN 182490-50-2 CAPLUS

CN Carbamic acid, (1-phenylcyclopropyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester  
(9CI) (CA INDEX NAME)




RN 182490-56-8 CAPLUS

CN Carbamic acid, [1-(4-chlorophenyl)cyclobutyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182490-63-7 CAPLUS

CN Carbamic acid, [1-(4-chlorophenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182490-71-7 CAPLUS

CN Carbamic acid, [1-(4-methylphenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182490-83-1 CAPLUS

CN Carbamic acid, [1-(4-chlorophenyl)cyclohexyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182490-93-3 CAPLUS

CN Carbamic acid, (1-phenylcyclobutyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester (9CI) (CA INDEX NAME)



RN 182491-09-4 CAPLUS

CN Carbamic acid, [1-(4-nitrophenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




IT 182489-31-2P 182489-34-5P 182489-36-7P  
 182489-38-9P 182489-41-4P 182489-44-7P  
 182489-47-0P 182489-51-6P 182489-55-0P  
 182489-61-8P 182489-65-2P 182489-71-0P  
 182489-86-7P 182489-92-5P 182490-01-3P  
 182490-04-6P 182490-08-0P 182490-12-6P  
 182490-24-0P 182490-28-4P 182490-33-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of carbamate derivs. as selective muscarine M3 receptor antagonists)

RN 182489-31-2 CAPLUS

CN Carbamic acid, (1-phenylcyclobutyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 182489-34-5 CAPLUS

CN Carbamic acid, (1-phenylcyclopentyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 182489-33-4

CMF C19 H26 N2 O2




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 182489-36-7 CAPLUS


CN Carbamic acid, (1-phenylcyclopropyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 182489-38-9 CAPLUS


CN Carbamic acid, [1-(4-chlorophenyl)cyclobutyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 182489-41-4 CAPLUS


CN Carbamic acid, [1-(4-chlorophenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 182489-44-7 CAPLUS

CN Carbamic acid, [1-(4-methylphenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 182489-47-0 CAPLUS  
 CN Carbamic acid, [1-(4-methoxyphenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 182489-51-6 CAPLUS  
 CN Carbamic acid, (1-phenylcyclohexyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 182489-50-5  
 CMF C20 H28 N2 O2



CM 2


CRN 110-17-8  
 CMF C4 H4 O4

Double bond geometry as shown.



RN 182489-55-0 CAPLUS

CN Carbamic acid, [1-(4-chlorophenyl)cyclohexyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 182489-61-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(1-azabicyclo[2.2.2]oct-3-yloxy)carbonyl]amino]-4-phenyl-, 1,1-dimethylethyl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 182489-60-7

CMF C24 H35 N3 O4




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 182489-65-2 CAPLUS

CN Carbamic acid, (1-phenylcyclobutyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 182489-71-0 CAPLUS  
 CN Carbamic acid, (tetrahydro-4-phenyl-2H-pyran-4-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 182489-70-9  
 CMF C19 H26 N2 O3



CM 2

CRN 110-17-8  
 CMF C4 H4 O4

Double bond geometry as shown.




RN 182489-86-7 CAPLUS  
 CN Carbamic acid, (4-phenyl-4-piperidinyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 182489-85-6  
 CMF C19 H27 N3 O2






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 182489-92-5 CAPLUS

CN Carbamic acid, (1-methyl-4-phenyl-4-piperidiny]-, 1-azabicyclo[2.2.2]oct-3-yl ester, (2E)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 182489-91-4

CMF C20 H29 N3 O2




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 182490-01-3 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(1-phenylcyclobutyl)amino]carbonyl]oxy]-, iodide (9CI) (CA INDEX NAME)



● I<sup>-</sup>

RN 182490-04-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-4-[[[(1-phenylcyclobutyl)amino]carbonyl]oxy]-, iodide (9CI) (CA INDEX NAME)



● I<sup>-</sup>


RN 182490-08-0 CAPLUS

CN Carbamic acid, [1-(4-nitrophenyl)cyclopentyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 182490-12-6 CAPLUS  
 CN Carbamic acid, (1-phenylcyclobutyl)-, 1-oxido-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 182490-24-0 CAPLUS  
 CN Carbamic acid, (1-phenylcyclopentyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester (9CI) (CA INDEX NAME)



RN 182490-28-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[[[(1-phenylcyclopentyl)amino]carbonyl]oxy]-, iodide (9CI) (CA INDEX NAME)



RN 182490-33-1 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-4-[[[(1-phenylcyclopentyl)amino]carbonyl]oxy]-, bromide (9CI) (CA INDEX NAME)



L3 ANSWER 29 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:502473 CAPLUS

DOCUMENT NUMBER: 125:158489

ORIGINAL REFERENCE NO.: 125:29411a,29414a

TITLE: The comparative genotoxicological study of new local anesthetics, 3-(2-alkoxyphenylcarbamoxyloxy)quinuclidium chlorides, on *Salmonella typhimurium*, *Saccharomyces cerevisiae*, *Vicia faba*, *Hordeum vulgare* and *Drosophila melanogaster*

AUTHOR(S): Miadokova, E.; Vlckova, V.; Duhova, V.; Trebaticka, M.; Grolmus, J.; Bohmova, B.; Podstavkova, S.; Rauko, P.; Plesnikova, I.; Vlcek, D.

CORPORATE SOURCE: Department Genetics, Comenius University, Bratislava, Slovakia

SOURCE: Cell Biology and Toxicology (1996), 12(3), 135-145  
CODEN: CBTOE2; ISSN: 0742-2091

PUBLISHER: Kluwer

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Potential genotoxicity of five new local anesthetics, derivs. of phenylcarbamic acid differing in the length of the alkyl chain of the alkoxy substituent, was studied on five test systems. There was a direct relation with increased toxic effect in bacteria and yeast as a function of the elongation of the alkyl chain of the alkoxy substituents of the phenylcarbamic acid esters. No structure-toxicity relation was found after application of 3-(2-alkoxyphenylcarbamoxyloxy)-quinuclidium chlorides on plants and *Drosophila*. All anesthetics were nonmutagenic to *Salmonella typhimurium* strains TA98, TA98, TA100, and TA102 in the absence and in the presence of S9 mix. Pentyloxy and heptyloxy derivs. increased rates of genetic changes in *Saccharomyces cerevisiae*, mainly revertants at the isoleucine locus. Pentyloxy and hexyloxy derivs. increased the frequency of chromosome aberrations in *Vicia faba* root-tip meristems. No chlorophyll mutations were detected after treatment of *Hordeum vulgare* with pentyloxy, hexyloxy and heptyloxy derivs. No sex-linked recessive lethals were scored in *Drosophila melanogaster* males. The rates of aneuploids induced in their germ cells were significantly increased after treatment with butoxy and octyloxy derivs. However, the local toxic and genotoxic effects of test anesthetics on the microorganisms of the anesthetized tissues may be of some importance. In particular, the genotoxic effect exhibited in fungi by the heptyloxy derivative, a potent local anesthetic, was remarkable.


IT 180423-60-3 180423-61-4 180423-62-5  
180423-63-6 180423-64-7 180423-65-8D, alkoxy  
derivs.

RL: ADV (Adverse effect, including toxicity); PRP (Properties); BIOL  
(Biological study)

(genotoxicol. study of local anesthetics 3-(2-  
alkoxyphenylcarbamoxyloxy)quinuclidium chlorides)

RN 180423-60-3 CAPLUS


CN Carbamic acid, [2-(pentyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-4-yl ester,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 180423-61-4 CAPLUS


CN Carbamic acid, (2-butoxyphenyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 180423-62-5 CAPLUS

CN Carbamic acid, [2-(hexyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 180423-63-6 CAPLUS  
 CN Carbamic acid, [2-(heptyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 180423-64-7 CAPLUS  
 CN Carbamic acid, [2-(octyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 180423-65-8 CAPLUS

CN Carbamic acid, (2-hydroxyphenyl)-, 1-azabicyclo[2.2.2]oct-4-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



L3 ANSWER 30 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:276839 CAPLUS

DOCUMENT NUMBER: 124:310199

ORIGINAL REFERENCE NO.: 124:57339a,57342a

TITLE: Phytotoxic and clastogenic effects of new local anesthetics, 3-(2-alkoxyphenylcarbamoyloxy)quinuclidium chlorides, on *Vicia sativa* L.

AUTHOR(S): Duhova, Viola; Blaskovicova, Martina; Miadokova, Eva

CORPORATE SOURCE: Faculty Science, Comenius University, Bratislava, SK-842 15, Slovakia

SOURCE: Biologia (Bratislava) (1996), 51(1), 37-41

CODEN: BLOAAO; ISSN: 0006-3088

PUBLISHER: Slovak Academic Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Phytotoxic and clastogenic effects of 5 new local anesthetics, derivs. of alkoxyphenylcarbamic acid, differing in the length of the alkyl chain of the alkoxy substituent, on *V. sativa* were assessed. The phytotoxic effect was increased as a function of concentration used, and the rank order of derivs.

was: heptyloxy < octyloxy < butoxy < pentyloxy < hexyloxy. Test compds. did not exhibit any clastogenic effect. With the exception of hexyloxy derivative, they did not reduce the mitotic activity of *V. sativa*.

IT 151643-48-0 151643-49-1 151643-50-4


151643-51-5 151643-52-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(phytotoxic and clastogenic effects of, on *Vicia sativa*)

RN 151643-48-0 CAPLUS


CN Carbamic acid, (2-butoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151643-49-1 CAPLUS

CN Carbamic acid, [2-(pentyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-50-4 CAPLUS  
CN Carbamic acid, [2-(hexyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-51-5 CAPLUS  
CN Carbamic acid, [2-(heptyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-52-6 CAPLUS  
CN Carbamic acid, [2-(octyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester,  
monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L3 ANSWER 31 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:63508 CAPLUS

DOCUMENT NUMBER: 124:194015

ORIGINAL REFERENCE NO.: 124:35607a,35610a

TITLE: Synthesis of esters of aliphatic and aromatic carbamic acids. A comparative study of properties and local anesthetic activity of these compounds

AUTHOR(S): Gregan, F.; Remko, M.; Racanska, E.; Csolei, J.

CORPORATE SOURCE: Fac. Pharmacy, Comenius Univ., Bratislava, 832 32, Slovakia

SOURCE: Bollettino Chimico Farmaceutico (1995), 134(8), 454-8  
CODEN: BCFAAI; ISSN: 0006-6648

PUBLISHER: Societa Editoriale Farmaceutica

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Four basic esters of cyclohexanecarbamic acid and their salts with hydrochloride were synthesized and evaluated for local anesthetic activity. It was found that also aliphatic carbamates studied exhibit local anesthetic activity comparable with the activity of analogous esters of aromatic (2-methoxyphenyl) carbamic acid. Our comparative investigation shows that the presence of aromatic group in the ester of carbamic acid influences local anesthetic activity, however the occurrence of aromatic moiety is not necessary condition for their activity.

IT 151643-45-7P 174228-24-1P 174228-25-2P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation and local anesthetic activity and properties of esters of aliphatic and aromatic carbamic acids)

RN 151643-45-7 CAPLUS


CN Carbamic acid, (2-methoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 174228-24-1 CAPLUS

CN Carbamic acid, cyclohexyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 174228-25-2 CAPLUS

CN Carbamic acid, cyclohexyl-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L3 ANSWER 32 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:1006746 CAPLUS  
DOCUMENT NUMBER: 124:202023  
ORIGINAL REFERENCE NO.: 124:37345a,37348a  
TITLE: 1-Azabicycloheptane derivatives with central  
muscarinic activity  
INVENTOR(S): Sabb, Annmarie L.; Stein, Reinhardt P.  
PATENT ASSIGNEE(S): American Home Products Corporation, USA  
SOURCE: U.S., 7 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5468875	A	19951121	US 1994-362695	19941222
PRIORITY APPLN. INFO.:			US 1994-362695	19941222
OTHER SOURCE(S):	MARPAT	124:202023		
GI				




AB Title compds. I [R = H, alkyl, haloalkyl, cycloalkyl, alkenyl or alkynyl; Y = O, S or NR<sub>2</sub> where R<sub>2</sub> = H or alkyl] and pharmaceutically acceptable salts are centrally active muscarinic agents, and are particularly active at M<sub>1</sub> receptors. For example, reaction of (+)-(exo)-1-azabicyclo[2.2.1]heptan-3-ol with MeNCO in THF containing pyridine at 50-60° gave (+)-exo-I [Y = O, R = Me]. This compound had an MED of 1 mg/kg for reversal of scopolamine-disrupted performance by rats in the 8-arm radial maze test.

IT 174001-79-7P 174001-80-0P 174001-83-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of azabicycloheptane derivs. as central muscarinic agents)

RN 174001-79-7 CAPLUS

CN Carbamic acid, cyclopropyl-, (1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 174001-80-0 CAPLUS

CN Carbamic acid, cyclopropyl-, (1S,3S,4R)-1-azabicyclo[2.2.1]hept-3-yl ester  
(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 174001-83-3 CAPLUS

CN Carbamic acid, cyclopropyl-, 1-azabicyclo[2.2.1]hept-3-yl ester, exo-(+)-  
(9CI) (CA INDEX NAME)

Rotation (+). Absolute stereochemistry unknown.



ACCESSION NUMBER: 1995:994203 CAPLUS  
 DOCUMENT NUMBER: 124:55800  
 ORIGINAL REFERENCE NO.: 124:10544h,10545a  
 TITLE: Preparation of novel heterocycllyl pyridyl- or phenyl(methyl)carbamate derivatives as selective antagonists for muscarine M3 receptor  
 INVENTOR(S): Takeuchi, Makoto; Naito, Ryo; Morihira, Koichiro; Hayakawa, Masahiko; Ikeda, Ken; Isomura, Yasuo  
 PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 76 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9521820	A1	19950817	WO 1995-JP168	19950208
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2182568	A1	19950817	CA 1995-2182568	19950208
AU 9515909	A	19950829	AU 1995-15909	19950208
AU 685225	B2	19980115		
EP 747355	A1	19961211	EP 1995-907855	19950208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1140447	A	19970115	CN 1995-191543	19950208
HU 76289	A2	19970728	HU 1996-2188	19950208
PRIORITY APPLN. INFO.:			JP 1994-16829	A 19940210
			JP 1994-35064	A 19940304
			JP 1994-102579	A 19940517
			JP 1994-221335	A 19940916
			JP 1994-267412	A 19941031
			WO 1995-JP168	W 19950208

OTHER SOURCE(S): MARPAT 124:55800

GI For diagram(s), see printed CA Issue.

AB Carbamates derivs. represented by general formula [I; ring A = a benzene or pyridine ring; ring B = a saturated nitrogenous heterocycle which may be substituted on the nitrogen atom or cross-linked, i.e. Q - Q2; wherein Z = N(O)qR2, N+R3R4.A-; Z1 = N(O)q, N+R5.A-; wherein A- = anion; R2 = H, alkyl, alkenyl, alkynyl, cycloalkylalkyl, (un)substituted aralkyl, heterocycllylalkyl having 1 or 2 heteroatoms and optional substituents on the heterocyclic ring and optionally condensed on the ring; R3 = alkyl, alkenyl, alkynyl, (un)substituted aralkyl, heterocycllylalkyl having 1 or 2 heteroatoms and optional substituents on the heterocyclic ring and optionally condensed on the ring; R4 = alkyl, alkenyl, alkynyl; R5 = alkyl, alkenyl, alkynyl, aralkyl; m, n = an integer of 1-4, provided that m + n = 3-5; p = an integer of 1-3; q = 0,1; r, s, t = an integer of 0-3, provided that r + s + t = 2 or 3; wherein R1 = optionally substituted Ph, C3-8 cycloalkyl or cycloalkenyl, or 5- or 6-membered nitrogenous heterocyclic group; X = a single bond or CH2; Y = a single bond, CO, optionally hydroxylated methylene, or -S(O)l; wherein l = an integer of 0, 1 or 2], salts, hydrates, or solvates thereof, useful for the treatment of prevention of digestive, respiratory or urol. diseases, are prepared In particular, a remedy or preventive for chronic obstructive lung diseases, chronic bronchitis, asthma, rhinitis, nervous pollakiurea (frequent urination), nervous bladder, nocturnal enuresis, unstable bladder, bladder


contracture, chronic cystitis, urinary incontinence, pollakiurea (frequent urination), irritable bowel syndrome, spasmodic colitis, or diverticulitis which is related to muscarine M3 receptor contains the said carbamate I as the active ingredient. Thus, 2.89 g (PhO)2P(O)N3 was added dropwise to a solution of 1.98 g 2-biphenylcarboxylic acid and 1.11 g Et3N in 50 mL toluene, stirred at 60° for 1.5 h, followed by adding 1.27 g 3-quinuclidinol, and the resulting mixture was refluxed for 6 h to give, after workup and silica gel chromatog., 2.47 g 3-quinuclidinyl N-(2-biphenyl)carbamate (II). The latter compound (0.46 g) was stirred with MeI in 2-butanone at room temperature for 5.5 h to give 0.58 g 3-[N-(2-biphenyl)carbamoyl]oxy]-1-methylquinuclidinium iodide (III). II and III showed a binding affinity with the dissociation constant Ki of 0.94 and 0.56 nM, resp., for muscarine M3 receptor preparation from submaxillary gland membrane and that of 25.9 and 14.4 nM, resp., for muscarine M2 receptor preparation from heart membrane and the binding affinity ratio of the muscarine M2 and M3 receptor was 27.6 and 25.7 for II and III, resp. II and III inhibited 50% the gallamine-induced contraction of a respiratory tract of guinea pig at 0.0045 and 0.0038 mg/kg i.v., resp., vs. 0.0008 mg/kg i.v. for atropine.

IT 171722-78-4P 171722-79-5P 171722-80-8P  
 171722-81-9P 171722-82-0P 171722-83-1P  
 171722-85-3P 171722-87-5P 171723-33-4P  
 171723-49-2P 171723-50-5P 171723-52-7P  
 171723-55-0P 171723-56-1P 171723-57-2P  
 171723-58-3P 171723-59-4P 171723-61-8P  
 171723-62-9P 171723-63-0P 171723-65-2P  
 171723-67-4P 171723-69-6P 171723-70-9P  
 171723-73-2P 171723-74-3P 171723-75-4P  
 171723-76-5P 171723-77-6P 171723-78-7P  
 171723-79-8P 171723-83-4P 171723-84-5P  
 171723-85-6P 171723-86-7P 171723-87-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of novel heterocyclyl pyridyl(methyl)- or phenyl(methyl)carbamate derivs. as selective antagonists for muscarine M3 receptor)

RN 171722-78-4 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 171722-79-5 CAPLUS

CN Carbamic acid, [2-(1H-pyrrol-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)






● HCl

RN 171722-80-8 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[([1,1'-biphenyl]-2-ylamino)carbonyl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)



● I<sup>-</sup>

RN 171722-81-9 CAPLUS


CN Carbamic acid, N-[1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-4-yl ester, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 171722-82-0 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 4-[[([1,1'-biphenyl]-2-ylamino)carbonyl]oxy]-1-methyl-, iodide (9CI) (CA INDEX NAME)




RN 171722-83-1 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 4-[[([1,1'-biphenyl]-2-ylamino)carbonyl]oxy]-1-methyl-, bromide (9CI) (CA INDEX NAME)




RN 171722-85-3 CAPLUS

CN Carbamic acid, [2-(phenylmethyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrobromide (9CI) (CA INDEX NAME)




● HBr


RN 171722-87-5 CAPLUS  
 CN Carbamic acid, (2-phenyl-3-pyridinyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 171722-86-4  
 CMF C19 H21 N3 O2




CM 2  
 CRN 144-62-7  
 CMF C2 H2 O4




RN 171723-33-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 4-[[([1,1'-biphenyl]-2-ylamino)carbonyl]oxy]-1-ethyl-, iodide (9CI) (CA INDEX NAME)



RN 171723-49-2 CAPLUS  
 CN Carbamic acid, (2-benzoylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester,  
 monohydrochloride (9CI) (CA INDEX NAME)



RN 171723-50-5 CAPLUS  
 CN Carbamic acid, (2'-methyl[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 171723-52-7 CAPLUS  
 CN Carbamic acid, (2'-nitro[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 171723-51-6  
 CMF C20 H21 N3 O4




CM 2

CRN 110-17-8  
 CMF C4 H4 O4


Double bond geometry as shown.




RN 171723-55-0 CAPLUS  
 CN Carbamic acid, (2'-hydroxy[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 171723-56-1 CAPLUS  
 CN Carbamic acid, (2'-hydroxy[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)  
 CM 1  
 CRN 171723-55-0  
 CMF C20 H22 N2 O3



CM 2  
 CRN 144-62-7  
 CMF C2 H2 O4




RN 171723-57-2 CAPLUS  
 CN Carbamic acid, (2'-amino[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, hydrochloride (10:19) (9CI) (CA INDEX NAME)



● 19/10 HCl

RN 171723-58-3 CAPLUS


CN Carbamic acid, [2-(hydroxyphenylmethyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171723-59-4 CAPLUS

CN Carbamic acid, [2-(2-cyclopenten-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 171723-61-8 CAPLUS


CN Carbamic acid, (2-cyclohexylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CRN 171723-60-7  
CMF C20 H28 N2 O2




CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 171723-62-9 CAPLUS  
CN Carbamic acid, [1,1'-biphenyl]-2-yl-, 1-oxido-1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 171723-63-0 CAPLUS  
CN Carbamic acid, [2-(phenylsulfonyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 171723-65-2 CAPLUS  
CN Carbamic acid, [2-(phenylsulfinyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl




ester, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 171723-64-1

CMF C20 H22 N2 O3 S




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 171723-67-4 CAPLUS

CN Carbamic acid, [2-(phenylthio)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 171723-69-6 CAPLUS

CN Carbamic acid, [2-(1-piperidiny)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 171723-68-5


CMF C19 H27 N3 O2



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 171723-70-9 CAPLUS

CN Carbamic acid, [2-(1-piperidinyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, ethanedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 171723-68-5


CMF C19 H27 N3 O2



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 171723-73-2 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 4-[[[([1,1'-biphenyl]-2-ylamino)carbonyl]oxy]-1-(2-propenyl)-, bromide (9CI) (CA INDEX NAME)




RN 171723-74-3 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 4-[[[1,1'-biphenyl]-2-ylamino)carbonyloxy]-1-(1-methylethyl)-, iodide (9CI) (CA INDEX NAME)




RN 171723-75-4 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 4-[[[1,1'-biphenyl]-2-ylamino)carbonyloxy]-1-propyl-, iodide (9CI) (CA INDEX NAME)



RN 171723-76-5 CAPLUS  
 CN 1-Azoniabicyclo[2.2.2]octane, 4-[[[1,1'-biphenyl]-2-ylamino)carbonyl]oxy]-3-methyl-1-(phenylmethyl)-, bromide (9CI) (CA INDEX NAME)




RN 171723-77-6 CAPLUS  
 CN Carbamic acid, [1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 171723-78-7 CAPLUS

CN Carbamic acid, [2-(1H-pyrrol-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 171723-79-8 CAPLUS

CN Carbamic acid, [1,1'-biphenyl]-2-yl-, 1-azabicyclo[2.2.2]oct-4-yl ester (9CI) (CA INDEX NAME)




RN 171723-83-4 CAPLUS

CN Carbamic acid, (2'-amino[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 171723-84-5 CAPLUS

CN Carbamic acid, (2-benzoylphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)  
(CA INDEX NAME)




RN 171723-85-6 CAPLUS

CN Carbamic acid, [2-(hydroxyphenylmethyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 171723-86-7 CAPLUS

CN Carbamic acid, [2-(2-cyclopenten-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 171723-87-8 CAPLUS

CN Carbamic acid, [2-(phenylsulfonyl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




IT 171723-51-6 171723-88-9 171723-89-0  
171723-90-3

RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction in preparation of novel heterocyclyl pyridyl(methyl)- or phenyl(methyl)carbamate derivs. as selective antagonists for muscarine M3 receptor)


RN 171723-51-6 CAPLUS

CN Carbamic acid, (2'-nitro[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 171723-88-9 CAPLUS

CN Carbamic acid, [2-(phenylthio)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




RN 171723-89-0 CAPLUS

CN Carbamic acid, [2-(2-cyclohexen-1-yl)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 171723-90-3 CAPLUS

CN Carbamic acid, (2'-methoxy[1,1'-biphenyl]-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)







L3 ANSWER 34 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1995:905942 CAPLUS  
DOCUMENT NUMBER: 124:86796  
ORIGINAL REFERENCE NO.: 124:16314h,16315a  
TITLE: Identification of a Series of 3-(Benzyloxy)-1-azabicyclo[2.2.2]octane Human NK1 Antagonists  
AUTHOR(S): Swain, Christopher J.; Sewart, Eileen M.; Cascieri, Margaret A.; Fong, Tung M.; Herbert, Richard; MacIntyre, D Euan; Merchant, Kevin J.; Owen, Simon N.; Owens, Andrew P.; et al.  
CORPORATE SOURCE: Neuroscience Research Centre, Merck Sharp and Dohme Research Laboratories, Harlow/Essex, CM20 2QR, UK  
SOURCE: Journal of Medicinal Chemistry (1995), 38(24), 4793-805  
CODEN: JMCMAR; ISSN: 0022-2623  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 124:86796

AB The synthesis and in vitro and in vivo evaluation of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2]octane NK1 antagonists are described. While a number of 3,5-disubstituted benzyl ethers afford high affinity, the 3,5-bis(trifluoromethyl)benzyl was found to combine high in vitro affinity with good oral activity. Detailed structure-activity relationship studies in conjunction with data from mol. modeling and mutagenesis work have allowed the construction of a model of the pharmacophore. Specific interactions that have been identified include an interaction between His-197 and one of the rings of the benzhydryl, a lipophilic pocket containing His-265 that the benzyl ether occupies, and a possible hydrogen bond between Asp-165 and the oxygen of the benzyl ether.

IT 172140-26-0P 172140-31-7P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of (benzyloxy)-1-azabicyclo[2.2.2]octane NK1 antagonists)

RN 172140-26-0 CAPLUS  
CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(diphenylmethyl)-, phenylcarbamate (ester), cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 172140-31-7 CAPLUS  
CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(diphenylmethyl)-, phenylcarbamate (ester), cis-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 172140-26-0  
CMF C27 H28 N2 O2

Relative stereochemistry.



CM 2

CRN 144-62-7  
CMF C2 H2 O4



ACCESSION NUMBER: 1995:574252 CAPLUS  
 DOCUMENT NUMBER: 122:310505  
 ORIGINAL REFERENCE NO.: 122:56365a,56368a  
 TITLE: Effects of 3-(2-alkoxyphenylcarbamoyloxy)chinuclidium chlorides on repair-deficient strains of *Chlamydomonas reinhardtii*  
 AUTHOR(S): Miadokova, E.; Sepakova, K.; Podstavkova, S.; Vlcek, D.  
 CORPORATE SOURCE: Faculty of Sciences, Comenius University, Bratislava, 84215, Slovakia  
 SOURCE: Biologia Plantarum (1995), 37(1), 15-19  
 CODEN: BPABAJ; ISSN: 0006-3134  
 PUBLISHER: Institute of Experimental Botany, Academy of Sciences of the Czech Republic  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English


AB The effect of five 3-(2-alkoxyphenylcarbamoyloxy)chinuclidium chlorides (alkoxy = butoxy - octyloxy) on survival of a wild-type strain and repair-deficient strains of *Chlamydomonas reinhardtii* was studied. There was a direct relationship with increased toxic effects in the algal strains as a function of the elongation of the alkyl chain of the alkoxy substituents of the phenylcarbamate acid derivs. Repair-deficient strains were more sensitive than the wild-type strain. The recombination-deficient strain *uvs10* expressed the highest sensitivity to the test agents. This suggests that a gene responsible for recombination repair is involved in an important role in DNA repair of damages induced in *C. reinhardtii* by the phenylcarbamic esters.

IT 151643-48-0 151643-49-1 151643-50-4  
 151643-51-5 151643-52-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (effect of 3-(2-alkoxyphenylcarbamoyloxy)chinuclidium chlorides on repair-deficient strains of *Chlamydomonas reinhardtii*)

RN 151643-48-0 CAPLUS


CN Carbamic acid, (2-butoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-49-1 CAPLUS


CN Carbamic acid, [2-(pentyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-50-4 CAPLUS


CN Carbamic acid, [2-(hexyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-51-5 CAPLUS


CN Carbamic acid, [2-(heptyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151643-52-6 CAPLUS

CN Carbamic acid, [2-(octyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

ACCESSION NUMBER: 1994:457282 CAPLUS  
 DOCUMENT NUMBER: 121:57282  
 ORIGINAL REFERENCE NO.: 121:10325a,10328a  
 TITLE: Quinuclidine-based NK-1 antagonists I:  
 3-benzyloxy-1-azabicyclo[2.2.2]octanes  
 AUTHOR(S): Seward, Eileen M.; Swain, Christopher J.; Merchant,  
 Kevin J.; Owen, Simon N.; Sabin, Verity; Cascieri,  
 Margaret A.; Sadowski, Sharon; Strader, Catherine;  
 Baker, Raymond  
 CORPORATE SOURCE: Neurosci. Res. Cent., Merck Sharp Dohme Res. Lab.,  
 Harlow/Essex, CM20 2QR, UK  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1993), 3(6),  
 1361-6  
 CODEN: BMCLE8; ISSN: 0960-894X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




AB Analogs I [R = Ph, X = NHCH<sub>2</sub>, NHCH<sub>2</sub>CH<sub>2</sub>, NHCO, OCO, etc.; RX =  
 (un)substituted benzyloxy] of CP-96,345 (II) were prepared and their  
 affinity for the human NK1 receptor tested. The 3-benzyloxy derivs. had  
 significant affinity for the human NK1 receptor. 3,5-Disubstitution of  
 the benzyl ether has been identified to be essential for high affinity.

IT 155618-06-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and NK-1 antagonist activity of)

RN 155618-06-7 CAPLUS


CN 1-Azabicyclo[2.2.2]octan-3-ol, 2-(diphenylmethyl)-, phenylcarbamate  
 (ester), (2S-cis)- (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1994:134470 CAPLUS  
 DOCUMENT NUMBER: 120:134470  
 ORIGINAL REFERENCE NO.: 120:23691a, 23694a  
 TITLE: Benzimidazoline-2-oxo-1-carboxylic acid derivatives  
 useful as serotonin receptor antagonists  
 INVENTOR(S): Turconi, Marco; Donetti, Arturo; Montagna, Ernesto;  
 Nicola, Massimo; Uberti, Annamaria; Micheletti,  
 Rosamaria; Giachetti, Antonio  
 PATENT ASSIGNEE(S): Boehringer Ingelheim Italia S.p.A., Italy  
 SOURCE: U.S., 13 pp. Cont-in-part of U.S. Ser. No. 768,497,  
 abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5223511	A	19930629	US 1992-845891	19920304
US 5358954	A	19941025	US 1993-33675	19930316
US 5552408	A	19960903	US 1995-432338	19950501
PRIORITY APPLN. INFO.:			IT 1987-21997	A 19870923
			US 1988-243949	B1 19880913
			US 1990-552353	B1 19900712
			US 1991-768497	B2 19910930
			US 1992-845891	A3 19920304
			US 1993-33675	A 19930316
			US 1994-267682	A 19940628


OTHER SOURCE(S): MARPAT 120:134470  
 GI



AB The title compds. I (R = H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl; R2 = H, halogen, C1-6 alkoxy; R5 = H, C1-6 alkyl, CR6:NR7; R6 = H, C1-4 alkyl, NH2; R7 = H, C1-C6 alkyl; Y = O, NH), which are serotonin receptor antagonists, useful as antiemetics and gastric prokinetic agents, are prepared and I-containing formulation presented. Thus, N-(endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2,3-dihydro-3-hexyl-2-oxo-1H-benzimidazole-1-carboxamide hydrochloride (m.p. 214-215°) was prepared and demonstrated 50% elimination of cisplatin-induced nausea in dogs at 1.3 µg/kg.


IT 123259-51-8P 152994-90-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepare and reaction of, in preparation of serotonin receptor antagonists)

RN 123259-51-8 CAPLUS  
 CN Carbamic acid, (2-aminophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)  
 (CA INDEX NAME)



RN 152994-90-6 CAPLUS

CN Carbamic acid, (2-nitrophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester,  
monohydrochloride (9CI) (CA INDEX NAME)




● HCl



L3 ANSWER 38 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:30656 CAPLUS  
DOCUMENT NUMBER: 120:30656  
ORIGINAL REFERENCE NO.: 120:5785a,5788a  
TITLE: Synthesis and local anesthetic activities of  
3-(2-alkoxyphenylcarbamoyloxy)quinuclidinium chlorides  
AUTHOR(S): Gregan, F.; Durinda, J.; Racanska, E.; Zamocka, J.  
CORPORATE SOURCE: Fac. Pharm., Comenius Univ., Bratislava, Czech.  
SOURCE: Pharmazie (1993), 48(6), 465-6  
CODEN: PHARAT; ISSN: 0031-7144  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI




I

AB The title compds. I (R = alkyl) were prepared by treating 3-quinuclidinol with alkoxyphenyl isocyanates. Local anesthetic activities and algicide min. inhibitory concns. were determined Mol. structure biol. activity relationships were discussed.

IT 151643-45-7P 151643-46-8P 151643-47-9P  
151643-48-0P 151643-49-1P 151643-50-4P  
151643-51-5P 151643-52-6P 151643-53-7P  
151643-54-8P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and local anesthetic and algicidal activity of)

RN 151643-45-7 CAPLUS


CN Carbamic acid, (2-methoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-46-8 CAPLUS


CN Carbamic acid, (2-ethoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-47-9 CAPLUS


CN Carbamic acid, (2-propoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-48-0 CAPLUS


CN Carbamic acid, (2-butoxyphenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-49-1 CAPLUS


CN Carbamic acid, [2-(pentyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-50-4 CAPLUS


CN Carbamic acid, [2-(hexyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-51-5 CAPLUS


CN Carbamic acid, [2-(heptyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 151643-52-6 CAPLUS

CN Carbamic acid, [2-(octyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 151643-53-7 CAPLUS  
 CN Carbamic acid, [2-(nonyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 151643-54-8 CAPLUS  
 CN Carbamic acid, [2-(decyloxy)phenyl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L3 ANSWER 39 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:459028 CAPLUS

DOCUMENT NUMBER: 113:59028

ORIGINAL REFERENCE NO.: 113:9987a,9990a

TITLE: Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT<sub>3</sub> receptor antagonists

AUTHOR(S): Turconi, Marco; Nicola, Massimo; Gil Quintero, Myrna; Maiocchi, Luciano; Micheletti, Rosella; Giraldo, Ettore; Donetti, Arturo


CORPORATE SOURCE: Dep. Med. Chem., Ist. De Angeli, Milan, I-20139, Italy  
SOURCE: Journal of Medicinal Chemistry (1990), 33(8), 2101-8  
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 113:59028

GI




AB A series of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid ester and amides containing a basic azabicycloalkyl or azacycloalkyl moiety, e.g., I and its analogs, were prepared and tested for their serotonin receptor-antagonist activity.

IT 123259-51-8

RL: RCT (Reactant); RACT (Reactant or reagent)  
(cyclocondensation reaction of, with trichloromethyl chloroformate, benzimidazolecarboxylate from)

RN 123259-51-8 CAPLUS

CN Carbamic acid, (2-aminophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)  
(CA INDEX NAME)



ACCESSION NUMBER: 1989:628221 CAPLUS  
 DOCUMENT NUMBER: 111:228221  
 ORIGINAL REFERENCE NO.: 111:37829a,37832a  
 TITLE: New photoaffinity labels for rat brain muscarinic acetylcholine receptors  
 AUTHOR(S): Ilie, Brigitte; Mejean, Annick; Hirth, Christian  
 CORPORATE SOURCE: Fac. Pharm., Univ. Louis Pasteur, Illkirch, 67401, Fr.  
 SOURCE: Biochemical Pharmacology (1989), 38(17), 2879-87  
 CODEN: BCPA6; ISSN: 0006-2952  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Localization of the ligand binding site on muscarinic acetylcholine receptors is 1 of the new fields of interest opened by the recent determination of


their primary structures. Owing to their interesting photochem. properties, aryldiazonium salts may be considered as appropriate tools for tagging the agonist/antagonist binding domain and to get precise identification and positioning of covalently labeled residues along the primary sequence of these receptors. A series of aryldiazonium derivs. and some of their azido-analogs were synthesized and their reversible muscarinic binding component was assessed through competition expts. involving either the whole population of receptor sites ([3H]QNB assay) or the super high affinity of their agonist binding sites ([3H]OXO-M assay). Three compds. fulfilled the criteria for efficient photolabels, allowing substantial and irreversible occupation of the receptor sites to be obtained. Interestingly, the 2 diazonium derivs. which were selected have been previously described as potent photoprobes of the peripheral nicotinic receptor of acetylcholinesterase, though displaying lower binding affinities for these acetylcholine binding proteins than for the muscarinic receptors. These findings, together with the all-to-none photolabeling efficiency observed for a quinuclidine derivative, substituted either by an azido or a diazonium group, are discussed. Finally, the apparent lack of binding selectivity of these new photoaffinity probes towards muscarinic receptor affinity states or subtypes should allow comparative studies of the acetylcholine binding site on different muscarinic receptor proteins, obtained either through purification procedures or expression of sep. gene products.

IT 123733-03-9P

RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent) (preparation and deprotection of)

RN 123733-03-9 CAPLUS

CN Carbamic acid, (4-aminophenyl)phenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




IT 123733-02-8P

RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent) (preparation and reduction of)

RN 123733-02-8 CAPLUS

CN Carbamic acid, (4-nitrophenyl)phenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




IT 122842-65-3P 123732-97-8P

RL: PREP (Preparation)

(preparation of and photoaffinity labeling by, of brain muscarinic acetylcholine receptors)


RN 122842-65-3 CAPLUS

CN Carbamic acid, (4-azidophenyl)phenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



RN 123732-97-8 CAPLUS

CN Benzenediazonium, 4-[[[(1-azabicyclo[2.2.2]oct-3-yl)oxy]carbonyl]phenylamino]- (CA INDEX NAME)




L3 ANSWER 41 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 1989:594763 CAPLUS  
DOCUMENT NUMBER: 111:194763  
ORIGINAL REFERENCE NO.: 111:32379a,32382a  
TITLE: Benzimidazoline-2-oxo-1-carboxylic acid derivatives  
useful as serotonin receptor antagonists  
INVENTOR(S): Turconi, Marco; Donetti, Arturo; Micheletti,  
Rosamaria; Uberti, Annamaria; Nicola, Massimo;  
Giachetti, Antonio  
PATENT ASSIGNEE(S): Istituto De Angeli S.p.A., Italy  
SOURCE: Eur. Pat. Appl., 28 pp.  
CODEN: EPXXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
EP 309423	A2	19890329	EP 1988-830375	19880919
EP 309423	A3	19891129		
EP 309423	B1	19940615		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
PL 151434	B1	19900928	PL 1988-274751	19880919
DD 285354	A5	19901212	DD 1988-319929	19880919
PL 152951	B1	19910228	PL 1988-279346	19880919
IL 87795	A	19930221	IL 1988-87795	19880919
ES 2054872	T3	19940816	ES 1988-830375	19880919
JP 01106882	A	19890424	JP 1988-236179	19880920
JP 06031225	B	19940427		
CA 1337347	C	19951017	CA 1988-577840	19880920
AU 8822378	A	19890323	AU 1988-22378	19880921
AU 610040	B2	19910509		
DK 8805261	A	19890324	DK 1988-5261	19880922
DK 172226	B1	19980112		
FI 8804350	A	19890324	FI 1988-4350	19880922
FI 89920	B	19930831		
FI 89920	C	19931210		
NO 8804202	A	19890328	NO 1988-4202	19880922
NO 169286	B	19920224		
NO 169286	C	19920603		
HU 48250	A2	19890529	HU 1988-4970	19880922
HU 200770	B	19900828		
ZA 8807083	A	19900530	ZA 1988-7083	19880922
SU 1676451	A3	19910907	SU 1988-4356601	19880922
CZ 279864	B6	19950712	CZ 1988-6307	19880922
SK 278812	B6	19980304	SK 1988-6307	19880922
LV 11035	B	19960820	LV 1995-33	19950217
PRIORITY APPLN. INFO.:			IT 1987-21997	A 19870923
OTHER SOURCE(S):	MARPAT	111:194763		
GI				





- AB Title compds. I [R = H, C1-6 alkyl, C1-6 alkynyl; R1,R2 = H, halo, CF3, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 acyl, CO2H, C1-6 alkoxy carbonyl, OH, NO2, (mono- or di- C1-4 alkyl-substituted)NH2, C1-6 acylamino, C1-6 alkoxy carbonylamino, (N-mono- or di- C1-4 alkyl-substituted) carbamoyl, (N-mono- or di- C1-4 alkyl-substituted) aminosulfonylamino; Y = O, NR3; R3 = H, C1-6 alkyl, C1-6 alkoxy-substituted PhCH2; A = 1-azabicyclo[2.2.2]octanyl, 1-azabicyclo[3.3.1]nonan-4-yl, Q1,Q2; p = 0 or 1; r = 0-3; R4 = H, C1-4 alkyl; R5 = H, C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-4 alkyl, (substituted)phenyl-C1-4 alkyl; R6 = H, C1-4 alkyl, NH2; R7 = metal), or III (R7 = COX; X = leaving group). Treatment of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carbonyl chloride with endo-8-Me-8-azabicyclo[3.2.1]octan-3-amine in THF gave I [R = R1 = R2 = H; YA = endo-8-Me-8-azabicyclo[3.2.1]oct-3-ylamino]. The latter showed ED50 s' of 0.3 µg/kg i.v. and 0.4 µg/kg i.v. for bradycardia and hypotension in 5-HT-treated rats, resp. Tablets were formulated containing I 250, lactose 270, corn starch 76, and Mg stearate 4 mg.
- IT 123259-51-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and reaction of, in preparation of serotonin antagonists)
- RN 123259-51-8 CAPLUS
- CN Carbamic acid, (2-aminophenyl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI)  
 (CA INDEX NAME)



L3 ANSWER 42 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1989:549839 CAPLUS

DOCUMENT NUMBER: 111:149839

ORIGINAL REFERENCE NO.: 111:24913a,24916a

TITLE: Direct and energy-transfer photolabeling of brain muscarinic acetylcholine receptors

AUTHOR(S): Ilie, Brigitte; Hirth, Christian

CORPORATE SOURCE: Fac. Pharm., Univ. Louis Pasteur, Illkirch, Fr.

SOURCE: European Journal of Biochemistry (1989), 183(2), 331-7  
CODEN: EJBCAI; ISSN: 0014-2956

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Efficient photolabeling of muscarinic acetylcholine receptors was done by using either 2 aryl diazonium salts or an azido derivative. These probes did not discriminate between muscarinic binding subtypes or affinity states and became irreversibly bound to the receptor sites, in an entirely atropine-protectable manner, upon UV irradiation. The extent of labeling was dependent both on probe concentration and on time of irradiation and reached up to

80% of the receptor population, under optimal alkylating conditions. In contrast to the azido derivative, both diazonium salts behave as potent irreversible labels of muscarinic receptors, provided energy-transfer photolabeling conditions were followed. Such an indirect activation of diazonium ligands, through an energy transfer from photoexcited tryptophan residues, has been previously found to increase the site-specificity and the rate of labeling of other acetylcholine binding proteins. Analogies in the photolabeling process of acetylcholinesterase or of nicotinic and muscarinic receptors by the 2 diazonium salts are discussed. The findings suggest that these new probes may be promising tools to investigate the location and the topog. of the agonist-antagonist binding domain on purified muscarinic receptors, through amino acid and/or sequence analyses of radioactive, photolabeled residues.


IT 122842-65-3

RL: ANST (Analytical study)

(photolabeling by, of muscarinic acetylcholine receptors of brain)


RN 122842-65-3 CAPLUS

CN Carbamic acid, (4-azidophenyl)phenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)




L3 ANSWER 43 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1976:432768 CAPLUS  
DOCUMENT NUMBER: 85:32768  
ORIGINAL REFERENCE NO.: 85:5313a,5316a  
TITLE: Synthesis and pharmacological properties of new  
compounds related to 2-aminochromone  
AUTHOR(S): Payard, Marc; Paris, Joelle; Couquelet, Jacques;  
Bastide, Janine; Lapalus, Philippe; Alves, Pierrette;  
Mongourd, Nicole  
CORPORATE SOURCE: Lab. Pharm. Chim., Fac. Pharm., Clermont-Ferrand, Fr.  
SOURCE: European Journal of Medicinal Chemistry (1976), 11(1),  
13-18  
CODEN: EJMCA5; ISSN: 0223-5234  
DOCUMENT TYPE: Journal  
LANGUAGE: French  
OTHER SOURCE(S): CASREACT 85:32768  
GI



AB Acylaminochromones I (R = substituted phenyl, aralkyl, pyridyl, heterocyclic substituted methyl, substituted amino, alkoxy) (38 compds.) were prepared by Curtius rearrangement of 2-chromonecarbonyl azide in the presence of carboxylic acids, alcs., or amines. I have analgesic, anticonvulsant, and antilipemic properties and the 2-aminochromone moiety confers very low toxicity.  
IT 59629-45-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 59629-45-7 CAPLUS  
CN Carbamic acid, (4-oxo-4H-1-benzopyran-2-yl)-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA INDEX NAME)



L3 ANSWER 44 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1973:111296 CAPLUS  
DOCUMENT NUMBER: 78:111296  
ORIGINAL REFERENCE NO.: 78:17871a,17874a  
TITLE: Penicillin saccharimides  
PATENT ASSIGNEE(S): Gist-Brocades N. V.  
SOURCE: Neth. Appl., 28 pp.  
CODEN: NAXXAN  
DOCUMENT TYPE: Patent  
LANGUAGE: Dutch  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
NL 7207022	A	19721205	NL 1972-7022	19720525
US 3726861	A	19730410	US 1971-149819	19710603
US 3726860	A	19730410	US 1971-149847	19710603
US 3734906	A	19730522	US 1971-149795	19710603
US 3734903	A	19730522	US 1971-149848	19710603
PRIORITY APPLN. INFO.:			US 1971-149795	A 19710603
			US 1971-149819	A 19710603
			US 1971-149847	A 19710603
			US 1971-149848	A 19710603

GI For diagram(s), see printed CA Issue.

AB The penicillins I (R1 = Me2NCH2CH2S, 3-quinuclidinyloxy, BuNH, PhCMe2CH2NMe, 3-morpholinopropylamino, PhMeNNH, 1-methyl-4-pyrrolidino-1,2,5,6-tetrahydropyridin-3-yl) were prepared by treating II with R1H.


IT 40278-39-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 40278-39-5 CAPLUS

CN Carbamic acid, [2-[(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)carbonyl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-, 1-azabicyclo[2.2.2]oct-3-yl ester, [2S-(2 $\alpha$ ,5 $\alpha$ ,6 $\beta$ )]- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 45 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1970:464632 CAPLUS

DOCUMENT NUMBER: 73:64632

ORIGINAL REFERENCE NO.: 73:10583a,10586a

TITLE: Carbanilic acid esters of cyclic amino alcohols. III.  
Esters of ecgonine, tropine, and some related bicyclic  
alcohols as local anesthetics

AUTHOR(S): Nilsson, J. Lars G.; Dahlbom, Richard; Akerman, Bengt

CORPORATE SOURCE: Dep. Org. Chem., Farm. Fak., Stockholm, Swed.

SOURCE: Acta Pharmaceutica Suecica (1970), 7(3), 239-46

CODEN: APSXAS; ISSN: 0001-6675

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A number of carbanilic acid esters of ecgonine methyl ester, pseudoecgonine  
methyl ester, tropine, pseudotropine, 3 $\alpha$ -granatanol, and  
3-quinuclidinol were prepared and tested for local anesthetic activity.  
Primary screening data reveal that some of the compds. have very high  
activity.


IT 29440-70-8 29440-71-9 29440-72-0

RL: PROC (Process)

(local anesthetic action of)

RN 29440-70-8 CAPLUS


CN Carbanilic acid, 2-chloro-6-methyl-, 3-quinuclidinyl ester,  
monohydrochloride (8CI) (CA INDEX NAME)



● HCl


RN 29440-71-9 CAPLUS

CN Carbanilic acid, o-methyl-, 3-quinuclidinyl ester (8CI) (CA INDEX NAME)



RN 29440-72-0 CAPLUS

CN Carbanilic acid, 2,6-dimethyl-, 3-quinuclidinyl ester (8CI) (CA INDEX  
NAME)





L3 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1968:435886 CAPLUS  
DOCUMENT NUMBER: 69:35886  
ORIGINAL REFERENCE NO.: 69:6683a,6686a  
TITLE: Some quinuclidine derivatives with potential  
antimalarial activity  
AUTHOR(S): Nilsson, J. Lars G.; Wagermark, Jorgen; Dahlbom,  
Richard  
CORPORATE SOURCE: Kungl. Farm. Inst., Stockholm, Swed.  
SOURCE: Acta Pharmaceutica Suecica (1968), 5(2), 71-6  
CODEN: APSXAS; ISSN: 0001-6675  
DOCUMENT TYPE: Journal  
LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB A series of carbamates and Schiff bases were prepared with a structural  
similarity to quinine. To 3.3 g. 3-quinuclidinol in 50 ml. dry PhMe was  
added 0.6 g. powdered Na and the mixture refluxed 2 hrs. to form the  
alcoholate. N,N-Diphenylcarbamoyl chloride (6 g.) dissolved in 25 ml.  
PhMe was then slowly added, and the mixture stirred and refluxed 1 hr. to  
yield 74% 3-quinuclidinyl N,N-diphenylcarbamate, m. 79-80°. The  
following I were similarly prepared (R, % yield, and m.p. given):  
phenothiazino, 85, 183-4°; N-ethylanilino, 44, 190-2°;  
indolino, 82, 125°. II were synthesized by the usual procedure  
(same data given): diphenylmethyl, 62, 108°; 9-fluorenyl, 35,  
189-90°; cyclohexyl, 80, 75-6°. The carbamates showed  
strong anticholinergic activity both centrally and peripherally.

IT 17656-14-3P 18692-63-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 17656-14-3 CAPLUS

CN Carbamic acid, diphenyl-, 1-azabicyclo[2.2.2]oct-3-yl ester (9CI) (CA  
INDEX NAME)



RN 18692-63-2 CAPLUS

CN Carbanilic acid, N-ethyl-, 3-quinuclidinyl ester, monohydrochloride (8CI)  
(CA INDEX NAME)



● HCl

L3 ANSWER 47 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1967:464199 CAPLUS  
DOCUMENT NUMBER: 67:64199  
ORIGINAL REFERENCE NO.: 67:12067a,12070a  
TITLE: 3,4,5-Trimethoxyphenylcarbamic acid esters of some  
cyclic amino alcohols  
AUTHOR(S): Dahlbom, Richard; Karlen, Bo; Nilsson, Lars  
CORPORATE SOURCE: Kungl. Farm. Inst., Stockholm, Swed.  
SOURCE: Acta Pharmaceutica Suecica (1967), 4(3), 211-16  
CODEN: APSXAS; ISSN: 0001-6675  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Ten 3,4,5-trimethoxyphenyl-carbamic acid esters of cyclic amino alcs. were prepared by the Curtius rearrangement. Thus, a solution of 0.02 mole 3,4,5-trimethoxybenzoyl azide and 0.03 mole amino alc. in dry benzene was refluxed 2 hrs. Quaternary ammonium salts were prepared by dissolving 0.015 mole amino ester in 20 ml. acetone and adding 5 ml. MeBr. The mixture was kept overnight at room temperature. I prepared are (R1, m.p., and % yield given):


N-methyl-3-piperidyl, 99-100°, 46 [MeBr salt, m. 234-5° (decomposition)], 88; N-ethyl-3-piperidyl, 81-2.5° [50, MeBr salt m. 187-8° (decomposition)], 69; N-methyl-4-piperidyl, 142-3.5°, 64 [MeBr salt m.p. 183.5-84° (decomposition)] 95; 1-azabicyclo[2.2.2]oct-3-yl, 173-4°, 78; 2-methyl-2-azabicyclo[1.3.2]oct-5-yl(axial), 175-7°, 77; 2-methyl-2-azabicyclo[1.3.2]oct-5-yl(equatorial) II, 215-16°, 91; 2-methyl-2-azabicyclo[1.3.3]non-5-yl(axial), 126-7°; 64; 4-methyl-2,5-methano-2H-furo[3,2-b]pyrrol-6-yl (IIa), 142.5-44°, 57; 2-methyl-4-carbomethoxy-2-azabicyclo[1.3.2]oct-5-yl(axial CO2Me) (III), 164-5°, 73; 2-methyl-4-carbomethoxy-2-azabicyclo[1.3.2]oct-5-yl(equatorial). The new compds. were tested in mice and only II and III showed some local anesthetic activity. 12 references.

IT 15436-52-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 15436-52-9 CAPLUS

CN Carbanilic acid, 3,4,5-trimethoxy-, 3-quinuclidinyl ester (8CI) (CA INDEX NAME)





ACCESSION NUMBER: 1966:465412 CAPLUS  
 DOCUMENT NUMBER: 65:65412  
 ORIGINAL REFERENCE NO.: 65:12163d-g  
 TITLE: New quinuclidine derivatives  
 AUTHOR(S): Tondeur, R.; Urbain, M.  
 CORPORATE SOURCE: Lab. Rech. Labaz, Brussels, Belg.  
 SOURCE: Chim. Therap (1966), 19(66(4)), 207-8  
 DOCUMENT TYPE: Journal  
 LANGUAGE: French

GI For diagram(s), see printed CA Issue.

AB Quinuclidin-3-ol (Sternbach and Kaiser, CA 48, 6437d) gave 3-quinuclidinyl benzoate-HCl, m. 225° (Mikhlin and Rubetsov, CA 54, 22632h), p-nitrobenzoate-HCl, m. 258-60° (loc. cit.), and p-aminobenzoate-HCl, (I.HCl), m. 220°. I.HCl (359 mg.) heated 2 hrs. at 45-50° in 2 cc. H<sub>2</sub>O with 200 mg. ClCO<sub>2</sub>Et, and then left overnight in an ice chest gave a crystalline precipitate of IIa.HCl; yield 400 mg., m.

225° (H<sub>2</sub>O). To a mixture of 266 mg. I (base) in 3 cc. C<sub>6</sub>H<sub>6</sub> and 68 mg. NMe<sub>3</sub> in C<sub>6</sub>H<sub>6</sub>, was added with stirring, 136.5 mg. ClCO<sub>2</sub>Bu. The product was collected and recrystd. from Me<sub>2</sub>COAcOEt to give 91 mg. IIb.HCl, m. 222°. To a Grignard reagent from 0.48 g. Mg and 3.1 g. PhBr in 10 cc. Et<sub>2</sub>O was added during 20 min. 0.88 g. Me quinuclidine-3-carboxylate in 10 cc. Et<sub>2</sub>O, after refluxing 1 hr. the mixture was treated with 25 cc.

saturated

NH<sub>4</sub>Cl and 25 g. ice. The aqueous layer was washed with Et<sub>2</sub>O, and the combined Et<sub>2</sub>O solns. on evaporation gave 520 mg. unidentified amorphous substance. From the aqueous layer was filtered 1.28 g. diphenyl-3-quinuclidinylcarbinol-HCl (IIIa.HCl), m. 285-90° (EtOH); IIIa m. 239°. In the similar preparation of bis(p-methoxyphenyl)-3-quinuclidinylcarbinol (IIIb), the aqueous solution of reaction product, after extraction with Et<sub>2</sub>O, was made alkaline

with NH<sub>4</sub>OH


and extracted with CHCl<sub>3</sub>. The extract yielded 3.5 g. IIIb (base), m. 198-200° (AcOEt). An organic solution of IIIb treated with an Et<sub>2</sub>O solution of HCl gas gave 3-bis[(p-methoxyphenyl)methylene] quinuclidine HCl salt, m. 243° (MeOH-Me<sub>2</sub>CO). I, IIa, and IIIa had slight spasmolytic activity.

IT 859037-31-3P, Carbanilic acid, p-carboxy-, N-ethyl 3-quinuclidinyl ester, hydrochloride

RL: PREP (Preparation)  
 (preparation of)

RN 859037-31-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED




● HCl

ACCESSION NUMBER: 1965:472047 CAPLUS  
 DOCUMENT NUMBER: 63:72047  
 ORIGINAL REFERENCE NO.: 63:13276g-h,13277a-b  
 TITLE: N-Benzodioxanylcarbamates  
 PATENT ASSIGNEE(S): Lakeside Laboratories, Inc.  
 SOURCE: 6 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 998878		19650721	GB 1961-39225	19611102
PRIORITY APPLN. INFO.:			US	19610125

GI For diagram(s), see printed CA Issue.  
 AB Title compds. (I) where n = 0-3 and R = dialkylamino or a cyclic amino structure, were prepared from 2-benzodioxanyl isocyanate (II) and amino alcs. II was prepared from benzodioxane-2-carbonyl chloride (III) and NaN<sub>3</sub>. Thus, 20 g. III in 100 cc. dry PhMe was added to 42.5 g. NaN<sub>3</sub> in 100 cc. dry PhMe at 50°, the mixture refluxed 15 hrs., the salts filtered off, and the resulting II solution refluxed 1 hr. with 19.2 g. N-benzyl-3-hydroxypiperidine. PhMe was distilled at reduced pressure, the residue dissolved in 300 cc. dry Et<sub>2</sub>O, and treated with ethereal HCl. The precipitate was washed with 100 cc. MeCN to yield 19.3 g. I (n = 0, R = N-benzyl-3-piperidinyl) hydrochloride (IV), m. 211-12°. Similarly prepared were the following I [n, R, salt, m.p. of salt, hrs. reflux, and % yield (if reported) given]: 3, NEt<sub>2</sub>, hydrochloride, 136-7°, 2, 56; 1, N-ethyl-2-pyrrolidinyl, acid fumarate, 167-8° (decomposition), 2, 38; 0, 3-quinuclidyl, acid fumarate, 176-7° (decomposition), 2; 3, 4-d-(1-phenyl-2-propyl)piperazino, di-acid fumarate, 188-90°, 2, 69.5; 3, 4-methylpiperazino, di-acid fumarate, 191-3° (EtOH), 2; 0, N-methyl-3-piperidinyl, free base, 142-4° (Et<sub>2</sub>O-n-hexane), 1. IV (15.4 g.) in 200 cc. MeOH hydrogenated 20 min. at 60 psi. in the presence of 3 g. 10% Pd-C gave 10.2 g. I (n = 0, R = 3-piperidinyl) hydrochloride, m. 170-1° (MeCN-Et<sub>2</sub>O). I have analgetic properties and are skeletal muscle relaxants and mild tranquilizers.  
 IT 2318-38-9P, 3-Quinuclidinol, 1,4-benzodioxan-2-carbamate (ester) 2456-61-3P, 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester, fumarate (1:1)  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 2318-38-9 CAPLUS  
 CN 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester (7CI, 8CI) (CA INDEX NAME)



RN 2456-61-3 CAPLUS  
 CN 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester, fumarate (1:1) (8CI) (CA INDEX NAME)


CRN 2318-38-9  
CMF C16 H20 N2 O4



CM 2

CRN 110-17-8  
CMF C4 H4 O4


Double bond geometry as shown.



ACCESSION NUMBER: 1965:416892 CAPLUS  
 DOCUMENT NUMBER: 63:16892  
 ORIGINAL REFERENCE NO.: 63:2982a-c  
 TITLE: Aminoalkyl N-[2-(1,4-benzodioxyl)]carbamates  
 INVENTOR(S): Judd, Claude I.  
 PATENT ASSIGNEE(S): Colgate-Palmolive Co.  
 SOURCE: 4 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3185692		19650525	US 1962-205849	19610125


PRIORITY APPLN. INFO.: US 19610125  
 GI For diagram(s), see printed CA Issue.  
 AB Esters of the general formula I are prepared and can be used as skeletal muscle relaxants. Thus, a solution of 20 g. 1,4-benzodioxane-2-carbonyl chloride in 100 ml. PhMe is added at 50° to a mixture of 42.5 g. NaN<sub>3</sub> in 100 ml. PhMe, the mixture is refluxed .apprx.1 1/2 hrs. and filtered, 42.5 g. NaN<sub>3</sub> is added, and the mixture is refluxed 16 hrs. and filtered. The filtrate is treated with 0.1 mole N-methyl-3-hydroxypiperidine, the mixture is refluxed 1 hr., and the solvent is distilled in vacuo to give 14.9 g. 1-methyl-3-piperidyl N-[2-(1,4-benzodioxyl)]carbamate, m. 142-4° (ether-hexane), HCl salt m. 136° (decomposition). Similarly prepared are the following I (R, m.p. acid fumarate, and m.p. di acid fumarate given): 1-benzyl-3-piperidyl, --, --, HCl salt m. 211-12°; 3-[4-d-(1-phenyl-2-propyl)-1-piperazinyl]propyl, --, 188-90° (decomposition); 1-ethyl-2-pyrrolidylmethyl, 167-8° (decomposition); γ-(4-pyridyl)propyl, 139-40° (MeCN), --; 3-(4-methylpiperazino)propyl, --, 191-3° (EtOH); 3-quinuclidyl, 176-7° (decomposition), --; Et<sub>2</sub>N(CH<sub>2</sub>)<sub>3</sub>, --, --, HCl salt m. 136-7°.  
 IT 2318-38-9P, 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester  
 2456-61-3P, 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester, fumarate (1:1)  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 2318-38-9 CAPLUS  
 CN 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester (7CI, 8CI) (CA INDEX NAME)



RN 2456-61-3 CAPLUS  
 CN 1,4-Benzodioxan-2-carbamic acid, 3-quinuclidinyl ester, fumarate (1:1)  
 (8CI) (CA INDEX NAME)

CM 1

CRN 2318-38-9  
 CMF C16 H20 N2 O4




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

276.34

454.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-40.00

-40.00

STN INTERNATIONAL LOGOFF AT 11:23:01 ON 05 JUN 2008